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2  Introduction 
2.1 Brief History of Macromolecular Therapy 
Most of the therapeutic drugs on market today are small molecules. But the advent of 
recombinant DNA technology1-3 and an increasing molecular knowledge of 
metabolism and cause of many diseases slowly shifted the focus of development 
towards macromolecular therapy options. 
Insulin was the first clinically used macromolecular therapeutic and was 
commercialized as extract of bovine pancreas in the early 1930s by Lilly. It’s role in 
diabetes was well known from 19224 and the successful application as therapeutic 
drug laid the foundations for a slow paradigm shift in drug development. As a 
consequence of the successful elucidation of its molecular mechanism medical 
research focused on the molecular basis of human metabolism and its connection to 
diseases. The focused work of the 1940–1960s resulted in the identification of many 
endogenous proteins with therapeutic potential5-6. But only the rapid advances in 
biotechnological production7 and protein design technologies8-9 allowed the explosion 
of the biopharmaceutical market we see today. 
Macromolecules differ from the classical small drug therapeutics in various ways. 
Small molecules are generally produced by direct chemical synthesis and obey to 
Lipinski’s “rule of five”10 stating that most of the therapeutically used drugs possess a 
Mw <500 Da, contain only a small number of hydrogen bond donors/acceptors, and a 
partition coefficient which allows diffusion through lipid bilayers. Biogenic 
macromolecules on the other hand are large (>1000 Da), often multiple charged and 
in most cases do not enter cells readily. These properties render most intracellular 
targets inaccessible therefore the majority of the used macromolecular drugs are 
either surface receptor ligands11-12 or antibodies targeting extracellular targets13 and 
surface proteins14. With the growing knowledge of genetics and protein expression 
the idea of treating diseases at their molecular root got more and more attention. The 
original concept of gene therapy15 is straightforward and elegant: genetic disorders 
are the result of a loss of genetic function either by a mutation in the protein-encoding 
gene (examples include Duchenne muscle dystrophy and cystic fibrosis) or by a 
mutation-impaired regulatory sequence. Stable replacement of the deficient gene  
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Figure 2.1: RNA intermediary 
shown (introns in grey, 5’-cap and poly
approaches are labeled by arrows (adapted from
 
(gene transfer) with a functional copy in the affected cell would restore the original 
function thereby serving a therapeutic goal
The concept has been studied using viral delivery systems for various monogenetic
disease model systems (Hemophilia A and 
immunodeficiency syndrome
vaccination20, infectious disease treatment and suicide gene cancer therapy
despite the persuasive ideas and first successful applications there still are a lot of 
technical problems to solve before gene therapy will be an standard option for 
medical treatment. 
In recent years antisense technology
to its complementary approach and the belief that there is a somehow reduced set of 
problems connected to it. As for gene therapy the basic concept of antisense is 
intriguing, the activity of antisense drugs stems from complementary Watson
hybridization22 allowing the generation of gene
not deliver new genetic information but are able to regulate gene expression by 
degrading target mRNA or regulating RNAs (
metabolism. Different steps in transcription and processing are 
(A) tail as plain text). Possible intervention sites using antisense 
16) 
17
. 
B, cystic fibrosis, severe combined 
18) and extended by including tissue engineering
 (Figure 2.1) received increasing attention due 
-specific drugs. Antisense therapies do 
Figure 2.1). While plasmid based gene 
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therapy has to reach the nucleus to express a therapeutic gene or achieve stable 
integration into the genome without causing mutagenesis23 the majority of antisense 
nucleic acids attack different sites of the mRNA metabolism in the cytosol (Figure 
2.1). One of the first reported approaches was the use of 13-25 bases long, 
complementary antisense oligodeoxynucleotides (asODN) to inhibit the translation of 
a mRNA transcript resulting in a target protein knockdown24. The expected 
mechanism was hypothesized as steric block through complementary Watson-Crick 
base pairing thereby inhibiting access of the translational machinery to the mRNA25-
26
. The discovery of the RNAse H pathway27 as a DNA-RNA duplex dependent 
protein translation inhibiting mechanism led to a detailed examination of the 
molecular basis of antisense activity.  RNAse H is able to recognize DNA-RNA 
duplexes and specifically cleaves the RNA thereby freeing the asODN resulting in a 
repetitive, catalytic process of duplex formation and degradation. This mechanism 
was exploited in the majority of the first generation antisense therapeutics28. A 
related mechanism is the dsRNA induced gene-silencing mechanism. In 1998 Fire 
and Mello reported that introduction of exogenous dsRNA into cells of Caenorhabditis 
elegans inhibited cellular protein expression29 but additional experiments with human 
cells using synthetic dsRNAs (78 bp) only showed an interferon-induced non-specific 
response30. Three years later Tuschl et al. could demonstrate that use of small 21 – 
23 bp long dsRNAs (siRNAs) causes effective, sequence specific RNA interference 
in mammalian cells without significant side effects31-32.  The siRNAs are incorporated 
into a multi-protein complex known as RNA-induced silencing complex (RISC). 
During assembly of the complex the siRNA is further processed, resulting in release 
of the passenger strand and binding of the guide strand to the Ago2 protein33. This 
strand is used by the RISC as template to destroy complementary target RNA via an 
embedded RNAse activity of the Ago2 protein34. These discoveries led to a surge in 
interest to harness RNAi for biomedical research and drug development. 
While most of the used, antisense based therapeutic approaches aim at inhibiting 
protein expression they can also be used to correct splicing errors in the pre-mRNA35  
or to increase gene activity by degradation of regulatory RNA36. But despite the 
assumed advantages of antisense technology over gene therapy or their mechanistic 
differences they share one trait; without effective delivery their therapeutic use is 
limited. 
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2.2 Barriers in Macromolecular Drug Delivery 
Successful application of nucleic acids (NAs) in a therapeutic setting is strongly 
dependent on successful delivery of the nucleic acid payload into the target cell. The 
rather low efficiency of non-viral vectors stems from the numerous extracellular and 
intracellular barriers (Figure 2.2) entrapping or destroying significant amounts of the 
payload before entering the cell. In contrast to peptides and proteins, which show 
reasonable stability in circulation, nucleic acids are characterized by a rather short 
half-life due to rapid degradation by nucleases37 making efficient protection of the 
nucleic acid mandatory. Most non-viral delivery systems, including cationic lipids, 
polymers such as polyethyleneimine (PEI) or dendrimers,  achieve this by 
compacting the nucleic acid payload through electrostatic interactions of the cationic 
carriers with the negatively charged nucleic acid. But the resulting positive net charge 
of many non-viral delivery systems is partly responsible for additional deleterious 
effects of the extracellular environment. Positive net charge of polyplexes increases 
unspecific, electrostatically induced interactions with negatively charged components 
of the biological environment like cell membranes and proteins. These interactions 
result in a number of side effects with reduction of effective therapeutic dose being 
the most prominent, followed by cytotoxic effects38 and stimulation of the immune 
system.  
To overcome these problems strategies like dextran modification of the polycation39, 
hydrophobic backbone modifications40-41 or conversion of the polymeric backbone 
into a polyanion42 were reported. The most common and versatile solution is 
PEGylation of the carrier systems. Polyethylene glycol (PEG), a hydrophilic, 
uncharged polymer with excellent solvatization properties was described for the 
generation of less immunogenic proteins, characterized by extended circulation 
times43. PEGylation of liposomes is a long known strategy to reduce unspecific 
interactions during circulation and was transferred to PEI-based carrier systems by 
Ogris et al.44. The PEGylation of PEI results in reduced interactions with blood 
components and the innate immune system. Recently the beneficial role of 
PEGylation for polymeric oligonucleotide (ON) delivery systems in siRNA/PEI 
delivery was examined in more detail by using radioactively labeled compounds for a 
detailed study of the pharmacokinetics45.  
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system. After docking to the cell by ligand
endosomal vesicle which can be actively transported to
acidic pH-shift in the maturating endosome unmasks a domain which disrupts the endosomal 
membrane releasing the particles into the cytoplasm. Vector unpacking by degradation of the 
polymeric backbone (disulfide, ester bonds) may occur in a time
either in the cytosol or in the nucleus. Depending on the form of nucleic acid, the payload is processed 
in the cytosol (siRNA and asODN) or has to enter the nucleus (pDNA).  
 
 exemplified for a bioresponsive NA delivery 
–receptor interaction, the vector is internalized into an 
 the perinuclear region by microtubules. The 
- and environment
 
  
13 
 
-dependent fashion 
Introduction   
 
14 
 
After successful passage through the circulation the polyplex has to extravasate in 
the vicinity of the target cell and cross the extra-cellular matrix (ECM) to deliver its 
payload to the cell surface and into the cytosol. The ECM is a network of different, 
charged macromolecular species and able to disrupt electrostatically stabilized 
polymer-NA formulations46-47 resulting in a profound impact on delivery efficiency. 
Apart from being a physical barrier for successful delivery to cells the composition of 
the ECM can influence the gene expression itself48. 
Incorporation of targeting into a delivery platform improves the specificity of the 
carrier for certain tissues or organs and supports the uptake of the delivery systems 
resulting in improved delivery efficiency. To achieve this goal different passive and 
active targeting concepts were developed. Due to the abnormal neovascularization 
and an inadequate lymphatic drainage tumor vasculature generally is characterized 
by an increased leakiness resulting in enhanced permeability and retention (EPR) for 
macromolecular drug entities49. This effect can be exploited to enrich nucleic acid 
formulations in tumor tissue. The EPR-targeting effect is mostly dependent on the 
molecular weight (>50 kDa) of the used polymer or the size of the resulting 
nanoparticles and can be improved by increasing Mw and hydrophilicity of the carrier 
via PEGylation. By covalently attaching ligands to the carrier it is possible to improve 
uptake into cells specifically expressing or over-expressing the target receptor. Active 
targeting for nucleic acid formulations was introduced in 1987 by Wu et al.50 for 
hepatocyte targeting and has been used extensively for the generation of carrier 
systems with an increased specificity for certain cell types. Prominent examples for 
this ligand-driven strategy are the use of transferrin51, EGF51, folate52 and peptides 
like RGD, GE1153 or B654. Active targeting is also used to improve the cellular uptake 
of PEGylated formulations and was combined with reversible PEGylation to escape 
the PEG-dilemma55. 
After successful internalization several intracellular bottlenecks such as endosomal 
escape, cytosolic transport and successful vector unpacking have to be resolved by a 
pDNA delivery system. In contrast to pDNA-delivery systems, nuclear localization is 
irrelevant for most of the antisense therapeutics. However, in either case the 
formulation has to escape the endosomal compartment which will otherwise degrade 
the payload over time. While certain polymeric carriers like PEI or PAMAM- 
dendrimers can utilize their high, intrinsic buffer capacity to cause an osmotic burst of 
the endosome56 their efficiency of escaping the endosomal entrapment is still low. 
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Lipid-based formulations are not able to induce an osmotic burst but can escape the 
endosomal pathway by destabilizing the endosomal membrane57. This process is 
enhanced by the inclusion of helper lipids in cationic polymer formulations or lipid 
modification of cationic polymers. 
Another frequently used strategy is the modification of polymeric carriers with 
membrane disrupting agents. One of the most prominent examples is melittin, the 
major component of the bee venom. This pH-independent, strongly lytic peptide 
inserts into biological membranes and induces pore formation causing effective 
vesicle rupture. Modification of polymeric vectors with melittin increases their delivery 
efficiency but also increases cytotoxicity58. To circumvent the problem of unspecific 
lytic activity various peptide-based membrane active agents were developed, 
mimicking the endosomal escape strategies of viruses or certain bacteria. Peptides 
like the influenza peptide respond to the acidification of the endosome by an 
conformational shift which results in increased membrane destabilization. This 
concept was adapted for the design of membrane active synthetic peptides like 
GALA/KALA59. These amphipathic peptides change their conformation in acidic 
environment from random coil to an alpha-helical structure able to interact with lipid 
membranes, leading to membrane rupture and subsequent release of vesicle 
contents into the cytosol. 
Following the successful escape out of the endosomal pathway pDNA-based 
formulations have to be efficiently trafficked to the nucleus, followed by release from 
the carrier for successful gene expression. In case of non-dividing cells the pDNA 
payload has to pass the nuclear pore complex (NPC). These pores possess an inner 
diameter of ~ 9 nm making free diffusion of the carrier-NA complex into the nucleus a 
unlikely process. Proteins containing an exposed nuclear localization sequence 
(NLS) are recognized by importin, a cytosolic heterodimer carrier protein, dock to the 
NPC and are actively transported into the nucleus60. Most of the known NLS are 
characterized by clusters of basic amino acids that are recognized by the importins. 
By attaching the M9 sequence to a peptidic scaffold Subramanian et al.61 could 
demonstrate an increase nuclear import of pDNA resulting in a tenfold increase of 
expression. Zanta and coworkers62 demonstrated that covalent attachment of a 
single NLS to a plasmid  was sufficient for increased nuclear entry while attachment 
of several NLS inhibited the transport. 
Introduction   
 
16 
 
In conclusion, polymeric carriers have to cope with apparently contradictory 
demands: to stabilize the nucleic acid against degradation, but release it at its 
biological site of action; to shield the polyplex during circulation in the blood stream, 
but to deshield it upon cell entry; to leave the cell membranes intact, but to rapidly 
destabilize the endosomal membrane. It is unlikely that a simple homopolymer is up 
to these tasks. Dynamic, multi-domain delivery systems may be a more promising 
answer to this challenge. 
 
2.3 Delivery Systems for Nucleic Acids 
 
A major aim for any nucleic acid delivery strategy is efficient payload delivery into the 
target cell resulting in a therapeutic effect. This is a challenging task because of the 
unfavorable properties of the nucleic acid payload and the numerous extracellular 
and intracellular barriers preventing easy delivery. Administration of naked pDNA or 
RNAs did only in a few exceptional and not generally useful cases63-65 result in 
effective in vivo delivery. The limitation is due to the fast degradation of either DNA or 
RNA in in vivo settings by nucleases37 and limited extravasation66. Although gene 
expression/silencing can be achieved by either intramuscular/intratumoral67-68 
injection or physically assisted methods like electroporation69 or hydrodynamic 
delivery70 these methods miss general applicability or are characterized by a rather 
low efficiency. 
Viral vectors are considered to be the most efficient vector systems and are used in 
the majority of clinical gene therapy studies71. Due to their long evolution they are 
exceptionally suited to transport nucleic acids into foreign cells. By replacing viral 
genetic information with therapeutic nucleic acids viral systems can be used for 
effective delivery into target cells. But despite their advantageous properties it was a 
long way from the first, failed study in 1973 using shope papilloma virus to treat 
hyper-arginaemia by an ex vivo approach72 to the successful delivery of genetic 
material into humans in 199073. Despite their advantages in terms of efficiency viral 
delivery systems have disadvantages originating from their parent wild-type viruses. 
Major parts of the properties of a viral delivery system are defined by the wild-type 
they originate from, including loading capacity, tropism, maintenance of transgene 
expression, immunogenicity and inflammatory potential74. This results in difficulties  
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Figure 2.3: Schematic representations of the four major delivery system classes.
B: cationic lipid/liposome; C: cationic 
system, reproduced from75-76. 
 
regarding retargeting, potentially severe immune responses and the problem of 
mutagenesis. In general viruses are superior delivery systems but expensive in 
production, possess only a limited flexibility and are quite complicated in hand
In 1987 Felgner et al.77 
complex DNA through charged, liposomal structures and were able to transfect cells 
in a reliable, efficient way. These so called lipoplexes are electrostatically stabilized
complexes made from cationic lipids like DOTAP or DOPE and negatively charged 
nucleic acids. The lipid components spontaneously form micellar structures
cationic surfaces in aqueous environment. The cationic surface interacts with 
negatively charged nucleic acids to form complexes which enter cells via 
endocytosis. Internalized lipoplexes are able to escape the endosomal pathway by 
interactions with the endosomal membrane
cationic lipids interact with the negat
membrane perturbations resulting in a breakdown of the membrane and subsequent 
release of the complexed nucleic acids into the cytoplasm
polymeric delivery system; D: dynamic polymeric deliver
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vitro efficiency the susceptibility towards serum proteins restricts extensive use in 
vivo. Nevertheless cationic lipids are considered to be one of the best non-viral 
delivery systems and have already been tested in clinical trials71. 
Similar to liposomes, polymers offer some practical advantages over viral delivery 
systems. Polymeric delivery vehicles are cheap in production, easy to modify, not 
recognized by the immune system and show no size limitations for their payload. 
Over the last 15 years polyethylenimine advanced to the most used member of this 
class80. PEI polymers contain primary, secondary and, in case of branched PEI, 
tertiary amines which are only partially protonated under physiological conditions. 
This structural feature results in a high intrinsic buffer capacity and allows the 
compaction of nucleic acids into small nanoparticles (50-500 nm). These properties 
result in an exceptionally high in vitro efficiency compared to other polymeric vectors 
and also some in vivo efficacy. But despite its efficiency PEI has some 
disadvantages. Its transfection efficiency is only moderate compared to viral delivery 
systems. Major drawback of PEI-based delivery vehicles is a pronounced in vitro and 
in vivo toxicity81-84, mainly caused by the positive net charge of PEI polyplexes 
resulting in unspecific interactions44,85 with the biological environment. In contrast to 
peptide based delivery systems or polyarginine/-lysine polymers, PEI is not 
biodegradable resulting in inefficient metabolization and elimination. This property 
can lead to PEI accumulation in cells and organs, limiting its usefulness for repeated 
application. 
The limitations of homopolymers like PEI and the resulting problems led to the 
development of increasingly complex polymeric systems which are able to react to 
external stimuli. Modifications include improved biodegradability resulting in reduced 
toxicity86-87, targeted delivery using shielded formulations88 and carriers with 
covalently attached payload which is only released in the cytosol75-76. These systems 
are the first versions of the so called programmable polymeric delivery systems 
(PPDS), dealing with the contradicting requirements of successful delivery. 
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2.4 Design and Synthesis of Programmable Polymeric Carrier Systems by 
Solid-Phase Synthesis and CombiChem  
 
Polymer design for nucleic acid delivery suffers from the vast potential combinations 
of variables and the complex biological environment in which the carriers are 
employed. Furthermore, recent studies emphasize the need for specialized systems, 
as not every carrier is appropriate for every task and there is an increasing need for 
adaptive polymers which can deal with changing biochemical environments.46,75,89  
Combinatorial chemistry can drastically shorten the development cycles by producing 
a large set of system descriptors (chemical structures, physical properties and 
biological characteristics associated with these structures) which can be used for 
rational vector design. The concept of high throughput combinatorial chemistry was 
introduced to the gene therapy field by the Robert Langer lab, synthesizing a library 
of 2350 single entity poly(ß-amino esters)90 (PAEs). The information derived from this 
library was subsequently used in several applications, for example by Green et al.91 
to construct optimized PAEs for human endothelial cell transfections in high serum 
conditions. Starting with low-molecular weight 0.42 kDa and 1.8 kDa PEI and 24 bi- 
and oligo-acrylate esters, Thomas et al.92 developed a 144-member library. In vitro 
and in vivo screening identified nine effective polymers, of which two showed 
systemic in vivo gene delivery to the lung with reduced toxicity compared to PEI. To 
take full advantage of the potential of such encouraging combinatorial approaches, 
further optimization of polymer chemistry and purification, resulting in libraries of 
monodisperse polymers with defined size and topology, better models to correlate in 
vitro and in vivo efficacy, as well as computational assistance for elucidating 
structure-activity relations will be necessary. One has to emphasize that any high-
throughput screening which only uses standard in vitro test systems would not 
necessarily select candidate vectors with highest in vivo efficacy. 
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2.5 Sequence Defined Polymers Allow Detailed Structure
Relationship Studies
  
For better defined copolymer structures and libraries with defined molecular weight 
and topology,92-95 meaningful structure/transfection correlations are possible. 
However, more detailed studies are not possible, even with such systems, due to the 
limited design space and/or their polydispersity. This limitation may be circumvented 
by alternative chemistry methodologies, including for example dendrimer
synthesis and/or solid-phase synthesis
monodisperse products by control 
Hartmann et al.99-100 adopted standard solid phase chemistry to build up a small 
library of monodisperse, sequence
 
Figure 2.4: Schematic representations of de
(a) Generation 4 dendrimer, consisting of a trivalent core and four layers of bivalent building blocks. 
(b) Modular linear dendritic hybrid, consisting of targeting ligand, linear shielding domain and attache
generation 3 dendron for binding and compaction of nucleic acids. (c) Comparison of classical 
polymerization and solid-phase methodology; classical polymerization results in disperse systems with 
its design space limited to the starting materials. Solid
sequence-specific synthesis of monodisperse polymers with absolute control of position and 
composition of every monomer by sequential elongation of the polymeric chain.
 
98
 (Figure 2.4), which provide defined 
of position and structure of every unit in a polymer. 
-defined poly(amidoamine) (PAA) polymers.
fined, monodisperse polymeric delivery systems.
-phase supported synthesis allows the 
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Defined incorporation of PEG or oligopeptide blocks was possible. Different PEG-
PAA copolymers were synthesized, where the cationic nature of the PAA segments 
was systematically varied. This modulated the structure of the resulting polyplexes, 
ranging from extended ring-like structures to highly compact toroidal structures. 
Importantly, stable single-polynucleotide complexes could be generated, as 
described similarly for sequence-defined synthetic peptide-based block copolymers 
by DeRouchey et al.47 or previous published work for synthetic poly(lysine)-PEG 
conjugates.  
These reports demonstrate the slow shift of the field of polymeric delivery towards 
the increasingly complex systems of bio-responsive, programmable polymers and to 
the application of increasingly sophisticated chemical methods and strategies in the 
development of new carrier systems. 
Introduction   
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2.6 Aims of the Thesis 
 
The innovation speed of small molecule therapeutics decreased in the last years but 
the number of EMEA approved biologicals is on a steady rise for the last 15 years. It 
is only a question of time until the first intracellular targeted therapeutic options will 
arrive on the market. But the success of these concepts is closely connected to the 
development of efficient, reliable, non-toxic carrier systems - without an efficient 
mode of intracellular entry no effective therapeutic can enter the market. A major 
drawback of the established polymeric delivery systems is their heterogeneity in 
terms of molecular weight, the limited freedom in their molecular design and the 
resulting problems for synthesis of defined batches for clinical testing and controlled 
modification of the systems. The sometimes ambiguous results in biological assay 
systems and the lack of information for precise structure-activity relationships 
imposes further restrictions on the development of new carrier systems.  
While numerous literature examples show improvements of polymeric delivery 
efficacy101 most of these approaches rely on chemical modification of polydisperse 
polymer precursors. But due to the heterogenic nature of the starting material every 
modification results in an even more complex product. Aim of the first part of this 
thesis was the simplification and subsequent optimization of an already described 
efficient, modular, brPEI-based delivery system102. This previous delivery system was 
a tetraconjugate, composed of compaction (brPEI 25 kDa), targeting/shielding (EGF 
coupled to 3.2 kDa PEG) and lytic domains (all-D-Melittin). Despite its nucleic acid 
delivery efficiency, synthesis was too complex for further refinement and the overall 
yield was low. By development of a new synthetic strategy and a simplified modular 
setup in the current work we aimed at a better control over the production process 
and increased flexibility for ligand attachment.  
The second aim of the thesis was the development of a solid-phase synthesis 
platform for the rapid synthesis of sequence-defined, polyamine-based cationic 
carrier systems. Novel protected building blocks had to be synthesized and the solid-
phase assembly process to be optimized. Polymers derived with this method by 
nature of the synthetic approach should be monodisperse. The molecular precision of 
the assembly should allow the introduction of multiple chemical modifications which 
are compatible with the specific reaction conditions of the used solid-phase 
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chemistry. These polymers should allow the study of structure-activity relationships 
(SAR) in more detail and offer increased control over the polymer and thereby the 
possibility of fine-tuning their properties.  
The third aim of the thesis was the application of the novel solid-phase assisted 
method in the design and synthesis of precise polymers with nucleic acid carrier 
activity. The synthesized polymers had to be evaluated in biophysical assays (NA 
binding and lytic activty) and in vitro systems (pDNA and siRNA delivery) to construct 
SARs which can be used for further optimization of the polymers. 
Aim of the fourth part of the thesis was the more detailed design and analysis of the 
precise polymers as pDNA transfection agents. By screening them for in vitro 
transfection capabilities and correlating these to their biophysical parameters, first 
useful SARs and promising lead candidates should be identified.  
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3 Materials and Methods 
 
3.1 Chemicals and Reagents 
Fmoc-amino acids and resins (base resins and preloaded resins) were bought from 
IRIS Biotech, Marktredwitz and Novabiochem GmbH, Darmstadt. Pybop® was 
bought from Multisyntech GmbH, Witten. DCM, MeOH, THF were bought from Merck 
and distilled before use. DMSO, EtOH, ACN were bought in the highest quality 
available from Sigma and used without further purification. ACN for RP-
chromatography was HPLC quality and bought from Merck. Water was used as 
purified, deionized water.  
Branched polyethylenimine (PEI; average MW = 25 kDa) and poly(2-ethyl-2-
oxazoline) (PEOZ) 50 kDa, DTT, deuterated solvents and MTT bromide were 
obtained from Sigma-Aldrich (Munich, Germany). All small molecule reagents were 
bought from Sigma-Aldrich unless stated otherwise. PEG derivatives were custom 
synthesized by Rapp Polymere, Tübingen.  
Recombinant murine epidermal growth factor (mEGF) was obtained from Peprotech 
Germany (Hamburg, Germany). Cysteine-modified melittin (Mel) was obtained from 
IRIS Biotech GmbH (Marktredwitz, Germany). Mel had the sequence CIGA VLKV 
LTTG LPAL ISWI KRKR QQ (all-D-configuration), the C-terminal amino acid was 
introduced as carboxylic acid, the N-terminal amino acid as amine.  
Plasmid pEGFPLuc (encoding a fusion of enhanced green fluorescent protein 
(EGFP) and Photinus pyralis luciferase under control of the CMV promoter) was 
produced with the Qiagen Plasmid Giga Kit (Qiagen, Hilden, Germany) according to 
the manufacturer recommendations. 
Ready to use siRNA duplexes were synthesized by Dharmacon(Layafette, USA), 
namely GL3 luciferase duplex: 5′-CUUACGCUGAGUACUUCGAdTdT-3′ (sense), 5'-
UCGAAGUACUCAGCGUAAGdTdT-3' (antisense) and control-siRNA: siCONTROL 3 
5′-AUGUAUUGGCCUGUAUUAGUU-3′(sense),  5′-CUAAUACAGGCCAAUACAUUU-
3' (antisense). 
Cell culture media, antibiotics, and fetal calf serum were purchased from Invitrogen 
(Karlsruhe, Germany). Luciferase cell culture lysis buffer and D-luciferin sodium salt 
were obtained from Promega (Mannheim, Germany). 
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3.2 DMF Purification 
DMF was further purified due to the slow decomposition on storage. To entrap amine 
impurities and residual water 100 g of freshly activated molecular sieve (4 Å pore 
diameter) were added to 1 L of DMF p.a. and the bottle stored in the cold room for 7 
days before use. 
To check for amine impurities a bromophenol assay was performed. 1 mL DMF was 
pipetted into an eppendorf tube and 6 µL of a freshly prepared bromophenol blue 
solution (5 mg/mL) were added. If the color of the solution was not yellow the DMF 
was additionally purified by distillation. 
 
3.3 Quantification Assays 
 
Ellman’s Assay103 
The DTNB working solution contained 60 µl DTNB stock solution and 2440 µl of 
Ellman’s buffer. For a calibration curve cysteine solution with concentrations from 0.0 
to 0.5 µmol/ ml were prepared freshly for each measurement. The cysteine solutions 
were diluted in Ellman’s buffer. A solution with 0.25 µmol/ml of the test substance in 
HBG (pH 7.1), Tris (10 mM, pH 8.0) or acetic acid (10 mM, pH 2) was prepared. For 
the measurement 30 µl of the test substance or of the cysteine solutions were diluted 
in 170 µl DTNB-working solution. After incubating for 15 min at room temperature the 
content of free thiol groups was determined at A412 via calibration curve. 
 
Quantitative Analysis of brPEI104  
The concentration of PEI was measured by TNBS assay. Standard brPEI solutions 
and brPEI containing test solutions were serially diluted in 0.1 M sodium tetraborate 
buffer to a final volume of 100 µl using a 96 well plate, resulting in e.g. brPEI 
concentrations of 10 to 60 µg/ml. To each well 2.5 µl of TNBS (75 nmol, 22 µg; 
diluted in water) were added. After 5 - 20 minutes incubation time at RT (depending 
on the strength of the developed colour) the absorption was measured at 405 nm 
using a microplate reader (Spectrafluor Plus, Tecan Austria GmbH). 
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Quantitative Analysis of LPEI105  
Content of linear PEI in the conjugates after size exclusion chromatography was 
measured performing a copper assay. PEI was mixed with copper (II) ions for 
formation of dark blue cuprammonium complexes. These complexes were detected 
by UV-VIS spectrometry measuring absorption at 285 nm. For this purpose first a 
calibration curve was established. Linear PEI22 was diluted in water to a final volume 
of 100 µl and added to 100 µl of a 2.25 M copper solution, 0.1 M sodium acetate pH 
7.4. Finally the conjugates were diluted, mixed with CuSO4 solution and A285 nm was 
measured. 
 
3.4 Chromatography 
 
3.4.1 Analytical RP-HPLC 
Analytical HPLC runs were done using a Waters HPLC System consisting of a P-900 
gradient pump system and a 996 Photodiode array detector under the control of the 
Millenium software. Analytical columns were either a C18-RP-Phase (Waters 
Symmetry C18, 3.9 x 150 mm) or a C4-RP-Phase (YMC C4, 4.0 x 150 mm). All 
peptides were analyzed using an exploratory Water/ACN (buffered with 0.1% TFA) 
gradient starting at 95:5 reaching 0:100 in 45 min. 
 
3.4.2 Analytical IEX-HPLC 
Analytical IEX-HPLC runs were done on a GE Healthcare ÄKTA Basic system 
consisting of a P-900 dual-pump, a UV-900 three-channel UV-detector and F-950 
fraction collector under the control of the UNICORN software version 4.11. All 
analytical runs were done on a Resource S 1 mL column using a salt gradient 
starting at 5 mM reaching 3 M over 30 min in a 10 mM HCl buffer (pH 1.9) 30% ACN. 
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3.4.3  Desalting  
Desalting was done using a 10/30 G-10 column connected to an Äkta Basic System. 
Procedure for a typical desalting run: 10-30 mg of compound were dissolved in 1 mL 
of a 10 mM HCl buffer (pH 1.9) containing 30% ACN. The sample was applied to the 
column and the major peak (A214,280) collected. 
 
3.4.4 Thin Layer Chromatography (TLC) 
Silica gel coated glass (Merck, silica gel 60 F254) were used for thin layer 
chromatography. Detection methods were UV-detection at 254 nm or different 
staining baths. 
 
Cerium Stain (All Purpose Stain) 
15.0 g of ammonium cerium nitrate ((NH4)2Ce(NO3)6) and 15.0 g of ammonium 
heptamolybdate ((NH4)6Mo7O24) were covered with 270 mL distilled water. After the 
addition of 30 mL concentrated sulfuric acid (98 %) the resulting suspension was 
stirred at 50 °C for 30 min and filtered. 
 
Potassium Permanganate Stain (Oxidative Stain) 
3.0 g KMnO4 and 20.0 g K2CO3 were dissolved in 400 mL of MilliQ Water under 
addition of 2.5 mL of 10 % (w/v) NaOH. 
 
Ninhydrin Stain (Primary Amine Stain) 
0.8 g Ninhydrin p.a were dissolved in 400 mL of a mixture of n-butanol/water/acetic 
acid (100:4.5:0.5). 
 
Iodine Vapor Stain (Oxidative Stain/PEG Stain) 
A sufficient amount of iodine was loaded onto silica gel and stored in a stoppered 
flask. 
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3.4.5 Flash Column Chromatography (FCC) 
Flash chromatography was used like described by Still et al.106. Stationary phase was 
silica gel with a mean diameter of 0.035 – 0.073 mm unless otherwise stated. 
Column height and diameter were chosen in accordance to the general guidelines of 
the published method. 
 
3.4.6 Dry Column Vacuum Chromatography (DCVC) 
Dry column vacuum chromatography was performed like described by Pedersen et 
al.107. A sintered glass funnel (porosity of sinter filter: P3) of appropriate size was 
filled with about 6-7 cm of loose silica (Silica gel 60®, mean diameter 15-40 µm) and 
tapped to give a level surface. Vacuum was applied and the surface was pressed 
firmly to form a well compacted bed. The column was checked for voids and 
channels by pouring n-heptane onto the silica bed while vacuum was applied. The 
bed was covered with a filter paper of appropriate size to prevent disruption of the 
silica bed when charging it.  
The raw product mixture was dissolved in an appropriate amount of a low boiling 
solvent like DCM, methanol or ethyl acetate, and preabsorbed on Celite® 500 fine, 
followed by removal of solvent by evaporation. The loaded Celite® was grinded to a 
fine powder in a mortar and added as a thin, uniform layer on top of the column and 
vacuum was applied to compact the column. The column was then gradient-eluted 
with a suitable solvent system. Mixtures of n-heptane, chloroform, ethyl acetate and 
methanol were used, starting with the least polar solvent mixture, followed by solvent 
fractions typically with 1-10 % increments in the polar component. The fractions with 
a volume of 5-100 ml were monitored by TLC and product containing fractions were 
pooled and concentrated. 
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3.5 Spectroscopy and Spectrometry 
 
3.5.1 NMR Spectroscopy Instrumentation 
The 1H-NMR spectra were recorded using a JNMR-GX 400 (400 MHz) or a JNMR-
GX 500 (500 MHz) unit manufactured by Jeol. The coupling constant had an 
accuracy of 0.3 Hz. Deuterated chloroform or water were used as solvents as well as 
internal standards. The spectra were analyzed using the NMR-software packages 
NUTS (2 D professional version 20020107 by Acron NMR, 2002), MestreNova (Ver. 
5.2.5-4119 by Mestrelab Research) or Delta NMR processing and control software 
(version 4.3.1 by Jeol).  
 
3.5.2 Mass Spectrometry Instrumentation 
 
ESI-MS were measured on a ThermoScientific LTQ-FT Mass Spectrometer or on a 
Bruker Maxis ESI. MALDI-MS analysis was performed on a Bruker Autoflex MALDI-
TOF system. 
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3.6 LPEI-Conjugate Synthesis 
 
3.6.1 Synthesis of LPEI 22 kDa x HCl/Free Base 
Synthesis of LPEI was performed analogous to published procedures108 with 
modifications. Poly(2-ethyl-2-oxazoline) 50 kDa (5 g) were suspended in 50 ml of 
30% hydrochloric acid. The mixture was refluxed for 48 h yielding a fine white 
precipitate. The solid was isolated by filtration and washed four times using 30% HCl 
to remove traces of propionic acid. The resulting LPEI hydrochloride was air-dried 
over night, dissolved in 200 ml distilled water and freeze-dried. Yield: 3.5 g, 85% (1H-
NMR, D2O, 400 MHz: broad singlett 3.5 ppm)  
LPEI hydrochloride (2.5 g) were dissolved in 75 ml of 1 M NaOH at 100 °C. The 
solution was cooled to room temperature and the resulting LPEI precipitate isolated. 
The gel-like precipitate was washed 3 times with 75 ml 1 M NaOH and 5 times with 
75 ml distilled water. The resulting viscous gel was transferred into a round bottom 
flask, shock frosted using liquid nitrogen and lyophilized yielding 1 g (76%) of a white, 
fluffy lyophilizate. 
 
3.6.2 Removal of Low Mw Impurities From LPEI and brPEI 
50 mg of LPEI (hydrochloride) or brPEI (free base) were dissolved in 1 ml water and 
the pH was adjusted to 7.0 using NaOH or HCl respectively. Small molecular weight 
fractions of the polymer were removed by SEC chromatography using a G-25 
preparative grade Sephadex column and a 20 mM HEPES (pH 7.4) buffer for elution. 
The PEI containing fractions were pooled and concentrated. PEI concentrations were 
determined using photometric copper assay (see 3.3) for LPEI, or TNBS-assay (see 
3.3) for brPEI, respectively. 
 
Materials and Methods 
 
 
3.6.3 Synthesis of 3-(Pyridin
 
Dithiopyridine (3.770 g, 17.11 mmol
0.4% (v/v) acetic acid. A solution of 3
737 µL, 1 eq) in 20 mL EtOH abs. and
course of 1 h. After 2 h of stirring the solve
yellowish oil was purified by DCVC using basic 
(diameter 4 cm, h = 7 cm). Column was conditioned with C
using CHCl3/MeOH 8:2 and eluted until the collected fractions w
Product was eluted by including
fractions were pooled and solvent remnants removed by HV treatment for 48 h. 
 
C8H9NO2S2: 1.6436 g (90%). 
 
TLC: Rf = 0.84 (CH2Cl2/EtOH
1H NMR (500 MHz, CD3
3.04 (t, J = 6.9 Hz, 2 H, CH
Harom.), 8.40 (ddd, J = 4.9/1.8/0.9 Hz, 1H, H
MS (ESI); m/z  = 260.0068 [M+ HCOO
 
-2-ylsulfanyl)-propionic acid 
 
 
, 2 eq) was dissolved in 30 mL EtOH abs. 
-mercaptopropionic acid (0.900 g, 8.48 mmol, 
 0.4% acetic acid was added dropwise over the 
nt was evaporated and the resulting 
aluminia as stationary phase 
HCl3, the oil was loaded 
 4% acetic acid in the solvent. Product containing 
Colorless to yellowish oil.  
 = 3:2 + 4 % CH3COOH).  
OD, 19.2°C): δ = 2.71 (t, J = 6.8 Hz, 2 H, C
2COOH), 7.20 – 7.26 (m, 1 H, Harom.), 7.77 
arom.) ppm. 
H]+, 216.0145 [M+H]+ (C8H10O
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H2S),  
– 7.89 (m, 2 H, 
2N132S2). 
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3.6.4 Synthesis of N-Succinimidyl
 
 
3-(Pyridin-2-ylsulfanyl)-propionic acid (1.643 g, 7.634 mmol
dry DCM under nitrogen atmosphere. N
1.1 eq) was added and after complete dissolution DCC (1.7505 g, 8.688 mmol
eq) was added. After 4 h the resulting DCU was filtered off and the solution 
concentrated, yielding a yellowish waxy solid. The solid was 
(ø = 4.5 cm, h = 5 cm, CH
steps), followed by recrystallization from EtOH (50 °C to  
isolated by filtration and the recrystallization solution was concentrate
recrystallized again. 
 
 C12H12N2O4S2: 1.3355 g (56%).
 
TLC: Rf = 0.75 (CH2Cl2/MeOH
 
1H NMR (500 MHz, CDCl3, 22.9°C): 
2 H, SCH2CH2CO), 3.09 –
7.64–7.69 (m, 2 H, Harom.), 8.48
13C NMR (100 MHz, CDCl
COCH2CH2S), 32.9 (t, COCH
Carom.), 150.0 (d, Carom.), 159.3 (s, C
COCH2CH2CO) ppm.  
MS (EI, 70 eV); m/z = 312.0157 [M]
70 eV): [M+] ber. für C12H
312.0312 [M+H]+ 
 
-3-(2-pyridyldithio)-propionate (SPDP)
 
, 1 eq) was dissolved in 
-Hydroxysuccinimide (1.000 
further purified by DCVC 
3Cl/MeOH gradient, 50 mL fractions, MeOH 0
-20 °C). The product was 
 White solid.  
 = 10:1).  
δ = 2.84 (s, 4 H, COCH2CH2CO), 3.04
 3.15 (m, 2 H, SCH2CH2CO), 7.09–7.14 (m, 1 H, H
–8.51 (ddd, J = 4.7/1.3/1.2 Hz, 1 H, H
3, 20.5°C): δ = 25.7 (t, COCH2C
2CH2S), 120.1 (d, Carom.), 121.2 (d, C
arom.), 167.2 (s, COCH2CH
+
, 198.0105 (29), 143.9892, 110.9817. HRMS (EI, 
12N2O4S2, 312.0239; found 312.0194. 
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g, 8.688 mmol, 
, 1.1 
-15%,1% 
d and 
–3.09 (m, 
arom.), 
arom.) ppm.  
H2CO), 31.1 (t, 
arom.), 137.4 (d, 
2S), 169.1 (s, 
MS (ESI); m/z = 
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3.6.5 Synthesis of mEGF-SH 
Mercapto-modified EGF was synthesized analogously as described by Blessing et 
al.109. A solution of 10 mg of EGF (1.65 µmol, recombinant, murine) in 1.0 ml of 20 
mM HEPES buffer pH 7.1 was mixed with a solution of SPDP (5.2 mg, 16.5 µmol) in 
0.5 ml EtOH, resulting in a final concentration of 30% EtOH. After 2 h reaction time 
the resulting EGF-PDP was purified by SEC using a Sephadex G-25 superfine 
column and pH 7.1 HEPES/30% EtOH buffer for elution. The product containing 
fractions were collected and concentrated in a speedvac. Five mg of the resulting 
EGF-PDP in 2.5 ml of 20 mM HEPES pH 7.1 were treated with a 50-fold molar 
excess of DTT for 15 min under argon atmosphere. EGF-SH was purified by SEC on 
a Sephadex G-10 column using 20 mM HEPES pH 7.1 for elution yielding 3.5 mg 
EGF-SH (determined by A280). 
 
3.6.6 Synthesis of LPEI-PEG-OPSS Conjugates 
20 mg of LPEI (free base form, 0.9 µmol) were dissolved in 1 mL of EtOH by shaking 
for 30 min at 30 °C. The use of ethanol as solvent was superior over aqueous buffers 
and various other organic solvents in terms of reproducibility and yield. After 
complete dissolution 2.25 µmol of the appropriate NHS-PEG-OPSS or NHS-PEG in 
DMSO were added and agitated for 3 h. The resulting conjugate was purified using 
ion-exchange chromatography (20 mM HEPES pH 7.1, Elution with 20 mM HEPES 
containing 3 M NaCl) followed by dialysis (MWCO: 10 kDa) against 20 mM HEPES 
pH 7.1. Substitution grade was calculated by A343 after DTT induced 2-Pyridinethione 
release and/or 1H-NMR Analysis. 
 
3.6.7 Attachment of mEGF-SH to LPEI-PEG-OPSS Conjugates 
5 mg of LPEI-PEG-OPSS (corresponding to 0.2 µMol of OPSS) in 20 mM HEPES pH 
7.1 were mixed with a 1.5 molar surplus of mEGF-SH and incubated until A343 
indicated complete turnover. The resulting conjugate was purified using SEC on a 
Sephadex G-25 column and concentrated using a speedvac. Concentration was 
determined by photometric copper assay (see 3.3). 
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3.6.8 Synthesis of brPEI Tetraconjugate (Mel-brPEI-PEG-mEGF) 
EGF-PEG-brPEI-Mel was synthesized like described before102. Briefly, EGF-SH is 
anchored to NHS-PEG3.4k-maleinimide, the resulting EGF-PEG3.4k-NHS-Linker is 
conjugated to brPEI and the resulting conjugate purified by SEC. The construct is 
subsequently modified with  SPDP, purified by SEC and in the last step modified with 
melittin-SH, followed by SEC purification. This resulted in a conjugate with the 
nominal composition of EGF: PEG: brPEI: Mel = 2.5 : 2.5 : 1 : 5 . 
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3.7 Solid-Phase Synthesis
Synthesis of Bis-tfa-
bis(trifluoroacetylaminoethyl
ethylenepentamine Penta
10 g (26.9 mmol, 1 eq) tetraethylenepentamine pentahydrochloride were weighed in 
a 1 L round bottom flask and dissolved in 250
(134.5 mmol, 5 eq) TEA w
cooled down to 0 °C. 6.72 mL (56.3
in DCM (40 mL) and added dropwise over 2 h at 0°C.  The RBF wa s allowed to warm 
to RT after 2 h and was stirred for another hour. Di
107.6 mmol, 4 eq) was dissolved in 40
Afterwards 15 ml of triethylamine
stirred over night.  The organic phase was reduced to approximately 150
washed three times with saturated sodium bicarbonate, 
sodium citrate solution and finally three times with water. The organic phase was 
dried over sodium sulfate and the solvent was evaporated to a yellowish viscous, 
waxy solid. The residue was recrystallised: for this purpose
minimal amount of DCM (37
(65 mL) was added to the boiling DCM till clouding could be observed at the drop
point. The crystallisation solution was stored over night in a refrigerator at 4
crystalline residue was filtered, washed with cooled 
 
C27H45F6N5O8: 15.23 g (83.0
 
1
H NMR (500 MHz, CDCl3, 24.1 °C): 
(m, 16 H, CH2), 7.93 (d, J = 46.5, 0.15 H, NH), 8.21 (d, 
MS (ESI); m/z (%) = 699.3527 [M+NH
 Building blocks 
Tp(boc3) [Di-tert-butyl 5-tert-butoxycarbonyl
)-2,5,8-triazanonan-1,9-dioate] using 
-hydrochloride  
 
 ml DCM/MeOH (2:1). 18.75
ere added and after stirring for 2 - 12 h the
 mmol, 2.1 eq) ethyl trifluoroacetate 
-tert-butyl dicarbonate
 ml DCM and added dropwise over one hour. 
 (107 mmol, 4 eq ) were added and the mixture was 
followed by 
 it was dissolved in the 
 mL) which was heated to reflux. Then slowly 
n-hexane and dried.
 %)  
δ = 1.39–1.48 (m, 27 H, OC(CH
J = 41.3, 0.35 H, NH) ppm. 
4]
+
, 682.3268 [M+H]+  
  
35 
-2,8-
Tetra-
 mL 
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were diluted 
 (23.4 g, 
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n-hexane 
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Synthesis of Bis-tfa-
bis(trifluoroacetylaminoethyl)
Grade (85%) Tetraethylenepentamine
 
12 g (53,8 mmol, 1 eq) of tetraethylenepentamine (TEPA) were weighed in a 1
round bottom flask and dissolved in 500
0 °C. Trifluoroacetic ethyl ester (
in 220 ml DCM and transferred into a dropping funnel. It was added dropwise to the 
cooled mixture in the round bottom flask over 2.5
trifluoroacetic ethyl ester the react
Di-tert-butyl dicarbonate (47
added dropwise over one hour. Afterwards 30
mmol, 4 eq) were added and the mixture was stirr
The organic phase was reduced to approximately 150
with saturated sodium bicarbonate, 
solution and finally three times with water. The organic phase was dried over sodium 
sulfate and the solvent was evaporated to a yellowish viscous, waxy solid. The oily 
residue was re-crystallised: 
boiling DCM (60 ml). Then 
clouding was observed at the drop
over night in a refrigerator at 4
with cooled n-hexane and dried. Yield = 
 
C27H45F6N5O8: 23.1 g (63%)
 
1
H NMR (500 MHz, CDCl3, 24.
(m, 16 H, CH2), 7.93 (d, J = 46.5, 0.15 H, NH), 8.21 (d, 
MS (ESI); m/z (%) = 699.3527 [M+NH
Tp(boc3) [Di-tert-butyl 5-tert-butoxycarbonyl
-2,5,8-triazanonan-1,9-dioate] Using Technical 
 
 
 mL DCM. The mixture was cooled down to 
13.45 ml, 16.05 g, 112.6 mmol, 2.1
 h. After complete addition of the 
ion was stirred for an additional hour at RT.
 g, 215.3 mmol, 4 eq.) was dissolved in 80
 ml of triethylamine
ed over night.  
 mL and washed three times 
followed by three times 5 % sodium citrate 
for this purpose it was dissolved in the minimal amou
n-hexane (~ 140 ml) was added to the boiling DCM till 
-in site. The crystallisation solution was stored 
 °C. The microcrystalline residue was filtered, wash ed 
23.1 g (63%) 
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Synthesis of Tp(boc3) [Di
2,5,8-triazanonan-1,9-dioate]
 
10 g bis-tfa-Tp(boc3) (14.7 mmol, 1 eq) 
3 M aqueous sodium hydroxide
funnel under stirring. After a reaction time
and the aqueous phase was extracted with 3 x 100
phases were dried over sodium sulfate. After evaporation of the solvent and 6
treatment Tp(boc3) was isolated as viscous oil which so
crytallization seeds and storage at 4 °C.
 
C23H47N5O6: 7.201 g (99.8%)
 
1
H NMR (400 MHz, CDCl3, 50.0 °C): 
(bs, 4 H, NH2), 2.79-2.96 (bt, J = 5.1, 4 H, CH
MS (ESI); m/z (%) = 245.6837 [M+2H]
 
-tert-butyl 5-tert-butoxycarbonyl-2,8-
 
 
were suspended in 75 ml ethanol. 100
 (300 mmol, 20 eq) were slowly added via a dropping 
 of 6-20 hours the ethanol
 ml DCM. The pooled organic 
lidified after addition of 
 
 
δ = 1.40–1.50 (m, 27 H, OC(CH
2), 3.21 – 3.41 (m, 12 H, CH
+
, 490.3610 [M+H]+  
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Synthesis of Bis-tfa-Tt(boc
2,5-diazahexan-1,6-dioate
 
 
Triethylentetramine (2.0 g, 13.7 mmol, 2.05 ml, 1 eq) w
A solution of trifluoroacetic ethyl ester (4.09 g, 28.
CH2Cl2 was added dropwise at 0
28.8 mmol, 4.00 ml, 2.1 eq) was added and the reaction was brought to RT, follow
by dropwise addition of a solution of
eq) in 21 ml CH2Cl2. The reaction was stirred overnight and washed 3 x 5% NaHCO3 
solution, 3 x 5% citric acid solution and 3 x water dried over Na2SO4, filtered and 
concentrated. The resulting white solid was recrystallized from DCM/hexanes, 
yielding bis-tfa-Tt(boc2) as a white solid.
 
C20H32F6N4O6: 4.829 g (65%)
 
1H NMR (400 MHz, CDCl3, 50 °C): 
CH2), 7.70 (sbr, 0.66 H, NH), 8.84 (s
MS (ESI); m/z = 556.2572 [M+NH
 
2) [Di-tert-butyl 2,5-bis(trifluoroacetylaminoe
] 
 
as dissolved in 27 ml CH
9 mmol, 3.43 ml, 2.1 eq) in 57 ml 
 °C and stirred for 1 h at 0°C. Triethylamine
 di-tert-butyl dicarbonate (8.9838 g, 41.2 mmol, 3 
 
 
δ = 1.46 (s, 18 H, OC(CH3)3), 3.26
br, 0.67 H, NH) ppm.  
4]+, 539.2312 [M+H]+ 
  
38 
thyl)-
2Cl2. 
 (2.91 g, 
ed 
–3.65 (m, 12 H, 
Materials and Methods 
 
 
Synthesis of Tt(Boc2) [
dioate] 
 
4 g (7.4 mmol, 1 eq) bis-tfa
aqueous sodium hydroxide (
funnel under stirring. After a reaction time of 6
and the aqueous phase was extracted with 3 x 
phases were dried over sodium sulfate. After evaporation of the solvent and 6
treatment Tt(boc2) was isolated as 
 
C16H34N4O4: 1.72 g (66%) 
 
TLC: Rf = 0.23 (CH2Cl2/MeOH
 
1H NMR (400 MHz, CDCl
OC(CH3)3), 2.812 (t, J = 6.2 Hz, 4 H, CH
7.5 Hz, 4 H, CH2) ppm. 
 
13C NMR (125 MHz, CDCl3
41.3 (t, 1 C, CH2), 45.9 (t, 1 C, CH
C, CH2), 80.1 (q, 1 C, C(CH
 
Di-tert-butyl 2,5-bis(aminoethyl)-2,5
 
-Tt(boc2) were suspended in 47 ml EtOH. 
15 mmol, 20 eq) were slowly added via a dropping 
-20 hours the ethanol
50 ml DCM. The pooled organic 
white solid.  
 = 7:3 + 5% Triethylamin). 
3, 19.1 °C): δ = 1.24 (sbr, 4 H, NH2), 1.45 (s, 18 H, 
2), 3.25 (t, J = 6.2 Hz, 4 H, CH
, 21.3 °C): δ = 28.8 (q, 6 C, C(CH3)3), 40.9 (t, 1 C, CH
2), 46.2 (t, 1 C, CH2), 51.0 (t, 1 C, CH
3)3), 80.2 (q, 1 C, C(CH3)3), 156.0 (s, 2 C, C=O) ppm.
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Synthesis of Fmoc-Stp-OH [8,11,14
4,18-dioxo-5,8,11,14,17-pentaza
 
 
4.0 g of Tp(boc3) (8.2 mmol, 1 eq)
75 °C. 0.91 g ( 9 mmol, 1.1 eq
and added dropwise over the course of 2
hour at -75 °C and then for 1 h at RT. 4.19 mL DIPEA (
added to the RBF and the reaction mixture
mmol, 1.5 eq) were dissolved in a mixture of 
was added dropwise to the reaction mixture and stirred over night. The solution was 
concentrated to approximately 100 mL, mixed with 100 mL of DCM and was washed 
5 x with 0.1 M sodium citrate buffer (pH 5.2). The organic phase was dried
NaHCO3, concentrated and purifi
elute fmoc-byproducts, followed by a EtOAc/MeOH gradient.
 
C42H61N5O11: 2.65 g (40%), foamy, off
 
TLC: Rf = 0.63 (CHCl3/MeOH
 
1H-NMR (400 MHz, CDCl3, 19.1 °C): 
7.37 (t, 2H, J=8Hz), 7.27 (t, 2H, J=8Hz)
(m, 16H), 2.57-2.70 (m, 2H)
 
13C-NMR (100 MHz, CDCl
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Tepa), 35 (CH2-Suc), 33 (C
 
MS (ESI); m/z  = 812.4419 [M+H]
-tert-Butoxycarbonyl-20-fluoren
icosanoic acid] 
 were dissolved in 16.5 mL of THF and cooled to 
) of succinic anhydride were dissolved in 22
 h. The reaction was stirred for an additional 
3.1 g, 24.1 
 cooled to 0 °C. 4.128 g Fmoc
ACN/THF (25 mL/ 12 mL). This solution 
ed by DCVC using a n-Heptane/EtO
 
-white solid. 
 = 7:3) 
δ = 7.74 (d, 2H, J=8Hz), 7.56 (d, 2H, J=8Hz)
, 4.40 (m, 2H), 4.20 (t, 1H, J=7Hz
, 2.37-2.56 (m, 2H), 1.45 (s, 27H) ppm. 
3, 19.1 °C): δ =  172 (C=O, Suc), 171 (
-C-Fmoc), 80 (CH-Fmoc), 60 (OCH2-Fmoc), 47, 45 (
H2-Tepa), 28 (CH3-tert-But) ppm. 
+
, 829.4682 [M+NH4]+, 834.4237 [M+Na]
  
40 
-9-yl-19-oxa-
 
-
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 over 
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3.8 Solid-Phase Protocols 
3.8.1 Analytical Procedures 
Fmoc Quantification 
 
Accurately weighed samples of vacuum-dried resin (10 mg, ~ 1 µMol of fmoc) were 
placed in Eppendorf tubes. 1.0 mL 20 % piperidine in DMF was added to each tube. 
The tubes were vortexed briefly and agitated at RT for 1.25 h. At the end of this 
period, the tubes were vortexed and the resin was allowed to settle for approximately 
2 min. Aliquots of 50 µl of the supernatant of each samples, of a positive control 
(fmoc-Lys(boc)-Wang resin) and of a blank (consisting of 20 % piperidine in DMF) 
were diluted to 2 ml with DMF (dilution factor 40; see below). A301 of each UV sample 
(duplicates) was determined against the blank solution. The fmoc substitution 
(mmol/g) was calculated using the following equation: 
 
Substitution grade (mmol/ g) = 1000 × A301
mmg × 7800 × D 
 
A301 is absorbance at 301 nm, m is the mass of the resin, 7800 is the molar extinction 
coefficient in L mol−1 cm−1, D is the dilution factor mentioned above. 
 
Kaiser Test110 
 
Solution A: 5% ninhydrin in EtOH (w/v) 
Solution B: 80% phenol in EtOH (w/v) 
Solution C: KCN in pyridine: 2 mL 0.001 M KCN in 98 mL pyridine 
 
Some beads are transferred into an Eppendorf tube and washed three times with 
DMF and three times with MeOH. 1-2 drops of each solution are added and the tube 
placed into a heating block at 100 °C for 4 min. Fr ee amine residues are indicated by 
intense blue color. 
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Malachite Green Test111 
 
Solution A: 0.025% Malachite Green (w/v) in EtOH abs. 
Solution B: Triethylamine  
 
A couple of beads were transferred from the reaction vessel into an eppendorf tube. 
The beads were washed twice with methanol. 1 ml of Solution A and one drop of 
Solution B were added. After 2 min the beads were washed with ethanol until the 
supernatant was clear. Free carboxylic acid residues are indicated by green colored 
beads. 
 
TNBS Test112 
 
Solution A: 10 % DIPEA in DMF (v/v)  
Solution B: 1% 2,4,6-trinitrobenzenesulfonic acid in MilliQ water (w/v)  
 
A couple of beads were transferred from the reaction vessel into an eppendorf tube. 
The beads were washed thrice with DMF. Three drops of Solution A and B were 
added and the tube incubated for 10 min at RT. Orange color of the beads indicated 
free amines. 
 
3.8.2 General Procedure for 2-Chlorotrityl-Resin Loading 
 
1 g of 2-chlorotrityl chloride resin (Cl-load: 1.6 mmol/g) was weighed into a 50 ml 
peptide reactor. After adding 10 ml dry DCM and swelling for 10 min 1.25 eq (relative 
to desired load) fmoc-AA-OH and 2.4 eq DIPEA were added and the reactor was 
agitated for 1.5 h. The resin was washed four times with DCM and treated with a 
mixture of DCM/MeOH/DIPEA (10 ml/g, 80/15/5, v/v/v) to cap unreacted 2-chlorotrityl 
moieties. This step was repeated once. The resin was washed five times with DCM 
and twice with DMF and was treated twice with 20 % piperidine in DMF for 10/20 min 
to remove the terminal fmoc-protection group. The resin was washed five times with 
DMF, twice with DCM and once with n-hexane and dried over KOH in vacuo.  
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3.8.3 Downsizing of Resin Load for MAP-System Synthesis 
 
0.5 g of Fmoc-Ala-Wang-resin (load = 0.3 to 0.5 mmol/g) were placed in a manual 
reaction vessel and preswelled in DMF for 1 h. The resin was washed once with DMF 
and was covered with 4 mL of DMF. 0.065 mmol (38 mg) Fmoc-Lys(Fmoc)-OH, 
0.065 mmol (34 mg) PyBOP® and 0.065 mmol HOBt (10 mg) were dissolved in 1 mL 
DMF, 0.13 mmol DIPEA (23 µL) were added and the solution transferred into the 
reactor. After 2 h the reactor was drained, washed three times with DMF and 3 times 
with DCM. The resin was resuspended in 10 mL DCM, followed by the addition of 
0.75 mL acetic anhydride and agitated for 1h. Completeness of capping was checked 
by Kaiser test and the resin washed with DCM (4x), DFM (4x), DCM (4x) followed by 
hexanes (2x). The low-load resin was transferred into a glass container and dried 
over night under vacuum. 
 
3.8.4 Solid-Phase Synthesis Cycles 
General synthesis protocol A: Coupling Protocol Hartmann Synthesis99 
Reaction Description V [mL/g res] Repetitions/Time 
0a DCM swell 10 1 x 30 min 
(1)b DMF wash 10 3 x 1 min 
2c 20% Pip/DMF prewash 10 1 x 5 min 
3c 20% Pip/DMF deprotection 10 1 x 20 min 
4c DMF wash 10 5 x 1 min 
5 Anhydride coupling (10 eq) in DMF 10 1 x 30 min 
6d Kaiser/Malachit Green test   
7 20% DIPEA wash 10 2 x 3 min 
8 DMF wash 10 5 x 1 min 
9 Diamine/PyBOP®/HOBt (10 eq) in DMF 10 1 x 30 min 
10d Kaiser/Malachit Green test   
 
aPreswelling of trityl based resins before synthesis start 
bPreswelling of wang based resins before synthesis start 
cOptional, only if fmoc-protected residue on resin 
dIf Malachit Green/Kaiser test does not show completion of coupling reaction 
(>99.5), repeat coupling steps  
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General synthesis protocol B: Coupling Protocol Polyamidoamine/Peptides  
Reaction Description V [mL/g res] Repetitions/Time 
0a DCM swell 10 1 x 30 min 
(1)b DMF wash 10 3 x 1 min 
2 20% Pip/DMF prewash 10 1 x 5 min 
3 20% Pip/DMF deprotection 10 1 x 20 min 
4 DMF wash 10 5 x 1 min 
5 Preactivated Fmoc-AA (4 eq) in DMF 10 1 x 30 min 
6 DMF wash 10 5 x 1 min 
7c Kaiser/TNBS test   
 
aPreswelling of trityl based resins before synthesis start 
bPreswelling of wang based resins before synthesis start 
cIf Kaiser test does not show completion of coupling reaction (>99.5), repeat 4-7 
 
Shrinking Protocol for Long Term Resin Storage 
Reaction Description V [mL/g res] Repetitions/Time 
1 DMF wash 10 5 x 1 min 
2 DCM wash 10 3 x 1 min 
3 n-hexane wash 10 3 x 1 min 
After the last n-hexane wash the resin is predried by suction for 1 min. The damp 
resin is transferred into an container and dried in vacuo over KOH for 24 h. 
 
3.9 General Cleavage Procedures 
 
General Cleavage Procedure A:  Peptides and Non-Oleic Acid Containing PAAs 
The resin was transferred into a syringe reactor of appropriate size and treated with 
10 mL/g(resin) of a TFA/Water/TIS (95:2.5:2.5) mixture for 1-3 h. The resin was filtered 
and washed twice using pure TFA followed by two DCM washes. The combined 
filtrates were concentrated using a rotovap and either precipitated by dropwise 
addition into ice-cold MTBE (50 mL MTBE/1 mL TFA) or other suitable mixtures. If 
precipitation was not possible the TFA was further concentrated to a glassy film and 
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washed 3x with ice-cold MTBE. The precipitate/film was dissolved in 2.5% acetic 
acid, snap-frozen and lyophilized to obtain the crude peptide. 
Cleavage Procedure for Oleic Acid Containing PAAs 
The resin was transferred into a syringe reactor of appropriate size and treated with 
10 mL/g(resin) of a TFA/Water/EDT (95:2.5:2.5) mixture for 1-2 h. The resin was 
filtered off and washed twice using pure TFA followed by two DCM washes. The 
combined filtrates were concentrated in a rotovap and either precipitated by dropwise 
addition into ice-cold MTBE (50 mL MTBE/1 mL TFA) or other suitable mixtures. The 
precipitate was collected by centrifugation. If precipitation was not possible the TFA 
was further concentrated to a glassy film and washed 3x with ice-cold MTBE. The 
precipitate/film was dissolved in 5% acetic acid, snap-frozen and lyophilized to obtain 
the crude peptide. 
 
3.10  General Procedures Solid-Phase Synthesis 
3.10.1  Synthesis of N-Terminal Stp-Modified Peptides 
Peptides were assembled in a fully automatic fashion using fmoc/tBu chemistry on an 
Applied Biosystems 431A Peptide Synthesizer employing the Applied Biosystems 
Small Scale FastMoc® protocols. After successful synthesis the resin was 
transferred to a syringe reactor and was manually modified with Stp-units according 
to general method 3.8.4.B 
 
3.10.2  General Procedure: Synthesis of Stp-Chains 
An amount of resin corresponding to 25-50 µmole of loaded amino acid was weighed 
into a syringe reactor and swelled for 30 min in an appropriate solvent. Briefly, each 
cycle began with fmoc-removal by treatment with 20% piperidine in DMF followed by 
DMF washing steps. Coupling was normally done using a mixture of fmoc-AA-OH/ 
PyBOP®/HOBt/DIPEA (4/4/4/8 eq) for 30 min or until complete conversion was 
indicated by Kaiser test. For a general scheme see Table 3.8.4.B. 
 
Materials and Methods   
 
46 
 
3.10.3  General Procedure: Synthesis of i-Shapes with one FA: HO-K-Stp1-FA1 
After swelling of fmoc-Lys(boc)-Wang resin (0.05-0.20 mmol) in DMF and cleavage 
of the fmoc protecting group, four equivalents of a solution of fmoc-Stp(boc3)-OH in 
DMF, DIPEA (8 eq) and PyBOP®/HOBt (4 eq) were added to the resin and the 
vessel was agitated until Kaiser test indicated complete conversion (30 min). The 
reaction solvent was drained and the resin was washed five times with DMF. To cap 
residual, unreacted primary amino groups before introduction of the fatty acid the 
resin was acetylated using 5 equivalents of acetic anhydride and 10 equivalents of 
DIPEA, before the subsequent removal of the fmoc protecting group.  
After removal of the fmoc protecting group, the resin was washed three times with 
DMF followed by three DCM washes. Five equivalents of fatty acid were dissolved in 
DCM (as concentrated as possible) while 5 equivalents of PyBOP®/HOBt and 10 
equivalents of DIPEA dissolved in the smallest possible volume of DMF were added 
to the resin and the mixture was agitated until Kaiser test did indicate complete 
conversion (normally 30 min). After completion of the reaction the resin was washed 
and dried for 12 h over KOH in vacuo. For cleavage conditions see section 3.9. 
 
3.10.4  General Procedure:  Synthesis of i-Shapes with two FAs: HO-K-Stp1-K-
FA2 
After swelling of fmoc-Lys(boc)-Wang resin (0.05-0.20 mmol) in DMF and cleavage 
of the fmoc protecting group, four equivalents of a solution of fmoc-Stp(boc3)-OH in 
DMF, DIPEA (8 eq) and PyBOP®/HOBt (4 eq) were added to the resin and the 
vessel was agitated until Kaiser test indicated complete conversion (30 min). The 
reaction solvent was drained and the resin was washed five times with DMF. To 
couple two fatty acids to the N-terminus of the PAA, fmoc-Lys(fmoc)-OH was 
incorporated before the coupling of the fatty acid. To cap residual, unreacted primary 
amino groups before introduction of the fatty acid the resin was acetylated using 5 
equivalents of acetic anhydride and 10 equivalents of DIPEA, before subsequent 
removal of the fmoc protecting group. 
The resin was washed three times with DMF followed by three DCM washes after 
removal of the fmoc protecting group. Ten equivalents of the fatty acid were 
dissolved in DCM while 10 equivalents of PyBOP®/HOBt and 20 equivalents of 
DIPEA in the smallest possible amount of DMF were added to the resin and the 
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mixture was agitated until Kaiser test did indicate complete conversion (normally 
30 min). After completion of the reaction the resin was washed and dried for 12 h 
over KOH in vacuo. For cleavage conditions see section 3.9. 
 
3.10.5 General Procedure: Synthesis of i-Shapes with a Single Coupling 
Domain: HO-C-Stp1-K-FA2 
For PAAs containing a C-terminal cysteine fmoc-Cys(trt)-Wang resin was used. All 
other steps of the synthesis were performed as described in General Procedure 
3.10.3.  For cleavage conditions see section 3.9. 
 
3.10.6 General Procedure:  Synthesis of i-Shapes with Two Coupling Domains: 
HO-C-Stp3-C-K-FA2 
After swelling 0.035 mmol of a fmoc-Cys(trt)-Wang resin in DMF and cleavage of the 
fmoc protecting group, four equivalents of a solution of fmoc-Stp(boc3)-OH in DMF, 
DIPEA (8 eq) and PyBOP®/HOBt (4 eq) were added to the resin and the vessel was 
agitated until Kaiser test indicated complete conversion (normally 30 min). The 
reaction solvent was drained and the resin was washed five times with DMF. This 
cycle was repeated twice. Afterwards the amino acid fmoc-Cys(trt)-OH was coupled. 
Then, in order to couple two fatty acids to the linear PAA, fmoc-Lys(fmoc)-OH was 
incorporated N-terminal before the coupling of the fatty acid. To cap unreacted 
primary amino groups, the resin was acetylated using 5 equivalents of acetic 
anhydride and 10 equivalents of DIPEA, before the subsequent removal of the fmoc 
protecting group. To couple the fatty acid, the solvent was changed to DCM after 
fmoc cleavage. Therefore, after removal of the fmoc protecting group, the resin was 
washed three times with DMF and DCM. 10 equivalents of the fatty acid were 
dissolved in DCM, 20 equivalents of DIPEA and 20 equivalents of PyBOP®/HOBt in 
DMF were added to the resin and the mixture was agitated for 30 min. After 
completion of the reaction the resin was washed and dried over KOH in vacuo. For 
cleavage conditions see section 3.9. 
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3.10.7 Synthesis of t-Shapes with One FA: HO-C-Stp1-K(FA)-Stp1-C-H 
After swelling 0.05-0.20 mmol of fmoc-Cys(trt)-Wang resin in DMF for 30 min the 
fmoc-protection group was cleaved by double treatment with 20% piperidine in DMF. 
After washing the resin, four equivalents (related to resin loading) of fmoc-Stp(boc3)-
OH, DIPEA (8 eq) and PyBOP®/ HOBt (4 eq) were added for 30 min. The reaction 
solvent was drained and the resin was washed five times with DMF. Reaction 
progress was monitored by Kaiser test. To introduce a branching point dde-
Lys(fmoc)-OH was used in the next coupling step. Dde-Lys(fmoc)-OH (4 eq) solved 
in DMF, DIPEA (8 eq) and PyBOP®/HOBt (4 eq) solved in DMF were added and the 
synthesis vessel was agitated for 30 min. After a negative Kaiser test, the resin was 
washed with DMF. To cap unreacted primary amino groups, the resin was acetylated 
using 5 equivalents of acetic anhydride and 10 equivalents of DIPEA, before the 
subsequent removal of the fmoc protecting group. To couple the fatty acid, the 
solvent was changed to DCM after fmoc-cleavage. Therefore the resin was washed 
three times with DMF and DCM after removal of the fmoc-protecting group. 5 
equivalents of the fatty acid solved in DCM, 10 equivalents of DIPEA and 5 
equivalents of PyBOP®/HOBt were added to the resin for 30 min. After completion of 
the reaction the resin was washed five times with DCM and three times with DMF.  
The dde-protecting group was cleaved with 2% hydrazine monohydrate in DMF (v/v) 
(5-10 times for 5 min) till no significant A300 was measurable in the deprotection 
mixture. In-between the deprotection-steps the resin was washed twice with DMF. 
fmoc-Stp(boc3)-OH solved in DMF, DIPEA (8 eq) and PyBOP®/HOBt (4 eq) were 
added for 30 min. After a successful reaction the resin was treated twice with 20% 
piperidine in DMF. After washing the resin, boc-Cys(trt)-OH (4 eq) solved in DMF, 
DIPEA (8 eq) and PyBOP®/HOBt (4 eq) were added and the vessel agitated for 
30 min. Afterwards the resin was washed and dried over KOH in vacuo. For cleavage 
conditions see section 3.9. 
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3.10.8 Synthesis of t-Shapes with Two FAs: HO-C-Stp1-K(K-FA2)-Stp1-C-H 
After swelling 0.05-0.20 mmol of fmoc-Cys(trt)-Wang resin in DMF for 30 min the 
fmoc-protection group was cleaved by double treatment with 20 % piperidine in DMF. 
After washing the resin, four equivalents (related to resin loading) of fmoc-Stp(boc3)-
OH, DIPEA (8 eq) and PyBOP®/HOBt (4 eq) were added for 30 min. The reaction 
solvent was drained and the resin was washed five times with DMF. Reaction 
progress was monitored by Kaiser test. To introduce a branching point dde-
Lys(fmoc)-OH was used in the next coupling step. Dde-Lys(fmoc)-OH (4 eq) solved 
in DMF, DIPEA (8 eq) and PyBOP®/HOBt (4 eq) solved in DMF were added and the 
synthesis vessel was agitated for 30 min. After a negative Kaiser test, the resin was 
washed with DMF. After treatment with 20 % piperidine in DMF and washing the 
resin with DMF, fmoc-Lys(fmoc)-OH (4 eq), DIPEA (8 eq) and PyBOP®)/HOBt (4 eq) 
was added. In order to cap unreacted primary amino groups, the resin was 
acetylated using 5 equivalents of acetic anhydride and 10 equivalents of DIPEA, 
before the subsequent removal of the fmoc protecting group. To couple the fatty acid, 
the solvent was changed to DCM after fmoc-cleavage. Therefore the resin was 
washed three times with DMF and DCM after removal of the fmoc-protecting group. 
10 equivalents of the fatty acid solved in the minimal amount of DCM, 20 equivalents 
of DIPEA and 10 equivalents of PyBOP®/HOBt were added to the resin for 30 min. 
After completion of the reaction the resin was washed five times with DCM and three 
times with DMF.  
The dde-protecting group was cleaved with 2% hydrazine monohydrate in DMF (v/v) 
(5-10 times for 5 min) till no significant A300 was measurable in the deprotection 
mixture. In-between the deprotection-steps the resin was washed twice with DMF. 
fmoc-Stp(boc3)-OH solved in DMF, DIPEA (8 eq) and PyBOP®/HOBt (4 eq) were 
added for 30 min. After successful reaction the resin was treated twice with 20 % 
piperidine in DMF. After washing the resin, boc-Cys(trt)-OH (4 eq) solved in DMF, 
DIPEA (8 eq) and PyBOP(R)/ HOBt (4 eq) were added for 30 min. Afterwards the 
resin was washed and dried over KOH in vacuo. For cleavage conditions see section 
3.9. 
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3.11  Biophysical and Biological Methods 
3.11.1 Polyplex Formation 
DNA Polyplex Formation Using PEI-based Carriers 
Polyplex formulations for DNA delivery were prepared as follows: 200 ng of DNA/well 
and the calculated amount of polymer were diluted in the same volume of HBG (pH 
7.1) using separate tubes. The DNA solution was added to the polymer, rapidly 
mixed by pipetting and incubated for 30-40 min at RT to form the polyplexes 
necessary for transfection and gel-shift experiments. 
 
poly(I:C)/poly(I) Polyplex Formation Using PEI-based Carriers 
Polyplex formulations for p(I:C)/p(I) delivery were prepared as follows: the indicated 
amount of p(I:C)/p(I) and the calculated amount of polymer were diluted in the same 
volume of HBG (pH 7.1) using separate tubes. The RNA solution was added to the 
polymer, rapidly mixed by pipetting up and down and incubated for 30-40 min at RT 
to form the polyplexes necessary for transfection and gel-shift experiments. 
 
siRNA Polyplex Formation Using PAA-based Carriers 
Polyplex formulations for siRNA delivery were prepared as follows: 500 ng of 
siRNA/well and the calculated amount of PAA were diluted in separate tubes in HBG 
pH 8.3. The RNA solution was added to the polycations solution, mixed by pipetting 
and incubated for 30-40 min at RT in order to form the polyplexes necessary for 
transfection and gel-shift experiments. 
 
DNA Polyplex Formation Using PAA-based Carriers  
Polyplex formulations for DNA delivery were prepared as follows: 200 ng of DNA/well 
and the calculated amount of PAA were diluted in separate tubes in HBG pH 8.3. The 
DNA solution was added to the polycations solution, mixed by pipetting and 
incubated for 30-40 min at RT in order to form the polyplexes necessary for 
transfection and gel-shift experiments. 
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3.11.2 Size and Zetapotential Measurements 
Particle size of siRNA and DNA formulations was measured by laser-light scattering 
using a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, U.K.). Polyplexes 
were formed for 30-40 min at RT, containing 10 µg nucleic acid and the 
corresponding amount of polymer. For measurement of zetapotential polyplexes 
were diluted with 1 mM NaCl to give a final volume of 1 ml and a nucleic acid 
concentration of 10 µg/ml. The polyplexes were diluted to 500 µl with HBG or H2O 
before measurement. 
 
3.11.3 Gel-Shift Assays 
DNA Gel-shift Assay 
A 1% agarose gel was prepared by dissolving 1.2 g agarose in 120 ml TBE buffer 
and heating the mixture to 100 °C. After cooling do wn to approximately 50 °C, 120 µl 
Gel-Red (1 mg/mL) were added and the gel was poured in the casting unit. Polyplex-
samples containing 100 ng DNA, polymer, HBG-buffer and loading buffer were 
placed into the pockets after an incubation time of 30 min at RT. Electrophoresis was 
performed at 120 V for 80 min. 
 
siRNA Gel-shift Assay 
A 2.5% agarose gel was prepared by dissolving 3.0 g agarose in 120 ml TBE buffer 
and heating the mixture to 100 °C. After cooling do wn to approximately 50 °C, 120 µL 
Gel-Red (1 mg/mL) were added and the gel was poured in the casting unit. Polyplex-
samples containing 500 ng siRNA, polymer, HBG-buffer and loading buffer were 
placed into the pockets after an incubation time of 30 min at RT. Electrophoresis was 
performed at 120 V for 40 min. 
 
Polyplex Dissociation Assay 
The agarose gels were prepared as described above. The polyplexes contained 
either 100 ng DNA or 500 ng siRNA and polymer in HBG-buffer. To inhibit 
electrostatic interactions between the nucleic acid and the polycation, the polyplex 
samples were incubated with heparin (0.01-0.5 I.U./ 0.5 µg siRNA or 0.1 µg DNA) for 
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5 min. After adding loading buffer the samples were placed into the gel-pockets. 
Electrophoresis was performed at 120 V for 40 min (siRNA)/ 80 min (DNA). 
 
3.11.4 Erythrocyte Leakage Assay 
Freshly collected, citrate buffered murine blood was washed by four centrifugation 
cycles, each in phosphate-buffered saline (PBS) at 2000 rpm (600-800 g) at 4 °C for 
10 min. The erythrocytes in the pellet were counted. The pellet was then diluted with 
different PBS buffers (pH 7.4, 6.5 and 5.5) to 5 x 107 erythrocytes/mL. The 
suspension was always freshly prepared and used within 24 h. 75 µl of the PAA 
solutions prepared at different concentration and different pH-values were mixed with 
75 µl erythrocyte suspension in a 96-well plate (NUNC, V-bottom, Denmark). After 
incubating the plates under constant shaking at 37 °C for 60 min, intact blood cells 
and cell debris was removed by centrifugation (4 °C , 600-800 g (2000 rpm), 10 min). 
80 µl of the supernatant was transferred to a new 96-well plate (TPP 96F, 
Trasadingen, Switzerland). Hemoglobin absorption was determined at 405 nm using 
a microplate reader (Spectrafluor Plus, Tecan Austria GmbH, Grödig, Austria). PBS-
buffers with pH-values of 7.4, 6.5 and 5.5 were used as negative control, 1 % 
TritonX-100 in PBS as positive control. Relative hemolysis was defined as   
%[haemolysis]= A405(PAA)-A405(Buffer)A405(TritonX-100)-A405(Buffer) × 100 
 
3.11.5 Cell Viability Assay (MTT Assay)  
The metabolic activity of the cells was determined using a methylthiazole tetrazolium 
(MTT)113 assay as follows: 10 µL per 100 µL of medium of a 5 mg/mL solution of MTT 
in sterile PBS-buffer was added to each well of the 96-well plate. After incubation for 
1-2 h at 37 °C the medium was removed and the cells  were frozen at -80 °C for at 
least 1 h. 200 µl DMSO were added and the samples were incubated under constant 
shaking at 37 °C for 30 min to dissolve the crystal s completely. The optical 
absorbance was measured at 590 nm with a reference wavelength of 630 nm using a 
microplate reader (Spectrafluor Plus,Tecan Autstria GmbH, Grödig, Austria). The cell 
viability was defined as percent:  
%[viability]= A590(treated)A590(untreated control) × 100 
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3.11.6 Luciferase Gene Silencing 
All experiments were performed in stably transfected Neuro2A-eGFPLuc cells. Cells 
were seeded in 96-well plates (TPP, Trasadingen, Switzerland) using 5000 cells/well 
24 h prior to transfection. Transfection complexes containing siRNA were then added 
to cells in 100 µl culture medium containing 10% serum, 100 U/ml penicillin and 100 
µg/ml streptomycin (final siRNA-concentration 367 nM). 48 h after initial transfection 
medium was removed and cells were lysed in 50 µl 0.5X Promega cell lysis solution 
to measure the gene expression as described below. Transfections were performed 
in parallel using a non-specific control siRNA to distinguish between specific gene 
silencing and unspecific knockdown of protein expression due to carrier toxicity. 
Qualitative information on the toxicity of the conjugates was obtained by diminution in 
luciferase expression upon delivery of the non-specific control siRNA compared to 
the luciferase expression from the same number of untreated control cells. 
 
3.11.7 Luciferase Reporter Gene Expression 
Cells were plated in 96 well plates at a density of 10.000 cells per well 24 h prior to 
transfection. The polyplexes formed using 200 ng of pDNA/well were added to the 
cells in 100 µl culture medium containing 10% serum, 100 U/ml penicillin and 100 
µg/ml streptomycin. 24 h after initial transfection medium was removed and cells 
were lysed in 50 µl 0.5X Promega cell lysis solution to measure the gene expression. 
Luciferase activity was measured using a Lumat LB9507 instrument (Berthold, Bad 
Wildbad, Germany). Luciferase light units were recorded from an 20 µl aliquot of the 
cell lysate with 10 s integration time after automatic injection of freshly prepared 
luciferin using the luciferase assay system (LAR, Promega, Mannheim, Germany). 
Transfection efficiency was evaluated as relative light units (RLU) per number of 
seeded cells. Two ng of recombinant luciferase (Promega, Mannheim, Germany) 
corresponded to 107 light units. 
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3.11.8 poly(I:C) Cell Culture and Cell Killing Assay in vitro 
U87MG and U87MGwtEGFR human glioblastoma cells were cultured on collagen 
coated flasks in DMEM (1 g of glucose/L) supplemented with 10% fetal calf serum 
(v/v) and 1% penicillin/streptomycin (v/v). U87MGwtEGFR were maintained under 
constant G-418 selection pressure. Always two parallel polyplex series were carried 
out in separate 96-well plates (TPP, Transadingen, Switzerland), one for the 
determination of cell killing efficacy of poly(I:C) polyplex formulations, and one for the 
determination of cytotoxicity using analogous polyplexes of poly(I) as control. Cells 
were seeded 24 h prior to transfection with a density of 1 × 104 cells in 200 µl of 
culture medium per well. Immediately before transfection, medium was removed and 
100 µl of a dilution of transfection complexes in serum-containing culture medium 
were added to the cells. After 4 h of incubation at 37 °C, polyplex containing medium 
was replaced by 200 µl of fresh serum-containing medium. All experiments were 
performed in triplicates. Cell killing was evaluated 48 h after treatment by 
methylthiazole tetrazolium (MTT)/thiazolyl blue assay as described113. Optical 
absorbance was measured at 590 nm (reference wavelength 630 nm) using a micro 
plate reader (Spectrafluor Plus, Tecan Austria GmbH, Grödig, Austria). Metabolic 
activity was expressed relative to the metabolic activity of untreated control cells, 
defined as 100%. 
A431 cells were cultured on collagen coated flasks in DMEM (1 g of glucose/L) 
supplemented with 10% fetal calf serum (v/v) and 1% penicillin/streptomycin (v/v). 
Two parallel polyplex series were carried out, one for the determination of cell killing 
efficacy of poly(I:C) polyplex formulations, and one for the determination of 
cytotoxicity using analogous polyplexes of polyglutamate (poly(Glu)) as control. Cells 
were seeded 24 h prior to transfection with a density of 4 × 103 cells in 200 µl of 
culture medium per well. Immediately before transfection, medium was removed and 
100 µl of a dilution of transfection complexes in serum-containing culture medium 
were added to the cells. After 4 h of incubation at 37 °C, 100 µl of fresh serum-
containing medium were added. All experiments were performed in duplicates. Cell 
killing was evaluated by methylthiazole tetrazolium (MTT)/thiazolyl blue assay as 
described above. 
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3.11.9 poly(I:C) in vivo Study 
In vivo anti-tumor activity of EGFR targeted poly(I:C) PEI polyplexes was measured 
using subcutaneous A431 mouse xenografts. Before the experiment, human 
epidermoid carcinoma A431 cells were cultured in DMEM supplemented with 10% 
fetal calf serum (v/v) and 1% penicillin/streptomycin. Two million A431 cells were 
dissolved in 200 µl PBS and injected subcutaneously into the right flank of immune 
compromised female athymic nude mice (Nude-Hsd, 5 weeks old). Volume of the 
growing tumors was calculated as follows: V=LW2/2 (L=length, W=width). When the 
tumors reached average volume of 100 mm3, mice were randomly divided into five 
groups (5 mice per group), and treatment was initiated. The complexes were 
delivered by intravenous injection every 48 hrs for 2 weeks. The first group received 
poly(I:C)/Melittin-PEI25-PEG-EGF (p(I:C)/MPPE) polyplexes in HBG buffer at 0.1 µg 
poly(I:C)/µl buffer (the total dose of poly(I:C) was 10 µg/injection). The second group 
received poly(I:C)/LPEI-PEG-EGF (poly(I:C)/PPE) polyplexes in HBG at the same 
dose and concentration. The control groups (poly(Glu)/MPPE and poly(Glu)/PPE) 
were treated with the same doses of polymer conjugates but replacing poly(I:C) by 
polyglutamate poly(Glu). The fifth group did not receive any treatment. Tumor volume 
was measured twice a week until day 14. 
 
3.12  Statistical Analysis 
Results were expressed as a mean ±standard deviation (SD). One-way analysis of 
variance (ANOVA) was used for evaluating statistical significance. Statistical analysis 
was performed with GraphPad Prism 5.0. Statistical significance was set when P< 
0.05. 
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4.1 Poly(I:C) Mediated Tumor Growth Suppression in EGF-receptor 
Overexpressing Tumors Using EGF-Polyethylene Glycol - Linear 
Polyethylenimine as Carrier 
 
4.1.1 Introduction 
The rapid progress in cancer therapy over the last years led to the identification of 
new therapeutic targets, the introduction of new therapeutic technologies like 
antibody or siRNA treatment and the implementation of personalized treatment 
regimes in therapy. But despite the effort invested in these new approaches, classical 
chemotherapeutic agents such as doxorubicin or cisplatin are still widely employed in 
clinics. The inherent drawbacks of these therapeutic approaches are the sometimes 
severe side effects and the intrinsic or acquired resistance of cancer cells towards 
the therapeutic drug. In an ideal therapeutic regime the cancer cells are effectively 
destroyed by the drug without harming the surrounding cells. This can be achieved 
by drug-targeting or by targeting cancer-specific cellular pathways.  
Hence new, promising nucleic acid based therapeutic concepts like antisense 
therapy or the application of siRNA have moved into the focus of scientific interest. 
But the application of gene or oligonucleotide based approaches has its own pitfalls, 
namely the identification of therapeutic target proteins and the specific delivery of the 
appropriate nucleic acid into the cancer cells. Especially the delivery is challenging 
as nucleic acids need lipid-based or polymer-based carrier systems114-121 which 
protect them in the extracellular environment, effectively transport them to the 
effector site and facilitate their release into the cytosol. 
To circumvent acquired chemoresistance of tumor cells and to increase the 
therapeutic efficacy, a triple effector strategy has been developed, combining 
targeted delivery, apoptosis induction and the immunostimulatory properties of the 
artificial dsRNA poly(I:C)102. By targeting the EGF receptor which is overexpressed in 
a variety of tumors a better uptake of poly(I:C) into target cells is possible, followed 
by interferon induction and apoptosis. Intratumoral application of poly(I:C)/cationic 
polymer complexes (polyplexes) in an orthotopic glioblastoma model or two other 
EGF receptor overexpressing tumor models caused complete tumor regression in 
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nude mice. These very promising therapeutic results were based on poly(I:C) 
polyplexes with a tetra-component conjugate, consisting of 25kDa branched 
polyethyleneimine (brPEI), EGF as targeting ligand and polyethylene glycol (PEG) for 
shielding109,122, and a synthetic derivative of the lytic peptide melittin123-124. The latter 
was found to be strictly required for cytosolic delivery of poly(I:C) and therapeutic 
efficacy. Though effective, the tetraconjugate is not practical for further development 
due to its complexity. In the current communication we report the synthesis of an 
improved EGF/PEI based carrier with reduced complexity. The chemically poorly 
defined brPEI was replaced by the analogous linear 22 kDa polymer (LPEI). LPEI 
can be synthesized in GMP compatible form125, has already been tested in human 
clinical trials as DNA formulation, and was found to be more effective as brPEI in 
several applications126-128. The generation of a melittin-free conjugate was possible 
by selecting an optimized PEG/PEI ratio (equimolar amounts using 2 kDa PEG). The 
newly developed LPEI based poly(I:C)-carrier system exhibits the key features of the 
old tetraconjugate, namely EGF receptor targeting and effective payload release into 
the cytosol of tumor cells. The new conjugate shows an improved therapeutic 
efficiency combined with a simpler synthesis route, allowing the convenient synthesis 
of larger amounts of the carrier. 
 
4.1.2 Synthesis of LPEI-PEG Conjugates 
A comparison of the chemical syntheses of the LPEI triconjugate and the brPEI 
tetraconjugate is presented in Figure 4.1. LPEI-PEG-EGF conjugates were 
synthesized by a two step procedure. In the first step NHS-PEG-OPSS is anchored 
to LPEI via its amine reactive NHS function using EtOH as solvent. The resulting 
PEGylated carrier can now be modified using any thiol containing ligand using an 
orthogonal disulfide exchange reaction which can be spectroscopically monitored. 
The brPEI tetraconjugate (EGF-PEG-brPEI-Mel) synthesis (performed by Wolfgang 
Rödl, Wagner lab) consists of four consecutive reaction steps with intermediate 
purification. In the first step EGF-SH is conjugated to NHS-PEG3.4 kDa-maleimide, 
which is subsequently grafted to brPEI. This conjugate is subsequently modified with 
SPDP, purified and in the last step modified with melittin-SH. 
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Figure 4.1: Overview of the synthetic strategies for A) EGF-PEG-LPEI triconjugates B) EGF-
PEG-brPEI-Mel tetraconjugates. 
 
Conjugate PEG/PEI 
ratio 
EGF/PEI 
ratio 
Mel/PEI 
ratio Linker  
brPEI - - - - 
LPEI - - - - 
LPEI-PEG10kDa 1.4 0 - - 
LPEI-PEG5kDa 1.2 0 - - 
LPEI-PEG2kDa 0.9 0 - - 
LPEI-PEG10kDa-EGF 1.4 1.4 - S-S 
LPEI-PEG5kDa-EGF 1.2 1.2 - S-S 
LPEI-PEG2kDa-EGF 0.9 0.9 - S-S 
Mel-brPEI-PEG3kDa-EGF 2.5 2.5 5 Maleimide 
Table 4.1: Comparison of the composition of the conjugates. 
 
4.1.3 Polyplex Formation and Biophysical Characterization 
The biophysical characteristics of the different conjugates were determined by zeta 
potential and particle size analysis (Table 4.2). Polyplexes prepared by complexation 
of unmodified PEIs result in well compacted particles (size ~ 120 nm) characterized 
by relatively high zeta potentials of ≥ +30 mV. The introduction of a PEG shielding 
domain leads to significant drop of zeta potential. This was more pronounced for the 
modification with 10 kDa PEG than for 2 kDa PEG (+11 vs. +24 mV) or 5 kDa PEG 
(+14 mV). The attachment of EGF leads to a slight increase in zeta potential for 
polyplexes with all PEGylated PEIs (+17 mV vs. +27 mV vs. +20 mV). 
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The brPEI tetraconjugate shows a very low zeta potential (+4 mV) and a larger, less 
uniform diameter (233 ± 122 nm), most probably resulting from the massive 
modifications of the brPEI backbone (Table 4.2). The results are also consistent with 
the fact that the brPEI conjugate was modified with approximately 2.5 molar 
equivalents of PEG3.4kDa-EGF chains, as opposed to about one PEG-EGF for the 
other three conjugates.  
The poly(I:C) binding capabilities of the conjugates were comparable as determined 
in an agarose gel-shift assay (Appendix 8.4). A heparin displacement assay 
(Appendix 8.4) revealed small differences between the different polymers. Most 
significant, a slightly weaker binding of poly(I:C) was found with LPEI (and LPEI 
conjugates) as opposed to branched brPEI (and the brPEI tetraconjugate). This 
might have a positive impact on poly(I:C) delivery and intracellular release (see 
below, next section). PEGylation of LPEI with 2 kDa PEG did not alter poly(I:C) 
binding, but modification with 10kDa PEG further weakened poly(I:C) binding. The 
effect of PEGylation however was far less pronounced than the influence of the 
cationic polymer carrier (LPEI vs. brPEI). 
 
# Conjugate Zeta potential [mV] Size [nm] 
1 brPEI 30.0 ± 1.6 120.1 ± 1.1 
2 LPEI 31.8 ± 0.8 122.9 ± 2.1 
3 LPEI-PEG10kDa 11.1 ± 0.5 114 ± 3.0 
4 LPEI-PEG5kDa 14.2 ± 1.3 137.8 ± 2.1 
5 LPEI-PEG2kDa 23.9 ± 2.7 121.6 ± 1.9 
6 LPEI-PEG10kDa-EGF 16.9 ± 1.4 143.9 ± 33.4 
7 LPEI-PEG5kDa-EGF 19.5 ± 0.6 210.5 ± 2.9 
8 LPEI-PEG2kDa-EGF 27.3 ± 2.3 210.4 ± 4.1 
9 Mel-brPEI-PEG3.4K-EGF 3.5 ± 0.9 233.0 ± 122.0 
Table 4.2: Biophysical characterization of the poly(I:C) polyplexes.  
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4.1.4 In vitro Antitumoral Activity of poly(I:C) Polyplexes 
Poly(I:C) delivery properties were determined by a cytotoxicity assay using the 
poly(I:C) sensitive EGF-R overexpressing glioblastoma cell line U87MGwtEGFR. To 
differentiate between poly(I:C) induced cell death and a potential carrier toxicity, 
single stranded poly(I) was used as control, as it is reported that the single-strand 
RNA does not induce apoptosis129-130. 
 
Plain PEI/poly(I:C) polyplexes 
To evaluate the suitability of LPEI as a better defined carrier backbone in poly(I:C) 
delivery, plain LPEI was compared to brPEI without any further modification of the 
polymers. In the tested poly(I:C) concentration range of 0.25 – 2.5 µg/ml, brPEI/ 
poly(I:C) polyplexes showed no effect on the viability of U87MGwtEGFR cells 
(Figure 4.2 top right panel). LPEI demonstrates a superior delivery efficiency at 
concentrations as low as 0.25 µg/ml, but this is accompanied by a fast shift into 
unspecific cytotoxicity beginning at 1 µg/ml (Figure 4.2 top left panel). For DNA 
transfections routinely a concentration of 0.8 µg/ml is well tolerated with only 
moderate toxicity, indicating a LPEI independent toxicity mechanism. This effect 
severely limits the use of unmodified LPEI because of unspecific uptake and a small 
therapeutic window. 
The extent of the far higher potency of LPEI compared to brPEI is surprising, but 
consistent with previous findings for DNA delivery, for example127,131. A better 
reversibility of nucleic acid complexation (see also section above) is hypothesized as 
key issue. Itaka et al.131 reported on an enhanced intracellular disassembly of LPEI 
as compared to brPEI DNA polyplexes by intracellular FRET experiments. 
Intracellular cytosolic release appears to be a critical requirement also for 
accessibility of poly(I:C). 
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Figure 4.2: In vitro antitumoral activity of poly(I:C) polyplexes against U87MGwtEGFR glioma 
cells. Comparison of brPEI versus LPEI (top panels), LPEI
PEG2kDa (left panels), and receptor
PEG5kDa-EGF and LPEI-PEG
ineffective conjugates and effective conjugates. For each dosage the same dose of poly(I) polyplexes 
served as negative control. 
-PEG10kDa versus LPEI
-targeted conjugates LPEI-PEG10kDa
2kDa-EGF (right panels). Please note the different dosages for 
  
61 
 
-PEG5kDa and 
-EGF versus LPEI-
Results   
 
62 
 
PEGylated PEI/ poly(I:C) polyplexes 
Various groups described the beneficial role of PEGylation on cytotoxicity of PEI 
polyplexes, but the grafting of PEG chains onto PEI may also be accompanied by a 
drop in delivery performance. This has been demonstrated for plasmid DNA 
delivery46,132-137, the situation may however be different in case of siRNA delivery138. 
Therefore, to evaluate the optimal PEG molecular weight for poly(I:C) delivery, 
PEG10kDa, PEG5kDa and PEG2kDa were grafted onto the brPEI or LPEI backbone. 
Figure 4.2 left panels show a huge impact of PEGylation of LPEI on the delivery 
efficiency. The attachment of a single PEG10kDa chain to LPEI renders the 
conjugate inactive. At concentration of 2.5 µg/ml of poly(I:C) or even higher (5 - 10 
µg/ml, Appendix 8.4) no significant cell killing is observed. Modification with 
PEG2kDa or PEG5kDa reduces the efficacy and cytotoxicity profile of the 
corresponding poly(I:C) polyplexes (Figure 4.2 left panels) considerably. 
 
Targeted EGF-containing PEGylated PEI/poly(I:C) polyplexes 
To evaluate the influence of a targeting ligand onto the delivery efficiency of the 
LPEI-PEG-conjugates, murine EGF was attached at the distal end of the 2 kDa, 5 
kDa or 10 kDa PEG spacer. The conjugates were tested as poly(I:C) polyplexes for 
their cell killing activity (Figure 4.2 right panels). As expected, introduction of the 
targeting ligand improved the activity of the PEG2kDa - LPEI conjugate, leading to an 
increased activity at lower concentrations with more than 60% cell killing at 1 µg/ml 
(Figure 4.2 bottom right panel). Cell killing was even more pronounced at 2.5 µg/ml, 
but poly(I) control polyplexes also triggered some killing. Interestingly, the 
incorporation of EGF into the PEG10kDa - LPEI conjugate did not recover any 
significant cytotoxic activity of the LPEI-PEG10kDa-EGF polyplexes (Figure 4.2 right 
upper panel), even at a higher dose of 5 µg/ml (Appendix 8.4). The LPEI-PEG5kDa-
EGF conjugate mediated specific poly(I:C) cell killing, but only at the higher 2.5 µg/ml 
dose (Figure 4.2 middle panel, right). 
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Figure 4.3: In vitro antitumoral activity of poly(I:C) polyplexes.
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Figure 4.4: Cell morphology of LPEI-PEG2kDa-EGF polyplex treated U87MGwtEGFR cells 48 h 
after transfection. A: poly(I:C) treated cells;  B: poly(I) treated cells (control). 
 
The two conjugates were also compared using the EGFR-overexpressing epidermoid 
carcinoma cell line A431 (Figure 4.5). In these and the following experiments, 
polyplexes of the nontoxic polyanion polyglutamic acid served as negative control. 
Efficient and poly(I:C)-specific cell killing was obtained at the lowest tested 1 µg/ml 
poly(I:C) dose in case of the LPEI-PEG2kDa-EGF conjugate, whereas high doses 
were required in case of the tetraconjugate.  
 
4.1.5 In vivo Anti-Tumor Activity  
In vivo anti-tumor activity of EGFR-targeted poly(I:C)/PEI polyplexes was examined 
using nu/nu mice bearing subcutaneous A431 tumors (performed by Alexei Shir, HU 
Jerusalem). Conjugate delivery activity was determined by tumor volume analysis 
after systemic application of tetra- and triconjugate and the control formulations. 
Intravenous administration of 0.5 mg/kg poly(I:C) started at day 0 and was repeated 
every second day, for a total of 7 times. Measurement of the average body mass of 
the mice showed that the mice tolerated the treatment well. 
As shown in Figure 4.6 the tumor volume of control/untreated groups was about 12 
times larger than the average tumor volume at day 0, indicating rapid tumor growth  
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Figure 4.5: In vitro antitumoral activity of poly(I:C) polyplexes against A431 cells. Comparison of 
the two EGF-conjugates (old tetraconjugate versus new triconjugate LPEI-PEG2kDa-EGF). The same 
doses of poly(Glu) polyplexes served as negative controls (Experiment by A. Shir, HU Jerusalem).  
 
and no tumor growth inhibition by the polyglutamate control polyplexes. Treatment 
with either EGF triconjugate (EPPlin) or EGF tetraconjugate (MPPEbrMel) resulted in 
significantly decreased tumor growth speed and tumor end volume. After 14 days of 
treatment (7 injections) the mean tumor volume of the tetraconjugate group was 
fourfold increased, while treatment with the triconjugate led to an only doubled tumor 
volume. The antitumoral effect was only observed in the poly(I:C) groups, showing 
significantly decreased tumor growth progression compared to the control group.  
 
 
Results   
 
66 
 
 
Figure 4.6: In vivo anti-tumor activity of EGFR targeted poly(I:C) PEI polyplexes. In vivo anti-
tumor activity of EGFR targeted poly(I:C) PEI polyplexes was measured using s.c. A431 bearing nude 
mice. Tumor volume analysis after i.v. injection of the two different formulations of poly(I:C) was done. 
Each group included 5 mice. Administration of 10 µg pI:C started on day 0 and was repeated on days 
2, 4, 6, 8, 10, 12, for a total of 7 times (indicated by arrows). Tumor volume was measured twice a 
week until day 14 (Experiment by A. Shir, HU Jerusalem). 
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4.2 Protocols and Building Blocks for the Solid-Phase Assisted Synthesis of 
Defined Polyamidoamines 
 
4.2.1 Introduction 
Despite the continuous progress in polymeric carrier development there still are 
inherent limitations which need to be addressed, namely low efficiency and poor 
definition of currently used polymeric delivery systems. Primary aim of this thesis was 
the development of solid-phase synthesis protocols to allow the synthesis of 
sequence-defined polyamidoamines for the delivery of nucleic acids. 
Solid-phase synthesis has a long history in the synthesis of peptides, a complex 
class of macromolecules. Peptides are comparatively short polymers (5-100 units) 
composed of different amino acids linked by amide bonds. Due to synthetic 
difficulties caused by their polarity, solubility properties and complex protection 
strategies the classical solution phase synthesis of peptides is laborious, time 
consuming and error prone139. In 1963 Merrifield98 published a landmark article, 
introducing the concept of peptide synthesis on a solid support. By anchoring the C-
terminal amino acid to an adequately functionalized, swellable microgel support it is 
possible to force amino acid coupling reactions to completion by using large excess 
of reagents and optimized synthetic protocols. Contaminants, reagents and reaction 
by-products are removed by a simple filtration step reducing overall synthesis time 
considerably. Since this breakthrough the field of macromolecular synthesis 
progressed at high speed, extending from peptides to oligonucleotides and other 
classes of oligomers. The method found wide acceptance in commercial and 
academic research and was further improved by the introduction of concepts like 
combinatorial chemistry140 and high-throughput screening.  
The first reports of application of the methodology to the design of transfection 
reagents appeared in the early nineties of the last century141-145, but despite apparent 
advantages the use and development of solid-phase derived polymers was never 
popular. Apart from precise dendrimer structures generated by solution chemistry146, 
ill defined, random polymerized cationic macromolecules continue to be the cutting 
edge of polymeric transfection reagents. This imbalance is probably the result of the 
few examples of polyamine and polyamidoamine synthesis in the literature and the 
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lack of commercial available building blocks. In fact, references to solid-phase 
derived polyamines are scarce before 1996147-148.  
In 2006 Hartmann et al.99 published a solid-phase based method to synthesize linear 
polyamidoamine (PAA) chains on a PS-PEG-support by a protocol employing 
alternating condensation steps using cyclic anhydrides and diamines (Figure 4.7). 
The first condensation generates a free carboxylic function on the resin via ring-
opening of the cyclic anhydride. The carboxylic function is subsequently activated on 
solid-phase and the diamine is condensed into the growing PAA chain. 3,3’-diamino-
N-methyldipropylamine and protected spermine were used as diamine building 
blocks. By repetition of this cycle linear PAAs are assembled.  As acceptable product 
purity can only be guaranteed if a conversion ≥ 98% is achieved in every step, 
constant reaction monitoring is necessary. The procedure allows the synthesis of 
linear PAAs in a high purity and with absolute control over every monomer unit.  
 
 
Figure 4.7: PAA solid-phase synthesis concept described by Hartmann et al.99  
 
Our initial aim was to adapt the strategy to generate a new polymer library for nucleic 
acid delivery based on ethylenimine units. Short linear oligoethylenimines instead of 
propylenimine or spermine should be used as amine building blocks, because 
oligoethylenimines were previously found to possess superior gene transfer 
properties149-150. By using the already published alternating condensation protocols99 
the problems of developing a new synthetic strategy might have been avoided.  
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4.2.2 Application of an Alternating Condensation Approach to Ethylenimine-
based PAAs  
 
 
Figure 4.8: Reaction conditions described by Hartman et al.99. i: 10 eq succininc anhydride, DMF, 
30 min; ii:10/10/10/20 eq diamine/PyBOP(R)/HOBt/DIPEA, DMF, 30 min; iii: TFA + scavengers, 1 - 2 h 
 
As depicted in Figure 4.8 the synthetic strategy is based on alternating condensation 
reactions of cyclic anhydrides and diamines. Variations in the number of repeating 
units in the oligoethylenimine building blocks (Figure 4.9) should have been used to 
analyze the impact of charge density and buffering capacity on NA delivery. 
By employing acid-labile boc-protection to the secondary amines of the 
oligoethyleneimine building blocks they are rendered inaccessible during the PAA 
synthesis, and possible side reactions are suppressed. Deprotection is achieved by 
the strongly acidic conditions necessary for the release of the PAA chain from the 
resin. 
 
Figure 4.9: Comparison of the used building blocks (R=Boc/H). left: propylenimine based building 
blocks: 1 3,3’-diamino-N-methyldipropylamin, 2 spermine (used by Hartman et al), right: ethylenimine 
based building blocks: 3 diethylenetriamine (Dt), 4 triethylenetetramine (Tt), 5 tetraethylenepentamine 
(Tp) 
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Figure 4.10: General synthetic route for diamine building blocks  
 
The boc-protected diamines were synthesized in a one-pot reaction according to a 
published method151. The primary amines of the linear oligoethylenimines were 
selectively152 protected by acylation using ethyl trifluoroacetate followed by protection 
of the secondary amines via di-tert-butyl dicarbonate. The resulting fully protected 
amines are readily purified by recrystallization. The trifluoroacetyl groups were 
removed by alkaline hydrolysis, yielding the pure corresponding diamine in moderate 
to high overall yields (Table 4.3). 
 
ID backbone Bistfaxboc derivative  diamine yield  Overall yield 
Dt(boc) DETA 73 % 63% a 46% 
Tt(boc2) TETA 65 % 66% a 43% 
Tp(boc3) TEPA (x 5 HCl) 83 % quantitative 83% 
Tp(boc3) TEPA tech. grade 68 % quantitative 68% 
Table: 4.3 Yields of the boc-protected amine building blocks; a not optimized 
 
By this simple three step procedure the diamine building blocks can be produced in 
large amounts (standard batch size 20 – 40 g) without the need for time-consuming 
chromatographic purification steps. 
 
Solid-Phase Synthesis: 
To establish the solid-phase procedures, the sequence HO-K-Succ-Tp-Succ-Tp-H 
was chosen as simple model PAA. In-synthesis reaction monitoring showed 
inconsistent results for the colorimetric assays in every step, accompanied by a lower 
resin mass gain than calculated. MS-analysis of the cleavage solution revealed the 
formation of the crosslinked product HO-K-Succ-Tp-Succ-K-OH (Figure 4.11). 
The incubation of the activated carboxylic acid function with the diamine building 
block results in crosslinking of a large degree of the adjacent reaction sites, 
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preventing further chain elongation. Using a Wang-Lys resin with a moderate loading 
(0.52 mmol/g) a product mixture of crosslinked and desired product could be 
identified by ESI-MS after the second coupling  step, however accompanied by very 
low yields.  
 
 
Figure 4.11: Left: Exemplary ESI-MS-spectrum of an alternating condensation reaction using a PS-
Wang-K resin. Upper Right: Proposed mechanism for on resin crosslinking Lower right: Formation of 
crosslinking product in dependency to various reaction conditions 
 
To evaluate the influence of experimental conditions on the formation of crosslinked 
products, different reaction conditions were tested. In each case the mass increase 
of the resin was less than predicted and colorimetric assays used for reaction 
monitoring showed unexpected behavior. The crosslinked product was always 
present in the different sequences. These results are consistent with reports in 
literature for on-resin carboxy activation followed by coupling of unprotected 
diamines. Jørgensen et al.153 describe crosslinking up to 60% (per step) of adjacent, 
activated carboxy sites on solid-phase using a related approach. 
Thus, in contrast to the successful application by Hartmann et al. the synthetic 
strategy yielded no reliable results in our case. Possible explanations include the 
increased steric requirements of the Tp(boc3) building block compared to the building 
blocks used in the original synthesis, changed reaction kinetics by using a Wang-PS 
resin opposed to Trityl-PEG-PS resin which generally shows faster reaction 
kinetics154 and the higher load of most of the used resins. 
In addition to the synthetic problems the versatility is limited by technical factors like 
building block solubility, possible side reactions when using new combinations of 
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diamines and diacids and the need for complex in situ analytics to ensure clean 
reaction progress. As robust and reliable reactions are a prerequisite to solid-phase 
assisted library synthesis, the first synthetic route was not further investigated. By 
adapting the synthetic concept to standard fmoc/tBu peptide synthesis conditions 
(Figure 4.12) it should be possible to use well-established peptide coupling 
protocols. This would be accompanied by the additional advantage of a decreased 
error rate resulting from transferring the critical condensation step into the building 
block synthesis. 
 
4.2.3 PAA Synthesis Using  Polyamino Acid Building Blocks 
 
 
Figure 4.12: Comparison of the two solid-phase PAA synthesis strategies. Left: classical solid-
phase peptide synthesis characterized by alternating coupling and deprotection cycles. Right: 
Hartmann PAA synthesis characterized by alternating condensation reactions. 
 
Fmoc/tBu peptide synthesis is characterized by alternating deprotection and 
elongation cycles. To adapt the PAA synthesis to fmoc/tBu conditions a building 
block like depicted in Figure 4.13 was needed. The protection strategy was adapted 
from fmoc/tBu-amino acids resulting in an orthogonal protected oligoamino acid 
constructed from diacid component, N-terminal fmoc protection and boc-protected 
amines. As large scale synthesis was already optimized for Tp(boc3) we chose that 
building block as model for the development of the fmoc/tBu building blocks.  
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Synthesis of the fmoc amino acid building blocks: 
 
 
Figure 4.13: fmoc-Stp(Boc3)-OH (n=3, m=2, R=H) 
 
# Reaction conditions Yield Comments 
1 
1) 1.1 eq Fmoc-Cl, 2 eq DIPEA, DCM -20 °C 12 h 
2) 3.0 eq Succinic anhydride, DCM, RT 3 h 
30% two-step synthesis 
2 
1) 1.1 eq Fmoc-Cl, 2 eq DIPEA, DCM -20 °C 12 h 
2) 3.0 eq Succinic anhydride, DCM, RT 3 h 
16% one-pot reaction 
3 
1) 1.1 eq 9-BBN, Fmoc-Cl, 2 eq DIPEA, DCM -20 °C 12 h 
2) 3.0 eq Succinic anhydride, DCM, RT 3 h 
20% 
in situ complexation 
 (9-BBN)  
4 
1) 1.1 Succinic anhydride, THF - 20 °C 4h 
2) 1.5 eq Fmoc-Cl, 3 eq DIPEA, THF, 0 °C to RT 12 h 
40% one pot-reaction 
5 
1) 1.1 Succinic anhydride, THF - 70 °C 4h 
2) 1.5 eq Fmoc-OSu, 3 eq DIPEA, THF, 0 °C to RT 12 h 
46% less side products 
Table 4.4: optimization of product yield/different reaction conditions for fmoc-Stp-OH 
 
The synthetic strategy to convert Tp(boc3) into the fmoc-Stp(Boc3)-OH building block 
required a mono-acylation in the first step, thereby differentiating the two amino 
functions. Initially that was achieved in a 2-step synthesis by using Fmoc-chloride 
followed by acylation via succinic anhydride obtaining fmoc-Stp(Boc3)-OH in an 
overall yield of 30%.  
As the purification of the intermediate fmoc-tp(Boc3)-NH2 was quite laborious and 
time-consuming, the two reaction steps were transferred into a one-pot reaction to 
ease synthesis and purification. This change was accompanied by a drop of yield to 
16%, unacceptable for further use. The yield limiting step was the first mono-
acylation, so different conditions were tested for an effective mono-acylation. The 
most common solution, using a large excess of the diamine155 was not an option as 
the protected diamine is the product of a 3 step synthesis and too valuable. The use 
of temporary protection strategies to selectively shield one amine via protonation156 
or complexation (Table 4.2, entry 3) via 9-BBN157 did not result in increased yields.  
In the end, succinic anhyride acylation at -70 °C i n THF followed by fmoc introduction 
using Fmoc-OSu was able to increase the yield to acceptable 40%. Furthermore the 
use of Fmoc-OSu gave rise to a cleaner raw product as use of Fmoc-Cl is often 
accompanied by dipeptide formation158 complicating the purification.  
See Table 4.4 
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The applicability of the optimized procedure to the synthesis of other oligoamino 
acids was in the meantime demonstrated by the synthesis of building blocks with 
close relationship to Stp using educts with varying n/m (unpublished results, Naresh 
Badgujar). These building blocks offer interesting opportunities to investigate the 
influence of the polyamine building block on NA complexation and delivery. By using 
these building blocks it is possible optimize the resulting PAAs by changing charge 
density, hydrophobicity or introducing structural strain. 
The developed synthetic route thereby provides convenient access to fully protected 
polyamino building blocks for use in fmoc/tBu solid-phase synthesis. 
 
 
Figure 4.14: Synthetic route to fmoc/tBu-polyamino acids. Optimized synthetic route to fmoc/tBu-
polyaminoamido acids, illustrating the general applicability of the synthetic route (Dr. Naresh Badgujar, 
Wagner lab) 
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4.2.4 Application of Fmoc
Synthesis of the model PAA HO
To evaluate the usefulness of solid
Stp(boc3)-OH building block th
charges) using standard PyBOP
analysis. RP-HPLC proved altogether to be unsuccessful due to the massive charge 
and the unpredictable buffering capacity of the PAAs
results. These problems are known from literature
High Resolution Ion-Exchange HPLC (IEX
IEX-HPLC trace of crude material after cleavage from the resin. 
example for one of the longer, unmodified PAAs of the library and shows that the 
developed coupling protocols work well, resulting in crude product purities > 85%.
 
Figure 4.15: IEX-HPLC/UV214
Resource S (6 mL) column was used for analysis. Elution by linear gradient over 40 min
to 60% B (A: 20 mM NaCl in 10 mM HCl; B: 3 M NaCl in 10 mM HCl), flow rate 4.0 mL/min 
  
Synthesis of the model Peptide 
To demonstrate the general compatibility of the fmoc
standard fmoc/tBu peptide synthesis the GE11 peptide sequence
modified with two Stp-units (Sequence: 
moderately hydrophobic (GRAVY= 
charged residues. The initial peptide sequence allows easy purity assessment by 
RP-HPLC before coupling of the Stp units. N
introduces 6 additional positive charge
-Stp(boc)3-OH to PAA and Peptide Synthesis
-K-Stp4-K-H 
-supported PAA-synthesis using the new fmoc
e sequence HO-K-Stp4-K-H was synthesized (15 
®
 coupling protocols159 and subjected to further 
 resulting in irreproducible 
99
 and were circumvented by using 
-HPLC) for analysis. Figure 4.
The sequence is an 
-trace of crude HO-K-Stp4-K-H(#18). A catio
HO-IVNQPTYGYWH-Stp2-H 
-polyamino acid building block to 
53
HO-IVNQPTYGYWH-Stp-Stp
-0.700) EGF-R targeting peptide, possessing no 
-terminal modification by two Stp units 
s into the peptide, resulting in a drastic change 
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n-exchange 
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 was N-terminal 
-H). GE11 is a 
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of chromatographic behavior under IEX conditions.  HR-IEX Analytical IEX 
chromatography of a mini cleavage (Figure 4.16) shows a purity > 90 % being 
consistent to the RP-HPLC run (insert Figure 4.16) of the peptide precursor.  
 
 
Figure 4.16: IEX-HPLC/UV280 trace of crude HO-IVNQPTYGYWH-Stp-Stp-H. A cation-
exchange Resource S (1 mL) column was used for analysis. Elution by linear gradient over 40 
min from 0 to 100% B (A: 20 mM NaCl in 10 mM HCl; B: 3 M NaCl in 10 mM HCl), flow rate 1.0 
mL/min Insert: RP18-HPLC/UV280 trace of crude HO-IVNQPTYGYWH-H. Elution by linear 
gradient over 20 min from 5% A  to 100% B (A: Water + 0.1% TFA; B: ACN + 0.1% TFA), flow 
rate 1.0 mL/min 
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4.3 Design and Evaluation of a Library of Precise, Sequence-defined 
Oligoamidoamines for Nucleic Acid Delivery 
4.3.1 Introduction 
Nucleic acid (NA) delivery systems hold great promise as research tool and in terms 
of therapeutic application. Nevertheless the development has been slowed down by 
various problems associated to the effective delivery of NAs into the target cells. Viral 
delivery, the far most efficient delivery platform, only slowly recovers from a series of 
serious setbacks associated with inherent safety problems160-161 (immunogenicity, 
insertional mutagenesis) and will not be applicable for all types of NAs and disease 
indications. The use of polymeric vectors is impaired by a different set of problems: 
low efficiency compared to viral systems, ill–defined structures, resulting in problems 
in structure-activity prediction and evaluation, and synthetic difficulties during the 
development of increasingly complex multi-domain polymers. 
It is questionable if the modification of polymeric macromolecules in a more or less 
random manner will allow these systems to compete successfully with their viral 
counterparts. Furthermore the structure activity relationships of polymers modified by 
these grafting approaches are difficult to analyze due to the large impact of the 
polymer backbone and their polydispersity. By stripping the used systems down to 
their essential parts and reassembling them as relatively small, precise polymers one 
can envision a construction set of functional domains for delivery system 
development. The different combinations can be screened for synergistic effects 
resulting in potent delivery vehicles characterized by defined structure and possibility 
of further extension. It is obvious that traditional polymerization strategies are not 
suited for this approach, as they cannot deliver the molecular precision necessary for 
these types of polymers. Reviews101 on the design of polymeric delivery systems 
agree on a minimal set of necessary structural properties with NA 
binding/compaction, cell entry, buffering capacity or lytic activity towards cell 
membranes, and intracellular release of the cargo being the most prominent. An 
ideal, smart polymeric system would encode these properties in its monomer 
sequence allowing the programming of properties and behavior during synthesis.  
Solid-phase synthesis is an ideal tool for the synthesis of precise, sequence defined 
polymers and can with the right set of protocols be used for macromolecular 
synthesis to reach Mw > 10 kDa162. Aim of this study was the design and evaluation 
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of a small solid-phase based polymer library to evaluate the influence of different 
modules in a polymeric NA delivery system. The library is still constrained by its 
limited design space, but the first results demonstrate the feasibility of the approach.  
Further development towards more complex modular structures may be able to cope 
with unsolved bottlenecks in polymeric delivery. 
 
4.3.2 Structural Overview and Rationale 
 
 
Figure 4.17: Structural overview over the different polymer classes. PAA chain (1), PAA chain 
with crosslinking cysteines (2); PAA with acylation at N-terminus (i-shape type) without (3), with one 
dimerizing (5), or with two crosslinking (4) cysteines; PAA with acylation in center (t-shape type) and 
crosslinking cysteines (6). 
The initial library design was governed by the fact that there is only little information 
on structure-activity relationships in the literature due to the lack of defined polymeric 
carriers. The few published examples are almost exclusively dendritic structures163, 
small peptides143 and PEG-PAAs100. Even by taking these defined structures into 
account the design motifs are dominated by Mw (> 10 kDa), variations in charge 
density and buffering properties. For the first evaluation of the modular solid-phase 
synthesis platform a big design space had to be covered using a minimal set of 
building blocks. To evaluate the potential of small PAAs in terms of NA delivery the 
design parameters were limited to four easily controllable structural parameters:  
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Building block ID Introduced Function 
 
Stp Nucleic acid binding & buffering 
 
Lys(K) Nucleic acid binding & branching point 
 
Cys(C) Dimerization/polymerization & possible anchoring point 
 
Fatty acids (FA)  Polyplex stability & membrane interaction 
Table 4.5: Overview over the used building blocks and their function in PAA design. 
length of buffering/compaction domain, hydrophilic/lipophilic balance, branching and 
dimerizing/crosslinking capability (Table 4.5). 
These four parameters were used to generate a PAA library which can be described 
by the 6 different families depicted in Figure 4.17. The simplest structural family is 
the PAA chain (structure 1), constructed by linear elongation using Stp and/or amino 
acid units. These structures closely resemble the prominent oligoethyleneimine motif 
of PEI and were synthesized to support the hypothesis that there is a minimal 
polymer length necessary for successful delivery of NAs164. The crosslinking-PAA 
chain (structure 2) is further modified by two cysteine residues and was designed to 
introduce a dynamic stabilization element into the polyplexes by either stabilizing the 
formed particle by crosslinking165 or through increased molecular weight caused by in 
situ polymerization. Both families were hydrophobically modified using fatty acids 
(FA) at the N-terminus, resulting in the i-shape families (structures 3 and 4). The 
hydrophobic moieties were introduced for two reasons, namely NA binding and 
membrane interaction40. The dimerizing i-shapes (structure 5) were synthesized to 
test polyplex stabilization while the symmetrical t-shapes (structure 6) were used to 
examine the influence of a changed polymer topology on transfection efficacy. To 
obtain first structure-function relationships in regard to biophysical properties, 
subsets of the library were tested for NA binding and pH-specificity of lysis. 
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4.3.3 Lytic Activity 
 
Figure 4.18:  Heatmap analysis of the lytic activity of the different sublibraries at a 
concentration of 5 µM at different pHs. Determined by erythrocyte leakage assay (synthesis and 
leakage assay performed by Christina Troiber, master thesis)  
 
To escape endosomal entrapment, an endosomal pH-specific lytic activity is a 
desired prerequisite for successful delivery of NAs into the cytosol. This is especially 
true for polymeric vectors without a distinctive proton sponge effect124 and has been 
introduced by attachment of lytic peptides166 or introduction of hydrophobic 
residues167-168. The different polymer families were screened in a erythrocyte leakage 
assay system166  to identify structural motifs resulting in a highly pH-specific lytic 
activity. By assaying the polymers at different pH-values comparable to the pH of 
different stages of the endosome169  potent sequences can be identified, which only 
attack cell membranes at a slightly acidic pH. By using pH-specific lytic delivery 
systems potential cytotoxic lytic interactions with cell membranes in the beginning of 
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the transfection process can be reduced, thereby lowering the cytotoxic potential of 
the carrier. 
Lytic activity of the unmodified polymer backbone was analyzed (Figure 4.18) using 
K-Stp1-K (#1), K-Stp2-K (#6); K-Stp5-K (#23) as model sequences. The plain PAA 
sequences did not express any lytic activity even at concentrations > 5 µM (data not 
shown). Introduction of a single N-terminal fatty acid into a K-Stp2 sequence (#34 – 
37) showed a slight increase in activity with oleic (#37) and myristic acid (#36) being 
the most effective modifications while polymers modified with fatty acids < C14 (#35, 
#34) were essentially non-lytic. A general advantageous trend of an increased 
activity at lower pH was observed for the fatty acid modified PAAs which is most 
probably caused by the increased protonation state of the polyamine backbone at 
endosomal pH and the resulting interaction with negatively charged domains of the 
cell membranes.  
Lytic potency of the polymers was further increased by using an N-terminal lysine as 
branching point and attaching two fatty acids to the lysine (double fatty acid motif). 
The increased lytic activity can be attributed to the close vicinity of the fatty acids 
resembling the general structure of amphipathic lipids. Acylation of the N-terminal 
lysine using caprylic acid (#8) chains did not result  in a strong lytic activity, probably 
due to the rather short alkyl chain. Incorporation of myristyl residues (#9) results in a 
strong, unspecific lysis causing up to 40% of erythrocyte rupture already at neutral 
pH. Oleic acid modification (#10) shows a moderate, highly specific lytic activity 
rendering this modification the most valuable. 
The chain length of the PAA backbone has only a moderate effect on lytic activity 
(#22 vs. #10, #9 vs. #21). Use of a larger backbone normally results in a diminished 
lytic activity. The most plausible explanation is the reduced molar proportion of lipid in 
the polymer indicating that 2 – 3 Stp units may be the optimal chain length for lytic 
activity using i-shape structures.  
The introduction of cysteine into the sequence as dimerization/polymerization anchor 
did not significantly alter the extent and pH-specificity of membrane lysis (#9, #68, 
#45 vs. #10, #69 , #46). This finding is especially interesting for the use of the 
polymers as NA delivery systems, as in situ crosslinking polymers may improve 
polyplex stability but would not cause significant change in cytotoxicity and 
endosomal escape potency. 
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4.3.4 Correlation of Cytotoxicity with Unspecific Lysis Activity 
The impact of different hydrophobic modifications of a PAA sequence on the 
cytotoxic potential of the resulting delivery formulation is exemplified in Figure 4.19. 
Modification of the essentially non-toxic sequence K-Stp2-K (Figure 4.19, #06) with a 
dual fatty acid motif shows an increased cytotoxicity (for fatty acids > C8) under in 
vitro siRNA-transfection conditions.  
In agreement with the observed lytic activity (Figure 4.19, #08) the modification with 
two C8 residues has no pronounced effect on cellular metabolic activity. If the C8 
residues are substituted with C14 residues (Figure 4.19, #09) the use of N/P 12 in the 
transfection results in a drop of metabolic activity to 30%. Erythrocyte leakage assay 
(Figure 4.19, #9) shows a lytic activity of 20 - 40% already at neutral pH reaching 
100% lysis at pH 6.4. The oleic acid modification (Figure 4.19, #10) shows a more 
specific lytic profile reaching 80% lysis not until a pH of 5.5. This is reflected in the 
relatively late onset of toxicity under in vitro conditions, a N/P ratio > 20 is needed for 
cytotoxic effects. 
The toxicity data correlates to the lytic activity of the polymers. Myristic acid 
modification showed the most potent but nevertheless mostly unspecific lytic activity 
of all tested polymers. This results in an increased cytotoxic activity when used in a 
carrier system, severely restricting the use of the myristic acid modification in these 
types of systems. 
 
Figure 4.19: Toxicity of siRNA/PAA polyplexes on Neuro2A Luc cells. Cell viability was assessed 
by measuring luciferase activity after 48 h of incubation with siRNA(scrambled)/PAA complexes and 
normalized using the luciferase expression of untreated control. 
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4.3.5 Structure-Activity Relationships in Nucleic Acid Binding 
A principal criterion for the design of polymeric delivery systems is the ability to 
condense nucleic acids, thereby protecting the payload from degradation and 
allowing the transport to target cells. This interaction has to be sufficiently stable to 
withstand competitive interactions from other anionic species in the environment 
which could result in a premature payload release. The ability of the PAAs to 
condense NA was studied using an agarose gel shift assay with binding strength 
correlating to the amount of polymer needed for NA retardation.  
As the sequences in the library were too short (< 6 Stp units) to show NA 
compaction, without additional refinement we were interested in identifying 
modifications that allow a strong NA compaction using such small backbones. 
Polymers containing only Stp and a C-terminal lysine were not able to bind either 
DNA or siRNA in the tested concentrations (Figure 4.20.1–4, K-Stp2-K, #6; K-Stp4-
K, #18). To identify a minimal binding motif for use in nucleic acid delivery systems, a 
short K-Stp2 sequence was modified with a single N-terminal fatty acid of differing 
chain lengths (Figure 4.21.1–6.; K-Stp2-OleA, #37; K-Stp2-MyrA, #36; K-Stp2-
CapA, #35). The hydrophobic modification had no influence onto the retardation of 
siRNA, independent of fatty acid chain length. For pDNA compaction the modification 
with an oleoyl residue showed weak compaction at N/P 40 (Figure 4.21.4, #37). This 
effect was further improved by the introduction of a second FA in close proximity 
using a N-terminal lysine as branching point. The dual FA motif resulted in strong 
pDNA polymer interactions with almost complete pDNA retardation at N/P 12 (Figure 
4.21.7–8) if the fatty acid was either C14 (#9) or C18 (#10), use of a C8 (#8) 
modification did not show interactions in the tested concentrations. 
For siRNA binding the effect was even more pronounced (Figure 4.21.7–9). Single 
fatty acid modified polymers showed no retardation up to a N/P of 40, while dual FA 
modified PAAs were able to compact siRNA at a N/P of 12. Interaction of caprylic 
acid modified PAAs to siRNA was not strong enough to cause retardation. 
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Figure 4.20: Comparison of unmodified PAAs regarding their DNA/siRNA binding in a gel shift 
assay. Lanes 1 + 2: K-Stp2-K (#6), K-Stp4-K (#18) DNA N/P 6/12/20; Lanes 3 + 4: #6, #18 siRNA N/P 
12/20/40 
 
Figure 4.21: Comparison NA interaction of mono or dual fatty acid modified PAAs to siRNA 
(Row A,C) and pDNA (Row B, D) by agarose gel-shift assay. Row A: siRNA N/P 20/40/60; Row B: 
DNA N/P 12/20/40 Row C: siRNA N/P 20/40/60; Row D: DNA N/P 12/20/40; 1+4: K-Stp2-OleA (#37), 
2+5: K-Stp2-MyrA (#36), 3+6: K-Stp2-CapA (#35), 7+10: K-Stp2-K-OleA2 (#10), 8+11: K-Stp2-K-MyrA2 
(#9), 9+12: K-Stp2-K-CapA2 (#8) 
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Figure 4.22: siRNA binding capabilities of K-Stp4-K-X2. left column siRNA control, all other 
columns siRNA complexed with polymer N/P 12/20/40, 1: K-Stp4-K-CapA2 (#20); 2: K-Stp4-K-OleA2 
(#22); 3: K-Stp4-K-MyrA2 (#21); 
 
To assess the influence of the PAA backbone length onto NA compaction and to rule 
out possible destabilization of the polyplexes by a changed hydrophilic-lipophilic ratio 
a longer, dual-FA modified PAA backbone was assayed for siRNA binding. Figure 
4.22 shows the influence of a longer Stp-sequence on the ability of the K-FA2 motif to 
complex siRNA. Oleoyl (Figure 4.22.2) and myristyl (Figure 4.22.3) modifications 
result in strong siRNA binding at N/P 12, while the use of caprylic acid (Figure 
4.22.1) did not result in a better compaction. The introduction of additional Stp units 
did not improve the binding of the caprylic acid modified PAA, supporting the 
hypothesis that siRNA binding using PAA systems is mostly governed by 
hydrophobic interactions. 
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4.3.6 Impact of the Different Domains on Nucleic Acid
Figure 4.23: Evaluation of different polymers in DNA and siRNA tran
delivery in Neuro2A cells (1 µg/mL DNA/well at w/w 10; 
Stp2-K-(K-OleA2)-Stp2-C) Lower panel:
siRNA/well at N/P 12 (~ 10 w/w); #10: K
(performed by Thomas Fröhlich, Wagner lab)
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activity of the transfected cells and can be further optimized by changes to their 
structural domains.  
The lower panel of Figure 4.23 shows a comparison of gene silencing and cytotoxic 
potential of different polymer/siRNA formulations. By comparison of three different 
classes of polymers (chain (#6), i-shape (#10), crosslinking t-shape (#49)) the 
synergistic influence of the different domains can be investigated. As already 
demonstrated for pDNA delivery the use of short unmodified Stp-chains (#6) did not 
result in any significant luciferase knockdown. Use of a dioleoyl modified chain (#10) 
likewise did not result in a significantly increased luciferase knockdown. These 
results are in line with the data derived from lysis/binding assays. Polymer #6 shows 
low lytic activity and forms no stable complexes with siRNA. Polymer #10 on the 
other hand has specific lytic activity (80-100% lysis at pH 5.5), forms reasonably 
stable complexes but fails in delivery. Polymer #49, an oleoyl modified t-shape which 
is further modified by the incorporation of two cysteines demonstrates a potent 
luciferase knockdown.  
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# Sequence Formula Mw protonable amines Type 
1 K-Stp1-K C24H51N9O5 545,72 6 chain 
3 K-Stp1-K-CapA2 C40H79N9O7 798,11 4 i-shape 
4 K-Stp1-K-MyrA2 C52H103N9O7 966,43 4 i-shape 
5 K-Stp1-K-OleA2 C60H115N9O7 1074,61 4 i-shape 
6 K-Stp2-K C36H76N14O7 817,08 9 chain 
8 K-Stp2-K-CapA2 C52H104N14O9 1069,47 7 i-shape 
9 K-Stp2-K-MyrA2 C64H128N14O9 1237,79 7 i-shape 
10 K-Stp2-K-OleA2 C72H140N14O9 1345,97 7 i-shape 
18 K-Stp4-K C60H126N24O11 1359,80 15 chain 
20 K-Stp4-K-CapA2 C76H154N24O13 1612,19 13 i-shape 
21 K-Stp4-K-MyrA2 C88H178N24O13 1780,51 13 i-shape 
22 K-Stp4-K-OleA2 C96H190N24O13 1888,69 13 i-shape 
23 K-Stp5-K C72H151N29O13 1631,16 18 chain 
25 K-Stp5-K-AraA2 C112H227N29O15 2220,19 16 i-shape 
26 K-Stp5-K-MyrA2 C100H203N29O15 2051,87 16 i-shape 
27 K-Stp5-K-OleA2 C108H215N29O15 2160,05 16 i-shape 
30 C-Stp1-K-CapA2 C37H72N8O7S 773,08 3 i-shape 
31 C-Stp1-K-SteA2 C57H112N8O7S 1053,61 3 i-shape 
34 K-Stp2-ButA1 C34H70N12O7 759,00 7 i-shape 
35 K-Stp2-CapA1 C38H78N12O7 815,10 7 i-shape 
36 K-Stp2-MyrA1 C44H90N12O7 899,26 7 i-shape 
37 K-Stp2-OleA1 C48H96N12O7 953,35 7 i-shape 
38 K-Stp1-ButA1 C22H45N7O5 487,64 4 i-shape 
39 K-Stp1-CapA1 C26H53N7O5 543,74 4 i-shape 
40 K-Stp1-MyrA1 C32H65N7O5 627,90 4 i-shape 
41 K-Stp1-OleA1 C36H71N7O5 681,99 4 i-shape 
45 C-Stp3-C-K-MyrA2 C76H151N19O12S2 1587,26 9 i-shape 
46 C-Stp3-C-K-OleA2 C84H163N19O12S2 1695,44 9 i-shape 
48 C-Stp2-K-(K-MyrA2)-Stp2-C C94H188N26O15S2 1986,79 13 t-shape 
49 C-Stp2-K-(K-OleA2)-Stp2-C C102H200N26O15S2 2094,98 13 t-shape 
50 K-Stp4-K-ArA2 C100H202N24O13 1948,83 13 i-shape 
51 C-Stp3-C-K C48H99N19O10S2 1166,55 11 chain 
56 C-Stp2-K(CapA)-Stp2-C C68H138N24O13S2 1564,11 13 t-shape 
57 C-Stp2-K(MyrA)-Stp2-C C74H150N24O13S2 1648,27 13 t-shape 
58 C-Stp2-K(OleA)-Stp2-C C78H156N24O13S2 1702,36 13 t-shape 
59 C-Stp2-K(ArA)-Stp2-C C80H162N24O13S2 1732,43 13 t-shape 
62 C-Stp2-K(K-ArA2)-Stp2-C C106H212N26O15S2 2155,11 13 t-shape 
66 C-Stp2-K(K-CapA2)Stp2-C C82H164N26O15S2 1818,47 13 t-shape 
67 C-Stp2-K-MyrA2 C61H121N13O9S 1212,76 6 i-shape 
68 C-K-Stp2-K-MyrA2 C67H133N15O10S 1340,93 7 i-shape 
69 C-K-Stp2-K-OleA2 C75H145N15O10S 1449,11 7 i-shape 
70 C-Stp2-K-OleA2 C69H133N13O9S 1320,94 6 i-shape 
71 C-Stp1-K(K-MyrA2)-Stp1-C C70H138N16O11S2 1444,07 7 t-shape 
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72 C-Stp1-K(K)-Stp1-C C42H86N16O9S2 1023,36 9 chain 
73 C-Stp1-K(K-SteA2)-Stp1-C C78H154N16O11S2 1556,29 7 t-shape 
74 C-Stp1-K(K-OleA2)-Stp1-C C78H150N16O11S2 1552,26 7 t-shape 
75 C-Stp3-K(K-MyrA2)-Stp3-C C118H238N36O19S2 2529,51 19 t-shape 
76 C-Stp3-K(K)-Stp3-C C90H186N36O17S2 2108,80 19 chain 
77 C-Stp3-K(K-SteA2)-Stp3-C C126H254N36O19S2 2641,73 17 t-shape 
78 C-Stp3-K(K-OleA2)-Stp3-C C126H250N36O19S2 2637,69 17 t-shape 
79 C-Stp4-K(K-MyrA2)-Stp4-C C142H288N46O23S2 3072,23 25 t-shape 
80 C-Stp4-K(K)-Stp4-C C112H234N48O21S2 2653,50 27 chain 
81 C-Stp4-K(K-SteA2)-Stp4-C C150H304N46O23S2 3184,44 25 t-shape 
82 C-Stp4-K(K-OleA2)-Stp4-C C148H298N48O23S2 3182,39 25 t-shape 
Table 4.6: List of tested polymers 
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4.4  Evaluation of Different PAA Families for in vitro DNA Delivery 
4.4.1 Introduction 
Development and modification of polymeric systems for NA delivery continues to be 
an attractive field of study as the delivery of genetic information into cells holds great 
therapeutic promise. Despite the significant maturation of polymer-based gene 
vectors over the last 20 years, they are still characterized by a rather low efficiency 
and the potential and the possibilities of modification are far from being fully 
exploited. Over the time certain design concepts101 were substantiated by numerous 
reports, including the use of cationic polymers to complex NAs170-171, modification 
with shielding and targeting domains172-173 and hydrophobic functionalization40,121 to 
promote cellular uptake and endosomal escape. A persisting problem of this classical 
approach to vector design is the limited information on precise structure-activity 
relationships. In most investigations the analyzed polymers have been heterogenic 
systems in terms of molecular weight, grade of polydispersity and sites of 
conjugations and other modifications. In this regard synthesis and screening of 
sequence-defined polymers offers the possibility of a more evidence-driven route to 
the design of polymeric vectors. 
The small library of sequence-defined polymers (as described in Chapter 5) was 
screened for DNA transfection potential. The used luciferase reporter gene system174 
has the advantage of being a positive readout system with a wide detection range, 
allowing the comparison of carrier efficiencies over more than four log scales. Aim of 
this first DNA transfection screening was to explore the elementary properties of this 
new class of sequence-defined polymers, to evaluate their potential as nucleic acid 
delivery agents and to identify promising lead structures for further optimization. The 
obtained results provide valuable information for the design of improved DNA 
transfection polymers, and to some extent also for the delivery of other nucleic acid 
derivatives (e.g. siRNA, PMOs, PNAs).  
 
4.4.2 in vitro DNA Delivery 
 
Following the generic biophysical characterization of the polymers (see Chapter 5) 
the most promising candidates were screened in vitro to identify structural motifs 
responsible for successful DNA delivery. The PAAs were used to complex a plasmid 
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encoding an EGFP-luciferase fusion protein (pEGFPLuc) and were screened on 
cultured Neuro2A murine neuroblastoma cells. Polyplexes were prepared in HBG at 
a pH of 8.3 (for a survey of the influence of pH on transfection efficiency see 
Appendix 8.5) using w/w ratios from 5 – 40 at a constant DNA dose of 2 µg/mL for 
transfection and were added to cells in standard serum-containing culture medium. 
After 24 h luciferase expression and metabolic activity were measured and compared 
to a LPEI control formulation.  
Due to the relatively small size (1-3 kDa) of the screened polymers even small 
property changes due to an altered polymer sequence will be reflected in transfection 
efficiency and cytotoxicity, allowing quick assessment of the potential benefit of a 
modification.  
 
4.4.3 DNA Delivery Using Non-thiol Containing Chains and i-shapes 
To evaluate the delivery properties of PAA delivery systems Stp-chains, optionally 
modified by N-terminal acylation with fatty acids (i-shapes), were screened (see 
Figure 4.25). These families are characterized by a number of 2-5 Stp units in a 
polymer and, in the case of i-shapes, by fatty acid modification (myristic, oleic, 
arachidic acid). The influence of the hydrophobic modifications on the NA binding is 
demonstrated in Figure 4.24. Polyplex stability is increased by the incorporation of 
longer chain fatty acids resulting in stabilization at N/P 6 (Figure 4.24.2+3 + 
4.24.6+7) while unmodified K-Stp5-K (#23) (Figure 4.24.1) shows no DNA binding 
even at polymer concentrations of N/P 20 (result not shown). The effect of 
hydrophobic modification on NA compaction is even more pronounced than the 
number of charges in the single molecule as seen by a comparison of K-Stp2-K-
MyrA2 (#9) and K-Stp4-K-MyrA2 (#21) (Figure 4.24.2 and 4.24.5). To assess delivery 
capability and toxicity of PAA chains and i-shapes the fatty acid modified sequences 
were compared to K-Stp5-K (#23) in an in vitro transfection assay. The sequence is 
comparable in Mw and amount of protonable amines to OEI800 a rather weak 
performing member of the PEI family (for a comparison see Table 4.7). As shown in 
Figure 4.25 even the use of relatively high polymer concentrations (w/w 20) shows 
no significant increase of luciferase expression compared to untreated cells. This can 
be explained by inferior condensation properties of the plain PAA sequences 
compared to the fatty acid modified polymers. Furthermore this is in agreement with 
results of erythrocyte leakage assays which showed no lytic activity (activity < 10% at 
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all pHs) for unmodified PAAs thereby reducing the probability of successful 
endosomal escape. These findings are additionally supported by the absence of 
toxicity in all tested concentrations (Figure 4.25). 
The synergistic effect of polyplex stabilization and lytic activity is reflected in the 
reporter gene expression profiles of the fatty acid modified polymers. Modification of 
a K-Stp2-K sequence with either myristic (#9) or oleic acid (#10) increases the 
transfection compared to K-Stp5-K (#23) (possessing the double amount of charges) 
tenfold at a w/w 10. Elongation of the chain by two additional Stp units results in an 
up to 100-fold increase of reporter gene expression. This is accompanied by an 
increased cytotoxicity for the myristic acid derivatives in all tested concentrations 
resulting in a metabolic activity < 10% at a w/w of 40 (Figure 4.25, #9 + #21). Oleic 
acid modification has a comparable effect on the transfection efficiency while the 
toxicity of the polymers in the tested concentration range is negligible (Figure 4.25, 
#10 + #22).  
 
 
Figure 4.24: DNA binding properties of the PAA chain polymers. 0.1 µg DNA was mixed with 
polymer at N/P ratios of 6 and 12 (corresponds to a average w/w of 5/10) and analyzed by gel 
retardation assay. 1: K-Stp5-K (#23); 2: K-Stp2-K-MyrA2(#9); 3: K-Stp2-K-OleA2(#10); 4: K-Stp4-K-
MyrA2(#21); 5: K-Stp4-K-OleA2(#22); 6: K-Stp4-K-AraA2 (#50) 
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Figure. 4.25: Reporter gene expression and metabolic activity of cells 24 h after transfection 
using i-shape type PAAs in comparision to a chain type PAA. 
using 200 ng pCMVLuc (2 µg/mL DNA) plasmid. Polyplexes were prepared at different w/w ratios and 
compared to standard LPEI polyplexes. Luciferase reporter gene expression (A) and metabolic activity 
(MTT Assay, B) are presented as mean value + SD of qui
 
In comparison to LPEI all these structures show 1000
them useless as gene transfer reagents. Nevertheless, the data demonstrate the 
beneficial influence of hydrophobic modifications on stability and delivery us
PAA fragments.  
 
4.4.4 Influence of a Dimerization Anchor on Transfection Efficiency
To study the influence of disulfide bridges on polyplex stabilization a C
cysteine was incorporated into an i
structures were initially synthesized to introduce a thiol handle for subsequent 
bioconjugation to siRNA or proteins, but attempts to prepare lytic siRNAs by direct 
conjugation to the 5’ end (sense strand) of a thiol
unsuccessful as the lytic activity collapsed (unpublished results Christian Dohmen). 
The introduction of a C-terminal cysteine showed no significant impact on NA 
complexation a w/w of 10 was sufficient for complete retardation (
Neuro2A cells were transfec
ntuplicates.  
-fold lower activity, rendering 
-shape sequence (HO-C-Stp
-modified siRNA duplex were 
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ing small 
 
-terminal 
n-K-FA2). These 
Figure 4.27.1-4). 
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Using these dimerizable, fatty acid modified PAAs for DNA delivery had a significant 
effect on reporter gene expression as shown in Figure 4.26. In comparison to their 
analog sequences K-Stp2-K-MyrA2 (#9) and K-Stp2-K-OleA2 (#10) introduction of a C-
terminal cysteine (#67 + #70) results in a 100-fold increased reporter gene 
expression at a w/w of 10. To evaluate the possible influence of the primary amine of 
the lysine residue on DNA delivery sequences without the additional lysine were 
screened. While the lysine had no significant effect on the oleic acid modified PAAs 
(Figure 4.26, #70 vs. #69) the delivery efficiency of #68 compared to #67 was 
increased 100-fold. Interestingly the toxicity of the myristic acid modified PAAs was 
not affected in the same manner. While the metabolic activity of cells treated with the 
non-thiol containing sequence #9 dropped to 10% (w/w 40), treatment with cysteine 
modified #68 only resulted in a decrease to 50% (w/w 40).  Oleic acid modification 
had no pronounced effect on cell viability regardless of sequence composition. 
C-terminal cysteine modification seems to be a viable option to increase the delivery 
capability of short chain PAAs and has the additional benefit of a reducing cellular 
toxicity in case of myristic acid modified PAAs. Oleic acid modification on the other 
hand shows a comparable increase in gene expression but without an increased 
cytotoxicity in the tested concentrations. Myristic acid modified PAAs induce a bell 
shaped expression profile wherein the reporter gene expression rises with increasing 
concentration until the onset of toxicity impairs reporter gene expression, while oleic 
acid modified PAAs reach a more or less stable expression plateau at a w/w of 10. 
These results support the hypothesis that the PAA polymers without the ability of  
disulfide bridge formation suffer from inadequately stabilization of the resulting 
polyplexes. This problem might be overcome by either synthesizing larger polymers 
or by using other means of stabilization like in situ thiol dimerization or crosslinking.  
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Figure 4.26: Reporter gene expression and metabolic activity of cells 24 h after transfection 
using dimerizable i-shape type PAAs. 
µg/mL DNA) plasmid. Polyplexes were prepared at different w
LPEI polyplexes. Luciferase reporter gene expression (A) and metabolic activity (MTT Assay, B) are 
presented as mean value + SD of quintuplicates
.  
 
 
Neuro2A cells were transfected using 200 ng pCMVLuc (2 
/w ratios and compared to standard 
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Figure 4.27: Comparison of the gel retardation of DNA of the different PAA families. All polymers 
were tested at a w/w of 10. Polymers showing no complete retardation at that concentration are shown 
in increasing concentrations. Picture 1 – 4 dimerizing i-shapes (#67, #68, #70, #69); Picture 5 – 7 i-
shape family (#45, #46, #51), w/w 5,10,20; Picture 8 – 11 t-shape family (#74, #49, #78, #82); 12 – 14 
crosslinking chains family (#72, #76, #80), w/w 5, 10  
 
4.4.5 DNA Delivery Using Crosslinking i-Shape Structures 
By insertion of a second cysteine into the sequence (HO-C-Stp3-C-K-FA2) the 
polymers gain the ability of in situ polymerization allowing formation of bigger 
polymeric structures. It was hypothesized that the introduction of crosslinking would 
be beneficial for NA binding and could further stabilize an already formed complex by 
crosslinking. Gel retardation assay (Figure 4.27, #5-7) shows that in comparison with 
single cysteine modified PAAs (Figure 4.27, #1-4) the NA complexation is improved 
but still heavily dependent on hydrophobic modifications (Figure 4.27.7). 
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Figure 4.28: Reporter gene expression and metabolic activity of cells 24 h after transfection 
using crosslinking i-shape type PAAs. 
µg/mL DNA) plasmid. Polyplexes were prepared at different w/w ratios and compa
LPEI polyplexes. Luciferase reporter gene expression (A) and metabolic activity (MTT Assay, B) are 
presented as mean value + SD of quintuplicates. 
 
Figure 4.28 shows the reporter gene expression of crosslinking i
with different fatty acid modifications on a HO
polymers are able to effectively transfer pDNA into target cells and show a 
expression profile characterized by a plateau phase beginning with w/w 10. As soon 
as a critical concentration is reached reporter gene expression is not increased by 
higher polymer concentrations. For certain other polymeric delivery systems this 
effect is connected to increasing cytotoxicity at higher concentrations, in these cases 
MTT assay did not show to
bottlenecks.  Myristic and oleic acid i
control demonstrating the delivery potential of these structures. 
The use of the backbone control (unmodified N
decrease of efficiency highlighting the importance of the hydrophobic modification. 
The promising delivery results renders this scaffold into one of the most interesting 
for further development. 
Neuro2A cells were transfected using 200 ng pCMVLuc (2 
 
-shape formulations 
-C-Stp3-C-K-H backbone. All tested 
xic side effects indicating additional intracellular delivery 
-shapes are able to compete with the LPEI 
 
-terminus) resulted in a 10 to 50
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4.4.6 DNA Delivery Using PAAs With t-Shape Topology 
By synthesizing a set of symmetrical i-shape polymers with a central hydrophobic 
domain (t-Shapes) the influence of parameters like the amount of protonable groups 
per molecule, hydrophilic-lipophilic ratio (HLR) of the molecule and influence of the 
hydrophobic modification on larger PAA structures were studied.  
Figure 4.24 compares the binding capabilities of di-oleoyl modified t-shapes (#8-11) 
with non hydrophobically modified linear chains with terminal cysteines (#12-14). The 
oleoyl t-Shape/DNA complexes are strong enough to prevent migration in the gel at a 
w/w of 10 while the interaction of the unmodified chains at the same w/w is not strong 
enough to prevent NA migration. Figure 4.29 shows the transfection efficiency and 
cytotoxic potential of oleoyl t-shapes with differing numbers of Stp building blocks per 
molecule. All tested polymers were synthesized with a dual oleic acid motif at the 
central lysine, as the oleic acid modification was the most effective modification in 
terms of toxicity and efficiency in the previous experiments. The balance between 
hydrophobic and cationic domain has a significant impact on efficacy as seen by 
comparing the transfection efficiency of #74 and #49. While increasing 
concentrations of #74 lead to reporter gene expression almost reaching the LPEI 
control the use of a polymer containing two additional Stp units results in an early, 
only moderate plateau of activity.  The introduction of additional Stp units didn’t 
improve their overall performance, regardless of the tested concentrations the 
reporter gene expression was always tenfold lower than the LPEI control. The results 
indicate a fine balance between hydrophobicity and hydrophilicity as exemplified by 
#74. #74 has the highest HLR in the screen (0.341, Table 4.7) and exhibits the 
strongest activity in terms of expression level. All other t-shape derivatives cannot 
compete in terms of expression level and reach their maximum level at lower 
concentrations of w/w 5. 
To study the influence of the hydrophobic domain onto the efficiency of the t-shape 
polymers in more detail, a second set of polymers without hydrophobic modification 
(crosslinking chains) was synthesized and screened (Figure 4.30). Here the trend 
was reversed #72, a structural analogue of #74 (2 Stp-units) did not show any 
reporter gene expression while an increase in Stp-building blocks per molecule did 
result in an increasing gene expression (#76, #80). Compared to the gene 
expression levels of the oleoyl t-shapes these polymers have the disadvantage of 
needing rather high polymer concentrations to achieve a comparable transfection 
Results 
 
 
efficiency. The dual fatty acid motif can increase the delivery efficiency but the 
influence of the modification diminishes with an increasing number of Stp
backbone. This supports earlier findings that the hydrophobic modification is more 
effective on smaller PAAs and can increase their efficiency dramatically, while an 
increasing amount of Stp units in a fatty acid
improved, but less efficient delivery.
 
 
Figure 4.29: Reporter gene expression and metabolic activity of cells 24 h after transfection 
using t-shape PAAs. Neuro2A cells were transfected using 200 ng pCMVLuc (2 µg/mL DNA) 
plasmid. Polyplexes were prepared at different w/w ratios and compared to standard LPEI polyplexes. 
Luciferase reporter gene expression (A) and metabolic activity (MTT Assay, B) are presented as mean 
value + SD of quintuplicates.  
-free polymer also results in 
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Figure 4.30: Reporter gene expression and metabolic a
using non-hydrophobically modified t
pCMVLuc (2 µg/mL DNA) plasmid. Polyplexes were prepared at different w/w ratios and compared to 
standard LPEI polyplexes. Luciferase reporter gene expression (A) and metabolic activity (MTT Assay, 
B) are presented as mean value + SD of quintuplicates. 
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# Sequence Mw Prot. 
Amines 
HLR Charge density 
[Da/charge] 
9 K-Stp2-K-MyrA2 1237,8 7 0,340 177 
10 K-Stp2-K-OleA2 1346,0 7 0,393 192 
21 K-Stp4-K-MyrA2 1780,5 13 0,236 137 
22 K-Stp4-K-OleA2 1888,7 13 0,280 145 
23 K-Stp5-K 1631,2 18 - 91 
45 C-Stp3-C-K-MyrA2 1587,3 9 0,265 176 
46 C-Stp3-C-K-OleA2 1695,4 9 0,312 188 
49 C-Stp2-K-(K-OleA2)-Stp2-C 2095,0 13 0,252 161 
51 C-Stp3-C-K 1166,6 11 - 106 
67 C-Stp2-K-MyrA2 1212,8 6 0,347 202 
68 C-K-Stp2-K-MyrA2 1340,9 7 0,314 192 
69 C-K-Stp2-K-OleA2 1449,1 7 0,365 207 
70 C-Stp2-K-OleicA2 1320,9 6 0,400 220 
72 C-Stp1-K(K)-Stp1-C 1023,4 9 - 114 
74 C-Stp1-K(K-OleA2)-Stp1-C 1552,3 7 0,341 222 
76 C-Stp3-K(K)-Stp3-C 2108,8 19 - 111 
78 C-Stp3-K(K-OleA2)-Stp3-C 2637,7 17 0,201 155 
80 C-Stp4-K(K)-Stp4-C 2653,5 27 - 98 
82 C-Stp4-K(K-OleA2)-Stp4-C 3182,4 25 0,166 127 
Literature examples     
OEI800 800 ~ 19  42 
LPEI22 22000 ~ 500  42 
PAMAM G3 6909,0 62  111 
Table 4.7: PAA Sequences used in DNA transfections (synthesized by Christina Troiber, master 
thesis, Wagner lab) in comparison to commonly used transfection reagents. 
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5.1 Poly(I:C) Mediated Tumor Killing by LPEI-PEG-EGF Complexation 
A virally infected host organism reacts with multiple innate and acquired defense 
mechanisms to avoid against further virus spread, including humoral and cellular 
immune responses against proteins and viral particles, and also responses against 
viral nucleic acid intermediates. A series of toll-like receptors (TLRs) at the cell 
surface and in endosomal vesicles and also cytosolic factors recognize viral nucleic 
acids which have different properties as compared to endogenous cellular RNA and 
DNA. This recognition often triggers inflammatory and interferon responses, shut-
down of protein production and suicide of infected cells by apoptosis. 
Synthetic viral nucleic acid analogs have been therapeutically applied as 
immunostimulatory and cytotoxic DNAs and RNAs175-178. poly(I:C) and analogs 
thereof129,179-181  mimic double-stranded RNA of virus-infected cells which via 
endosomal toll-like receptor TLR3 and cytosolic helicase mda-5 stimulation activate 
different pro-apoptotic processes simultaneously. This makes poly(I:C) an interesting 
tool for cancer treatment because the differently triggered host cell killing 
mechanisms reduce the probability of developing acquired chemoresistence; they 
lead to cell death, and the additional expression of anti-proliferative interferons and 
other cytokines and chemokines inhibits growth of neighbouring cancer cells that 
have not been “infected” with poly(I:C)102. 
Untargeted poly(I:C) and analogs have already been applied as adjuvants in cancer-
directed human immunotherapy studies, with some limited success but by far not all 
applications180-182. For example, poly(I:C) stabilized by polylysine and 
carboxymethylcellulose applied intramuscularly 3 times a week for 4 week as a single 
agent therapy did not improve progression-free survival of anaplastic glioma patients 
in a phase II study181. To fully exploit the therapeutic potential of both immune 
stimulation and tumor cell killing, poly(I:C) has to be delivered intracellularly into 
endosomes and also the cytosol, in a tumor-targeted fashion. Obviously, delivery 
presents the major bottleneck. Both liposomal and polymer-based strategies have 
been developed for poly(I:C). These include MHC antibody-targeted or pH-sensitive 
liposomes183-184, lipoplexes129,185, nontargeted polymer formulations180  or, as outlined 
in our previous work, EGF receptor-targeted poly(I:C) polyplexes102. In the latter 
paper Shir et al. demonstrated killing of EGFR overexpressing human tumors 
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including glioblastoma upon local administration. Polyplexes consisted of poly(I:C) 
complexed with either one or two branched polyethylenimine (brPEI) conjugates 
comprising recombinant EGF as targeting ligand and PEG as shielding 
domain109,122,186-187, and synthetic melittin peptide as endosomal release agent. Both 
targeting and endosomal domain was found to be essential for the observed 
biological activity102.  
The current work has been based on the task to develop an improved PEI-based 
carrier for poly(I:C) comprising all the mentioned EGFR targeting, PEG shielding, and 
endosomal release functions, but providing them within a polymer conjugate of 
reduced chemical complexity. This was achieved in the following way. At first, the 
chemically poorly defined brPEI was replaced by the analogous linear 22 kDa 
polymer LPEI122,188 which can be synthesized in GMP compatible form125 and has 
already been tested in human clinical trials for DNA delivery. Due to its higher 
inherent potency over brPEI127,131, plain LPEI actually mediated in vitro cell killing 
independent of receptor targeting or endosomolytic melittin (Figure 4.2). This effect 
however was accompanied by an unspecific, non-poly(I:C) related cytotoxicity at 
higher polyplex doses, as demonstrated with poly(I) control polyplexes.  
Secondly, LPEI was conjugated with PEG molecules of different molecular weight (2, 
5 kDa and 10 kDa). PEGylation strongly reduced the cytotoxicity but also poly(I:C) 
based cell killing. For 10 kDa PEG and 5 kDa PEG the activity was lost, for 2 kDa 
PEG only a hint of activity was obtained (Figure 4.2). Finally, incorporation of EGF 
as receptor targeting ligand restored activity for the LPEI-PEG2kDa conjugate but not 
LPEI-PEG10kDa conjugate (Figure 4.2). The LPEI-PEG5kDa mediated moderate 
activity at a higher dose. Such a “PEG dilemma” (indirect correlation of shielding and 
efficacy) is consistent with many previous observations by several 
laboratories132,135,189-191 and might be explained by the fact that for endosomal 
membrane disruption stable PEG-shielding is counter-productive55,137,192. Apparently 
the window between shielding / targeting specificity and efficient intracellular delivery 
is narrow. 
The newly developed LPEI-PEG2kDa-EGF conjugate exhibits the key features of the 
old tetraconjugate, namely higher potency on EGFR overexpressing U87MGwtEGFR 
gliomas as compared to low-expressing U87MG cells (Figure 4.3). An approximately 
2.5-fold improved therapeutic efficiency was observed in vitro in comparison to the 
old conjugate on U87MGwtEGFR gliomas (Figure 4.3). An efficient and specific 
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poly(I:C) mediated cell killing was also obtained with A431 cells (Figure 4.5). These 
epidermoid carcinoma cells express particularly high levels of EGF receptor. EGFR 
density is described with 2x106/cell, higher than U87MGwtEGFR (1x106/cell) and 
much higher than U87MG (1x105/cell)193-194. Most encouraging, systemic intravenous 
administration of poly(I:C) polyplexes were able to strongly retard growth of distant 
subcutaneous A431 tumors in vivo. The treatment was well tolerated by the mice. 
Once again, the effect was dependent on poly(I:C) as key component of the 
formulation. Polyplexes made from the novel conjugates showed the best therapeutic 
effect (Figure 4.6). 
 
5.2 Development of a Synthesis Platform for the Production of Defined 
Polyamidoamines  
 
The development of new strategies for polymer synthesis is a key issue in the field of 
polymeric delivery. The maturation of the already established systems over the last 
years resulted in the synthesis of dynamic and increasingly complex systems. But, 
despite the progress in the development of carrier systems, most of the used 
polymers continue to be ill-defined due to their synthesis by classical random 
polymerization methods. Precise incorporation of additional functional domains is not 
possible, thereby limiting further development of polymeric carriers. 
Aim of this study was the development of a solid-phase synthesis platform allowing 
the synthesis of precise oligoethylenimine-based polymers and integration of the 
platform into a parallel synthesis setting. In an attempt to use an already published 
alternating condensation strategy100 to generate an oligoethylenimine based 
polyamidoamine library, the corresponding boc-protected oligoethylenimine building 
blocks were synthesized.  But use of these protected oligoethylenimine building 
blocks together with the published synthesis protocols led to extensive crosslinking of 
PAA fragments on the resin, severely impeding the use of the synthetic strategy. The 
alternating condensation strategy is also limited by the need for complex in-reaction 
monitoring and the extensive MS analysis which has to be performed for every new 
monomer combination. These findings and concerns regarding limitations of the 
synthetic versatility of the strategy led us to an adaption of the fmoc/tBu strategy195-
196
 for the generation of oligoethylenimine-based libraries. 
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Use of a polyamino acid for chain elongation circumvents the critical on-resin 
activation step and through utilization of fmoc-protection for the terminal amine the 
formation of crosslinking products during the solid-phase synthesis is effectively 
omitted. 16-Amino-4-oxo-5,8,11,14-tetraazahexadecanoic acid (Stp) was chosen as 
model building block due to the convenient access to large amounts of the boc-
protected precursor and its advantageous properties regarding buffering capabilities 
and charge density. The synthesized fmoc-Stp(boc3)-OH building block is fully 
compatible to standard automated fmoc solid-phase synthesis. The synthesis of pure 
PAAs and PAA-Peptide chimeras by standard SPS protocols showed acceptable 
purity of raw product and full compatibility to normal peptide synthesis. 
To conclude, a versatile synthetic route for the fast synthesis of defined 
oligoethylenimine-based PAAs was developed. By using the well established 
fmoc/tBu SPPS methodology control over every monomer is possible, thereby 
introducing molecular programmability into the design of delivery vectors. The full 
compatibility to standard fmoc/tBu peptide synthesis gives access to the vast number 
of building blocks originally developed for peptide synthesis, allowing introduction of 
targeting moieties, lytic domains or PEGylation. By combining the synthetic 
possibilities of the platform with already described dynamic modules the generation 
of new classes of bio-responsive, dynamic vectors is possible. 
 
5.3 Design and Biophysical Evaluation of a PAA-Library for Nucleic Acid 
Delivery 
 
Since the formulation of the gene therapy concept in the seventies of the last 
century15 the polymeric nucleic acid delivery field maturated considerably. But 
despite the progress in carrier development most of the presently established 
polymeric carriers are only used in diagnostic settings or for target validation. So far 
viral vector systems dominate the clinical field of gene therapy71 but a series of 
setbacks shed light on inherent safety problems of viral vectors, rendering polymer-
based vectors a viable, but until now less efficient alternative. In spite of manifold 
opportunities for new, effective carrier systems the development of polymeric 
transfection systems is still characterized by rather low throughput and molecular 
precision. 
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The definition of a minimal domain construction set can be achieved by stripping the 
polymeric delivery system down to its essential parts and using it as template for 
solid-phase assisted library generation, followed by evaluation in biophysical assays. 
These domains can subsequently be optimized and used to build new carriers with 
programmed properties. For a first proof of concept a simple domain model was used 
to restrict the design space. By limiting the polymer domains to 4 easily controllable 
structural domains (Table 4.5) and incorporation of dynamic stabilization we aimed at 
a simple, flexible system that allows further optimization of these rather primitive 
vectors. To construct useful structure-function relationships we defined two key 
properties (lytic activity, NA binding) as essential biophysical screening parameters 
for a systematical evaluation of the library. 
Poor endosomal escape significantly limits the efficiency of polymeric carriers. 
Incorporation of either lytic peptides197 or lipophilic modifications40 for increased 
membrane interactions  are often employed to increase the endosomal escape. Initial 
screens of unmodified PAAs showed that the Stp-backbone has no intrinsic lytic 
potential and is probably too small for a distinct proton sponge effect. Modification of 
the Stp backbones with hydrophobic domains resulted in an increased, controllable 
lytic activity (Figure 4.18).  In contrast to the only minimal lytic activity of single fatty 
acid modified PAAs the introduction of a second fatty acid led to a significantly 
increased lytic activity which can be controlled by type of fatty acid, length of PAA 
molecule and thiol content. The pH-specificity of the lytic activity can be controlled by 
careful selection of the hydrophobic modification. The impact of specific lytic activity 
on the in vitro performance of an NA formulation is exemplified in Figure 4.19 
demonstrating that unspecific lytic activity contributes to in vitro toxicity.  
The second essential property for a nucleic acid delivery system is the ability to bind 
to the NA payload and to protect it during the transport to the target cell. As the 
accessible design space of the solid-phase synthesis platform is too big for an 
exhaustive evaluation we aimed on the fast identification of minimal binding motifs for 
pDNA and siRNA. The best hits should then serve as lead structures for further 
delivery system development. As expected, unmodified PAAs (Stpn < 6) were not 
able to bind effectively enough to either pDNA or siRNA to prevent migration of NA in 
a gel-shift assay. To identify a minimal binding motif for hydrophobically modified 
PAAs a K-Stp2-K-FA2 template was systematically acylated with different fatty acids. 
While introduction of one FA into the template already enabled pDNA binding at high 
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N/Ps siRNA complexation was not influenced significantly. Use of two FA acids 
resulted in complete retardation at low N/Ps of siRNA and pDNA if FAs with a chain 
length > 8 were used. An exemplary comparison of different classes of the polymers 
in siRNA/DNA delivery (Figure 4.23) shows the synergistic effects of the different 
domains. The most effective polymers are characterized by a hydrophobic domain 
containing fatty acids with a chain length > C8, at least two Stp units and thiol 
anchors for stabilization of the resulting polyplexes.  
To conclude, parallel synthesis of a modular PAA library followed by biophysical 
characterization allowed the construction of first PAA SAR models beneficial for the 
rational development of Stp-based NA delivery vectors. By restricting the library to 
small polymers with only little variance in their modules it was possible to identify 
efficient delivery vectors out of the different families. Thus useful domains for further 
development of programmed polymeric delivery systems could be identified. 
 
5.4 Evaluation of Different Stp-based PAA Families for in vitro DNA Delivery 
Better defined, modular polymer systems with a diverse and easily accessible design 
space can open new possibilities for the future development of carrier systems for 
NA delivery. We used a solid-phase assisted, parallel synthesis approach to 
generate a small library of defined Stp-Polymers, modified with fatty acids and amino 
acids. By screening of the library for desirable biophysical characteristics and 
subsequent in vitro evaluation of their DNA delivery capabilities we wanted to 
demonstrate the potential of modular designed polymers for DNA delivery. 
Comparison of four structural different families (cysteine free polymers, chains, i-
shapes and t-shapes) regarding DNA binding and transfection efficiency resulted in 
first SARs for Stp-polymers. Figures 4.24 and 4.27 show the influence of 
hydrophobic modifications on the NA binding properties of the PAA systems. Plain 
Stp-sequences did not condense DNA while polymers containing a dual fatty acid 
motif (chain length > C8) strongly bound DNA at N/Ps as low as 6. Introduction of two 
cysteines into linear Stp-sequences for lateral polyplex stabilization via disulfide 
bridges did not show a comparable impact on NA binding in the gel-shift assay. Even 
at N/Ps as high as 18, cysteine modified Stp-chains were not able to condense the 
pDNA completely. Comparison of both stabilization concepts under in vitro conditions 
showed that incorporation of the dual fatty acid motif results in an up to 100-fold 
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increase of luciferase signal while the cysteine modification results in a 1000-fold 
increase. The results demonstrate that hydrophobic modification of the polymers 
using different FAs has a significant impact on NA complexation. Good binding alone, 
however, does not result in effective transfection. Cysteine containing polymers did 
not condense DNA as good as the hydrophobically modified polymers, but were able 
to cause effective pDNA-delivery under in vitro conditions.  
Combination of hydrophobic and cysteine modification led to the most effective 
polymer families in terms of binding and in vitro performance. Systematic variation of 
HLR, type of incorporated fatty acid and Mw of the polymers showed that hydrophobic 
modification is most beneficial for small polymers (Figure 4.29) and is the most 
important contributor to cytotoxicity. While the overall toxicity of the polymers is quite 
low modification with myristyl residues resulted in significant in vitro toxicity, severely 
limiting the use of this modification in the design of transfection polymers. An 
increasing number of Stp units in the fatty acid modified polymers leads to no further 
improvement of transfection efficiency. The transfection efficiency of polymers 
without fatty acid modification is strongly dependent on the number of Stp-units per 
molecule. Approximately 6 Stp-units per molecule are required for an activity 
approaching the LPEI control. Nevertheless, their activity never reaches the level of 
the best performing i-shapes and t-shapes.    
To sum up, we demonstrated that modular design and solid-phase assisted synthesis 
of Stp-based polymers allows the synthesis of effective delivery systems. We 
identified two classes of Stp-polymers which were effective in DNA delivery and can 
serve as template for further development. Due to the variable, modular composition 
and the already effective delivery, additional domains like targeting ligands or 
shielding domains can be incorporated for further optimization of the systems. 
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6 Summary 
 
Polymeric nucleic acid delivery systems have great relevance in the therapeutic 
delivery of nucleic acids. But despite enormous advances over the last 20 years 
nucleic acid therapies are far from being a standard option in treatment. One of the 
biggest obstacles to development of polymeric carriers is the lack of precise design 
rules and rational design platforms. The almost exclusive use of polydisperse 
backbones that are modified with additional functional domains, led to increasingly 
complex, multi-domain polymers requiring complex synthesis routes and 
characterization efforts.  
By the redesign of an efficient, but complex, modular polymeric carrier for the 
poly(I:C) treatment of glioblastoma we were able to show that decreased complexity 
can be beneficial in terms of synthesis and efficacy. The new, LPEI-based 
triconjugate consisting of targeting ligand, PEG-spacer and LPEI-backbone allows 
the use of GMP grade materials for a more controlled production process amenable 
to scale-up and shows a significantly improved performance in an in vivo setting. 
Nevertheless, this approach is still biased by the inherent heterogeneity of the used 
polymeric reactants. This complicates rational conjugate design and exact structure-
activity-relationship studies. 
As a first step towards the synthesis of programmable polymeric delivery systems, 
novel polyamino acid building blocks and protocols for the solid-phase synthesis of 
Stp-polymers were developed. By applying solid-phase synthesis to the production of 
oligoethylenimine based delivery systems, well defined polymers with programmable 
properties were synthesized. The solid-phase methodology enables rapid parallel 
synthesis of PAAs for nucleic acid delivery, allowing library construction for a quick 
survey of their delivery potential. 
The new synthesis platform was used to construct a small library of Stp-based 
polymers comprising domains with differing properties regarding hydrophobicity, 
charge density or disulfide formation. The library was restricted to a small Mw range 
to evaluate the influence of the different domains on core parameters like nucleic 
acid compaction or lytic activity towards cell membranes. The biophysical screening 
identified 2 different families (i-shape, t-shape) with interesting properties and siRNA 
/DNA delivery potential demonstrating the synergistic effect of the different domains 
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on delivery efficiency. Screening of the library for in vitro DNA delivery identified a set 
of lead structures able to compete with LPEI.  
The presented carrier systems are still limited in terms of efficiency and application in 
therapeutic settings. The polymers developed in this work, however, can be seen as 
first model systems to increase the knowledge about the rational design of non-viral 
vectors. The platform itself is a tool allowing the design of cationic polymers with 
molecular precision. Future development will focus on new building blocks, functional 
domains and further screening to identify potent sequences. Introduction of other 
functional domains like targeting ligands, shielding or nuclear localization sequences 
could allow the design of true PPDS, leading to the elucidation of new delivery 
bottlenecks and potential therapeutic applications. 
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8 Appendix 
 
8.1 List of Used Polymers 
# Sequence Formula Mw protonable amines Type 
1 K-Stp1-K C24H51N9O5 545,72 6 chain 
3 K-Stp1-K-CapA2 C40H79N9O7 798,11 4 i-shape 
4 K-Stp1-K-MyrA2 C52H103N9O7 966,43 4 i-shape 
5 K-Stp1-K-OleA2 C60H115N9O7 1074,61 4 i-shape 
6 K-Stp2-K C36H76N14O7 817,08 9 chain 
8 K-Stp2-K-CapA2 C52H104N14O9 1069,47 7 i-shape 
9 K-Stp2-K-MyrA2 C64H128N14O9 1237,79 7 i-shape 
10 K-Stp2-K-OleA2 C72H140N14O9 1345,97 7 i-shape 
18 K-Stp4-K C60H126N24O11 1359,80 15 chain 
20 K-Stp4-K-CapA2 C76H154N24O13 1612,19 13 i-shape 
21 K-Stp4-K-MyrA2 C88H178N24O13 1780,51 13 i-shape 
22 K-Stp4-K-OleA2 C96H190N24O13 1888,69 13 i-shape 
23 K-Stp5-K C72H151N29O13 1631,16 18 chain 
25 K-Stp5-K-AraA2 C112H227N29O15 2220,19 16 i-shape 
26 K-Stp5-K-MyrA2 C100H203N29O15 2051,87 16 i-shape 
27 K-Stp5-K-OleA2 C108H215N29O15 2160,05 16 i-shape 
30 C-Stp1-K-CapA2 C37H72N8O7S 773,08 3 i-shape 
31 C-Stp1-K-SteA2 C57H112N8O7S 1053,61 3 i-shape 
34 K-Stp2-ButA1 C34H70N12O7 759,00 7 i-shape 
35 K-Stp2-CapA1 C38H78N12O7 815,10 7 i-shape 
36 K-Stp2-MyrA1 C44H90N12O7 899,26 7 i-shape 
37 K-Stp2-OleA1 C48H96N12O7 953,35 7 i-shape 
38 K-Stp1-ButA1 C22H45N7O5 487,64 4 i-shape 
39 K-Stp1-CapA1 C26H53N7O5 543,74 4 i-shape 
40 K-Stp1-MyrA1 C32H65N7O5 627,90 4 i-shape 
41 K-Stp1-OleA1 C36H71N7O5 681,99 4 i-shape 
45 C-Stp3-C-K-MyrA2 C76H151N19O12S2 1587,26 9 i-shape 
46 C-Stp3-C-K-OleA2 C84H163N19O12S2 1695,44 9 i-shape 
48 C-Stp2-K-(K-MyrA2)-Stp2-C C94H188N26O15S2 1986,79 13 t-shape 
49 C-Stp2-K-(K-OleA2)-Stp2-C C102H200N26O15S2 2094,98 13 t-shape 
50 K-Stp4-K-ArA2 C100H202N24O13 1948,83 13 i-shape 
51 C-Stp3-C-K C48H99N19O10S2 1166,55 11 chain 
56 C-Stp2-K(CapA)-Stp2-C C68H138N24O13S2 1564,11 13 t-shape 
57 C-Stp2-K(MyrA)-Stp2-C C74H150N24O13S2 1648,27 13 t-shape 
58 C-Stp2-K(OleA)-Stp2-C C78H156N24O13S2 1702,36 13 t-shape 
59 C-Stp2-K(ArA)-Stp2-C C80H162N24O13S2 1732,43 13 t-shape 
62 C-Stp2-K(K-ArA2)-Stp2-C C106H212N26O15S2 2155,11 13 t-shape 
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66 C-Stp2-K(K-CapA2)Stp2-C C82H164N26O15S2 1818,47 13 t-shape 
67 C-Stp2-K-MyrA2 C61H121N13O9S 1212,76 6 i-shape 
68 C-K-Stp2-K-MyrA2 C67H133N15O10S 1340,93 7 i-shape 
69 C-K-Stp2-K-OleA2 C75H145N15O10S 1449,11 7 i-shape 
70 C-Stp2-K-OleA2 C69H133N13O9S 1320,94 6 i-shape 
71 C-Stp1-K(K-MyrA2)-Stp1-C C70H138N16O11S2 1444,07 7 t-shape 
72 C-Stp1-K(K)-Stp1-C C42H86N16O9S2 1023,36 9 chain 
73 C-Stp1-K(K-SteA2)-Stp1-C C78H154N16O11S2 1556,29 7 t-shape 
74 C-Stp1-K(K-OleA2)-Stp1-C C78H150N16O11S2 1552,26 7 t-shape 
75 C-Stp3-K(K-MyrA2)-Stp3-C C118H238N36O19S2 2529,51 19 t-shape 
76 C-Stp3-K(K)-Stp3-C C90H186N36O17S2 2108,80 19 chain 
77 C-Stp3-K(K-SteA2)-Stp3-C C126H254N36O19S2 2641,73 17 t-shape 
78 C-Stp3-K(K-OleA2)-Stp3-C C126H250N36O19S2 2637,69 17 t-shape 
79 C-Stp4-K(K-MyrA2)-Stp4-C C142H288N46O23S2 3072,23 25 t-shape 
80 C-Stp4-K(K)-Stp4-C C112H234N48O21S2 2653,50 27 chain 
81 C-Stp4-K(K-SteA2)-Stp4-C C150H304N46O23S2 3184,44 25 t-shape 
82 C-Stp4-K(K-OleA2)-Stp4-C C148H298N48O23S2 3182,39 25 t-shape 
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8.2 Abbreviations 
 
Abbreviation Meaning 
  
2-ClTrt 2-Chlorotrityl 
9-BBN 9-Borabicyclo[3.3.1]nonane 
AA Amino acid 
ACN Acetonitrile 
asODN Antisense oligodeoxynucleotide 
boc tert-Butyloxycarbonyl 
brPEI Branched polyethylenimine 
CMV Cytomegalovirus 
Da Dalton 
DCM Dichloromethane 
DCU Dicyclohexylurea 
DCVC Dry column vacuum chromatography 
Dde N-(1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl) 
DIPEA Diisopropylethylamine 
DMEM Dulbecco’s modified eagle’s medium 
DMF Dimethylformamide 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DOPE Dioleoyl-phosphatidylethanolamine 
DOTAP N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium 
dsRNA Double-stranded ribonucleic acid 
DTNB Dithionitrobenzoic acid 
DTT DL-Dithiothreitol 
ECM Extracellular matrix 
EDT Ethanedithiol 
EDTA Ethylenediamine tetraacetic acid 
EGF Epithelial growth factor 
eGFP Enhanced green fluorescent protein 
EMEA European medicines agency 
EPR Enhanced permeability and retention 
ESI-MS Electrospray ionization mass spectrometry 
EtOH Ethanol 
FAB-MS Fast atom bombardment mass spectrometry 
FCS Fetal calf serum 
fmoc/tBu 9-Fluorenylmethyloxycarbonyl/tert-Butyl 
fmoc-AA-OH Fmoc-amino acid 
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FRET Foerster resonance energy transfer 
GMP Good manufacturing practice 
HBG HEPES buffered glucose 
HEPES N-(2-hydroethyl) piperazine-N‘-(2-ethansulfonic acid) 
HLR Hydrophilic-hydrophobic ratio 
HOBt 1-Hydroxybenzotriazole 
HPLC High-performance liquid chromatography 
HV High vacuum 
IEX Ion-exchange 
LPEI Linear polyethylenimine 
Luc Luciferase 
MALDI Matrix assisted laser desorption ionization mass 
spectrometry 
Mel Melittin 
MeOH Methanol 
mRNA Messenger RNA 
MS Mass spectrometry 
MTBE tert-Butyl methylether 
MTT Methylthiazolyldiphenyl-tetrazolium bromide 
Mw Molecular weight 
N/P ratio Number of protonable nitrogens to phosphates 
NA Nucleic acid 
NHS N-Hydroxysuccinimide 
NLS Nuclear localization sequence 
NMR Nuclear magnetic resonance 
NPC Nuclear pore complex 
OEI Oligoethylenimine 
ON Oligonucleotide 
OPSS ortho-Pyridyldisulfide 
PAA Polyamidoamine 
PAE Poly(ß-amino ester) 
PAMAM Polyamidoamine (in dendrimers nomenclature) 
pDNA Plasmid DNA 
PDP (2-pyridyldithio)-propionoyl modified 
PEG Polyethylene glycol 
pEGFPLuc Plasmid encoding a EGFP-Luciferase fusion 
PEI Polyethylenimine 
PEOZ Poly(2-ethyl-2-oxazoline) 
Pip Piperidine 
PMO Phosphorodiamidate morpholino oligo 
Poly(I) Polyinosinic acid 
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poly(I:C) Polyinosinic:polycytidylic acid duplex 
PPDS Programmable polymeric delivery system 
PS Polystyrole 
PyBOP® Benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate 
RBF Round-bottom flask 
RISC RNA-induced silencing complex 
RLU Relative light units 
RNA Ribonucleic acid 
RNAi RNA interference 
RP-HPLC Reversed-Phase High-performance liquid chromatography 
RT Room temperature 
SAR Structure-activity relationship 
SEC Size-exclusion chromatography 
siRNA Small inhibitory RNA 
SPDP N-Succinimidyl-3-(2-pyridyldithio)propionate 
Stp 16-Amino-4-oxo-5,8,11,14-tetraazahexadecanoic acid 
Succ Succinyl 
TBE Tris-Boric acid-EDTA Buffer 
TEA Triethylamine 
TFA Trifluoroacetic acid 
TfaEt Ethyl trifluoroacetate 
THF Tetrahydrofuran 
TIS Triisopropylsilane 
TLC Thin layer chromatography 
TLR Toll-like receptor 
TNBS Trinitrobenzenesulfonic acid 
UV-VIS Ultraviolett-Visible spectroscopy 
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8.3 Buffer List 
Buffer Ingredient  
DMEM LG 
Biochrom DMEM medium powder 
NaHCO3 
FCS 
Glucose monohydrate 
Penicillin 
Streptomycin 
Stable glutamine  
Adjusted to pH 7.4 
10.15 g/L 
3.7 g/L 
10% 
10 g 
1% 
1% 
1% 
 
DNA Loading Buffer 
0.5 M EDTA (pH 8.0) solution 
Glycerine 
MilliQ water 
Bromophenol blue 
2.4 mL 
12.0 mL 
5.6 mL 
40 mg 
DTNB-Stock Solution 
DTNB 
MilliQ water 
4 mg 
1 mL 
Ellman’s Buffer 
Na2HPO4 (0.2 M) 
EDTA disodium salt dihydrate 
Adjusted to pH 8.0 
28.4 g/L 
372 mg/L 
 
HBG 
HEPES (20 mM) 
Glucose monohydrate 
MilliQ 
pH adjusted to 7.1 
4.76 g/L 
50 g/L 
ad 1000 mL 
 
LAR 
1 M glycylglycine solution (pH 8.0) 
100 mM MgCl2 solution 
0.5 M EDTA solution (pH 8.0) 
DTT 
ATP 
Coenzyme A 
MilliQ water 
pH adjusted to 8.0 
Luciferine-Solution 
2 mL (20 mM) 
1 mL (1 mM) 
20 µL (0.1 mM) 
50.8 mg (3.2 mM) 
27.8 mg (0.55 mM) 
21.3 mg (0.27 mM) 
Ad 100 mL 
 
Ad 0.5 mM 
PBS 
KCl 
KH2PO4 
NaCl 
Anhydrous Na2PO4 
MilliQ water 
Adjusted to pH 7.4 
0.2 g 
0.24 g 
8.0 g 
1.15 g 
Ad 1000 mL 
 
RNA Loading Buffer 
0.5 M EDTA (pH 8.0) 
Glycerine 
MilliQ water 
Xylene cyanol 
2.4 mL 
12.0 mL 
5.6 mL 
40 mg 
TBE Buffer 
Trizma base 
Boric acid 
EDTA disodium salt dehydrate 
MilliQ water 
10.8 g 
5.5 g 
0.75 g 
Ad 1000 mL 
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8.4 Supporting Information Chapter 4.1
PEI/poly(I:C) binding 
Figure S1. Binding of poly(I:C) to PEI as analyzed by agarose gel shift assay.
poly(I:C) were complexed using either LPEI or brPEI and analyzed by gel shift assay. Both polymer 
backbones were able to efficiently complex poly(I:C) at a minimal N/
 
Heparin Dissociation Assay
Figure S2: Binding of poly(I:C) to PEI conjugates as analyzed by heparin dissociation and 
agarose gel shift assay. 800 ng poly(I:C) were complexed using indicated polymers at N/P ratio of 8 
and treated with indicated amounts of the polyanion heparin, resulting in partial release of poly(I:C) at 
higher concentrations. 
 
 
P ratio of 6. 
 
  
132 
 
 400 or 800 ng 
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Determination of the EGFR Count on U87MG/U87MGwtEGFR
Figure S3: Relative EGF receptor cell surface level on tumor cell lines.
U87MGwtEGFR cells (b) were incubated with a mouse anti
an Alexa-488 conjugated secondary polyclonal goat anti
as well as cells, incubated only with secondary antibody (2nd AB on
 
Poly(I:C) Dose Titration Using LPEI
Figure S4: In vitro antitumoral activity of poly(I:C) at different concentrations against 
U87MGwtEGFR glioma cells. Comparison of 
Conditions: 10.000 cells/well, Incubation for 48 h with indicated dose of poly(I:C), poly(I). Metabolic 
activity was measured by MTT test.
 
 
  
 
-EGFR antibody followed by treatment with 
-mouse antibody. Untreated cells (cells only) 
ly) served as negative control.
-PEG10kDa-EGF as Carrier 
 
poly(I:C) [black bars] with poly(I) control [grey bars].
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 U87MG (a), 
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8.5 Supporting Information Chapter 4.4
Figure S4. Influence of polyplex formation
Conditions: Neuro2A, 10.000 cells/well; polyplexes formed with pDNA(EGFPLuc) and polymer in pH 
adjusted buffer (HBG titrated with HCl/NaOH). Polyplexes were formed by mixing equal volumes of 
pDNA/Polymer solution, incubated f
24 h. Experiment shows pH dependency of the transfection protocol. Differences between pH 6.3 and 
pH 8.3 are highly significant.  
 
 
 buffer pH on transfection efficiency
or 30 min and added to the cells 20 µL on 80 µL and incubated for 
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8.6  Used Protective Groups and Polymer Nomenclature 
Amino acid Three letter 
code 
One letter 
code 
Used prot. 
group 
Residue 
weight (-H2O) 
Charge 
ß-Alanine ßAla - - 71.08 0 
Alanine Ala A - 71.08 0 
Arginine Arg R Pbf 156.19 +1 
Asparagine Asn N Trt 114.11 0 
Aspartic acid Asp D OtBu 115.09 -1 
Cysteine Cys C Trt|StBu 103.15 0 
Glutamic acid Glu E OtBu 129.12 -1 
Glutamine Gln Q Trt 128.13 0 
Glycine Gly G - 57.05 0 
Histidine His H Trt 137.14 0/+1 
Isoleucine Ile I - 113.16 0 
Leucine Leu L - 113.16 0 
Lysine Lys K Boc 128.18 +1 
Methionine Met M - 131.20 0 
Phenylalanine Phe F - 147.18 0 
Proline Pro P - 97.12 0 
Serine Ser S tBu 87.08 0 
Threonine Thr T tBu 101.11 0 
Tryptophan Trp W Boc 186.22 0 
Tyrosine Tyr Y tBu 163.18 0 
Valine Val V - 99.13 0 
      
SuccTEPA Stp - Boc 281.21 +3 
 
Fatty acid Four letter 
code 
Residue 
weight (-H2O) 
C:D n-x Δ X 
Acetic acid AceA 42.03 2:0 - - 
Butyric acid ButA 70.09 4:0 - - 
Caprylic acid CapA 126.19 8:0 - - 
Myristic acid MyrA 210.35 14:0 - - 
Oleic acid  OleA 264.44 18:1 n-9 cis-Δ9 
Arachidic acid AraA 294.51 20:0 - - 
 
Appendix   
 
136 
 
General Nomenclature of Synthesized PAAs and Peptides 
• Contrary to IUPAC peptide nomenclature all sequences are written in C→N 
direction, the carboxy terminal residue is indicated by the HO-prefix and N-
terminal residue (if present) is labeled with -H 
• Standard amino acids are always written in single letter code (e.g. A, K, C) 
• Polyaminoacids and all non-natural amino acids are always written using  
three letter code (eg. Stp, Dha )  
• Fatty acids are always written in 4 letters  (eg. LinA, OleA) where the forth 
letter is always an A 
• Polyaminoacid abbreviations are build with the following rules: 
1. Letter: Acid component → succinic acid → S 
2. Letter: Amine component → spacer unit part → tetraethylene → t 
3. Letter: Amine component → number of amines → pentamine → p 
• Branching is indicated by the use of round brackets followed by an index for 
the number of branches 
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8.7 Analytical Data 
Sequence: HO-K-Stp1-K-H #: 01 
Molecular formula: C24H51N9O5 Mw 545.72 
MALDI: 546.9  546.4 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 17.0 °C): δ = 1.29 - 1.48 (m, 4H, γ-CH2-, Lys), 
1.54 - 1.68 (m, 4H, δ-CH2-, Lys),1.69 - 1.93 (m, 4H, β-CH2-, Lys), 2.42 - 
2.52 (m, 2H, O=C-CH2-, Stp), 2.52 - 2.62 (m, 2H, O=C-CH2-, Stp), 2.87 
– 2.94 (t, J=7.6 Hz, 4H, ε−CH2-, Lys), 3.15 – 3.32 (m, 4H, N-CH2-, Stp), 
3.35 – 3.55 (m, 12H, N-CH2-, Stp), 3.89 – 3.99 (t, J=6.64 Hz, 1H, O=C-
C(R)H-NH-, Lys), 4.20 – 4.25 (dd, J=5.3, 8.8, 1H, O=C-C(R)H-NH-, Lys) 
ppm. 
 
Sequence: HO-K-Stp1-K-CapA2 #: 03 
Molecular formula: C40H79N9O7 Mw 798.11 
MALDI: 799.1 798.6 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 17.0 °C): δ = 0.73 – 0.83 (m, 6H, -CH3, CapA), 
1.11 – 1.27 (m, 16H, -CH2-, CapA), 1.28 - 1.90 (m, 16H, δ-CH2/γ-CH2/β-
CH2, Lys; O=C-CH2-CH2-, CapA), 2.10 – 2.32 (m, 4H, O=C-CH2, CapA), 
2.45 - 2.52 (m, 2H, O=C-CH2-, Stp), 2.52 - 2.59 (m, 2H, O=C-CH2-, Stp), 
2.88 – 2.96 (t, J=7.8 Hz, 2H, ε−CH2, Lys), 3.07 – 3.14 (m, 2H, ε−CH2, 
Lys), 3.16 – 3.25 (m, 4H, N-CH2-, Stp), 3.37 – 3.56 (m, 12H, N-CH2-, 
Stp), 4.07 – 4.16 (m, 1H, O=C-C(R)H-NH-, Lys), 4.18 – 4.29 (m, 1H, 
O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-K-Stp1-K-MyrA2 #: 04 
Molecular formula: C52H103N9O7 Mw 966.43 
MALDI: 967.4 967.4 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 17.0 °C): δ = 0.71 – 0.86 (m, 6H, -CH3, MyrA), 
1.02 – 1.31 (bs, 44H, -CH2-, MyrA), 1.31 – 2.05 (m, 16H, δ-CH2/γ-CH2/β-
CH2, Lys; O=C-CH2-CH2-, MyrA), 2.06 – 2.38 (m, 4H, O=C-CH2, MyrA), 
2.41 - 2.52 (m, 2H, O=C-CH2-, Stp), 2.52 - 2.65 (m, 2H, O=C-CH2-, Stp), 
2.88 – 2.97 (t, J=7.8 Hz, 2H, ε−CH2, Lys), 3.15 – 3.29 (m, 2H, ε−CH2, 
Lys), 3.15 – 3.29 (m, 4H, N-CH2-, Stp), 3.36 – 3.62 (m, 12H, N-CH2-, 
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Stp), 4.04 – 4.16 (m, 1H, O=C-C(R)H-NH-, Lys), 4.18 – 4.34 (m, 1H, 
O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-K-Stp1-K-OleA2 #: 05 
Molecular formula: C58H111N9O7 Mw 1074.61 
MALDI: Not determined    
NMR: 1H-NMR (400 MHz, D2O, 16.9 °C): δ = 0.67 – 0.88 (m, 6H, -CH3, OleA), 
0.91 – 1.93 (m, 64H, -CH2-, OleA; β-CH2,/δ-CH2/γ-CH2, Lys; -CH2-
CH=CH-CH2, O=C-CH2-CH2-; OleA), 2.06 – 2.38 (bm, 4H, O=C-CH2, 
OleA), 2.41 - 2.65 (m, 4H, O=C-CH2-, Stp), 2.87 – 2.99 (m, 4H, ε−CH2, 
Lys), 3.14 – 3.27 (m, 4H, N-CH2-, Stp), 3.29 – 3.62 (m, 12H, N-CH2-, 
Stp), 4.02 – 4.09 (m, 1H, O=C-C(R)H-NH-, Lys), 4.24 – 4.34 (m, 1H, 
O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-K-Stp2-K-H #: 06 
Molecular formula: C36H76N14O7 Mw 817.07 
MALDI: Not determined    
NMR: 1H-NMR (400 MHz, D2O, 16.8 °C): δ = 1.29 - 1.46 (m, 4H, γ-CH2-, Lys), 
1.56 - 1.76 (m, 4H, δ-CH2-, Lys),1.76 - 1.92 (m, 4H, β-CH2-, Lys), 2.43 - 
2.51 (m, 6H, O=C-CH2-, Stp), 2.52 - 2.62 (m, 2H, O=C-CH2-, Stp), 2.87 
– 2.95 (t, J=7.6 Hz, 4H, ε−CH2-, Lys), 3.13 – 3.29 (m, 8H, N-CH2-, Stp), 
3.35 – 3.55 (m, 24H, N-CH2-, Stp), 3.89 – 3.99 (t, J=6.64 Hz, 1H, O=C-
C(R)H-NH-, Lys), 4.20 – 4.25 (dd, J=5.2, 8.8, 1H, O=C-C(R)H-NH-, Lys) 
ppm. 
 
Sequence: HO-K-Stp2-K-CapA2 #: 08 
Molecular formula: C52H104N14O9 Mw 1068.81 
MALDI: 1070.5 1069.8 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 16.9 °C): δ = 0.72 – 0.81 (m, 6H, -CH3, CapA), 
1.09 – 1.25 (m, 16H, -CH2-, CapA), 1.26 - 1.90 (m, 16H, δ-CH2/γ-CH2/β-
CH2, Lys; O=C-CH2-CH2-, CapA), 2.08 – 2.32 (m, 4H, O=C-CH2, CapA), 
2.42 - 2.50 (m, 6H, O=C-CH2-, Stp), 2.52 - 2.59 (m, 2H, O=C-CH2-, Stp), 
2.87 – 2.95 (t, J=7.7 Hz, 2H, ε−CH2, Lys), 3.06 – 3.13 (m, 2H, ε−CH2, 
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Lys), 3.14 – 3.25 (m, 8H, N-CH2-, Stp), 3.33 – 3.56 (m, 24H, N-CH2-, 
Stp), 4.06 – 4.16 (m, 1H, O=C-C(R)H-NH-, Lys), 4.17 – 4.24 (m, 1H, 
O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-K-Stp2-K-MyrA2 #: 09 
Molecular formula: C64H128N14O9 Mw 1237.78 
MALDI: Not determined    
NMR: 1H-NMR (400 MHz, D2O, 16.8 °C): δ = 0.72 – 0.85 (m, 6H, -CH3, MyrA), 
1.06 – 1.28 (m, 40H, -CH2-, MyrA), 1.26 - 1.90 (m, 16H, γ-CH2/δ-CH2/β-
CH2, Lys; O=C-CH2-CH2-, MyrA), 2.08 – 2.32 (m, 4H, O=C-CH2, MyrA), 
2.42 - 2.53 (m, 6H, O=C-CH2-, Stp), 2.53 - 2.63 (m, 2H, O=C-CH2-, Stp), 
2.87 – 2.98 (t, J=7.6 Hz, 2H, ε−CH2, Lys), 3.04 – 3.14 (m, 2H, ε−CH2, 
Lys), 3.15 – 3.28 (m, 8H, N-CH2-, Stp), 3.33 – 3.58 (m, 24H, N-CH2-, 
Stp), 4.05 – 4.22 (m, 2H, O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-K-Stp2-K-OleA2 #: 10 
Molecular formula: C72H140N14O9 Mw 1345.97 
MALDI: Not determined    
NMR: 1H-NMR (400 MHz, D2O, 16.9 °C): δ = 0.69 – 0.82 (m, 6H, -CH3, OleA), 
0.99 – 1.30 (m, 40H, -CH2-, OleA), 1.32 – 1.91 (m, 24H, β-CH2,/δ-CH2/γ-
CH2, Lys; -CH2-CH=CH-CH2, O=C-CH2-CH2-; OleA), 1.92 – 1.99 (m, 
4H, O=C-CH2, OleA), 2.42 - 2.51 (m, 6H, O=C-CH2-, Stp), 2.51 - 2.60 
(m, 2H, O=C-CH2-, Stp), 2.87 – 2.99 (m, 4H, ε−CH2, Lys), 3.14 – 3.26 
(m, 8H, N-CH2-, Stp), 3.35 – 3.55 (m, 24H, N-CH2-, Stp), 4.11 – 4.31 (m, 
2H, O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-K-Stp4-K-H #: 18 
Molecular formula: C60H126N24O11 Mw 1359.79 
MALDI: 1360.0 1630.0 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 16.7 °C): δ = 1.30 - 1.45 (m, 4H, γ-CH2-, Lys), 
1.54 - 1.68 (m, 4H, δ-CH2-, Lys),1.69 - 1.93 (m, 4H, β-CH2-, Lys), 2.40 - 
2.51 (m, 14H, O=C-CH2-, Stp), 2.51 - 2.59 (m, 2H, O=C-CH2-, Stp), 2.86 
– 2.95 (t, J=7.6 Hz, 4H, δ−CH2-, Lys), 3.09 – 3.30 (m, 16H, N-CH2-, 
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Stp), 3.30 – 3.53 (m, 48H, N-CH2-, Stp), 3.89 – 3.99 (t, J=6.64 Hz, 1H, 
O=C-C(R)H-NH-, Lys), 4.20 – 4.25 (dd, J=5.2, 8.8, 1H, O=C-C(R)H-NH-
, Lys) ppm. 
 
Sequence: HO-K-Stp4-K-CapA2 #: 20 
Molecular formula: C76H154N24O13 Mw 1612.19 
MALDI: 1611.8 1612.2 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 16.8 °C): δ = 0.72 – 0.83 (m, 6H, -CH3, CapA), 
1.12 – 1.25 (m, 16H, -CH2-, CapA), 1.26 - 1.88 (m, 16H, δ-CH2/γ-CH2/β-
CH2, Lys; O=C-CH2-CH2-, CapA), 2.10 – 2.29 (m, 4H, O=C-CH2, CapA), 
2.42 - 2.52 (m, 14H, O=C-CH2-, Stp), 2.52 - 2.59 (m, 2H, O=C-CH2-, 
Stp), 2.88 – 2.95 (t, J=7.8 Hz, 2H, ε−CH2, Lys), 3.06 – 3.14 (m, 2H, 
ε−CH2, Lys), 3.14 – 3.25 (m, 16H, N-CH2-, Stp), 3.32 – 3.56 (m, 48H, N-
CH2-, Stp), 4.07 – 4.16 (m, 1H, O=C-C(R)H-NH-, Lys), 4.17 – 4.26 (m, 
1H, O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-K-Stp4-K-MyrA2 #: 21 
Molecular formula: C88H178N24O13 Mw 1780.51 
MALDI: 1782.7 1781.5 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 16.8 °C): δ = 0.72 – 0.85 (m, 6H, -CH3, MyrA), 
1.07 – 1.29 (m, 40H, -CH2-, MyrA), 1.26 - 1.88 (m, 16H, δ-CH2/γ-CH2/β-
CH2, Lys; O=C-CH2-CH2-, MyrA), 2.10 – 2.29 (m, 4H, O=C-CH2, MyrA), 
2.40 - 2.52 (m, 14H, O=C-CH2-, Stp), 2.52 - 2.63 (m, 2H, O=C-CH2-, 
Stp), 2.87 – 2.97 (t, J=7.8 Hz, 2H, ε−CH2, Lys), 3.06 – 3.14 (m, 2H, 
ε−CH2, Lys), 3.13 – 3.28 (m, 16H, N-CH2-, Stp), 3.28 – 3.56 (m, 48H, N-
CH2-, Stp), 4.06 – 4.22 (m, 1H, O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-K-Stp4-K-OleA2 #: 22 
Molecular formula: C96H190N24O13 Mw 1888.69 
MALDI: 1888.6 1888.5 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 16.9 °C): δ = 0.67 – 0.83 (m, 6H, -CH3, OleA), 
0.99 – 1.30 (m, 40H, -CH2-, OleA), 1.32 – 1.91 (m, 24H, β-CH2,/δ-CH2/γ-
CH2, Lys; -CH2-CH=CH-CH2, O=C-CH2-CH2-; OleA), 1.92 – 1.99 (m, 
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4H, O=C-CH2, OleA), 2.41 - 2.52 (m, 14H, O=C-CH2-, Stp), 2.52 - 2.60 
(m, 2H, O=C-CH2-, Stp), 2.87 – 2.96 (m, 2H, ε−CH2, Lys), 2.99 – 3.11 
(m, 2H, ε−CH2, Lys), 3.11 – 3.26 (m, 16H, N-CH2-, Stp), 3.30 – 3.55 (m, 
48H, N-CH2-, Stp), 4.07 – 4.24 (m, 2H, O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-K-Stp5-K-H #: 23 
Molecular formula: C72H151N29O13 Mw 1631.15 
MALDI: 1634.1 1631.2 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 17.1 °C): δ = 1.28 - 1.49 (m, 4H, γ-CH2-, Lys), 
1.49 - 1.88 (m, 8H, δ-CH2-/β-CH2-, Lys), 2.40 - 2.52 (m, 18H, O=C-CH2-, 
Stp), 2.52 - 2.60 (m, 2H, O=C-CH2-, Stp), 2.87 – 2.95 (t, J=7.6 Hz, 4H, 
ε−CH2, Lys), 3.13 – 3.26 (m, 20H, N-CH2-, Stp), 3.35 – 3.55 (m, 60H, N-
CH2-, Stp), 3.89 – 3.99 (t, J=6.64 Hz, 1H, O=C-C(R)H-NH-, Lys), 4.20 – 
4.25 (dd, J=5.2, 8.8, 1H, O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-K-Stp5-K-AraA2 #: 25 
Molecular formula: C112H227N29O15 Mw 2220.19 
MALDI: Not determined    
NMR: 1H-NMR (400 MHz, D2O, 17.0 °C): δ = 0.71 – 0.86 (m, 6H, -CH3, AraA), 
1.04 – 1.30 (m, 72H, -CH2-, AraA), 1.31 - 1.98 (m, 16H, δ-CH2/γ-CH2/β-
CH2, Lys; O=C-CH2-CH2-, AraA), 2.10 – 2.29 (m, 4H, O=C-CH2, AraA), 
2.40 - 2.52 (m, 18H, O=C-CH2-, Stp), 2.52 - 2.60 (m, 2H, O=C-CH2-, 
Stp), 2.87 – 2.97 (t, J=7.8 Hz, 2H, ε−CH2, Lys), 3.03 – 3.14 (m, 2H, 
ε−CH2, Lys), 3.13 – 3.28 (m, 20H, N-CH2-, Stp), 3.31 – 3.57 (m, 60H, N-
CH2-, Stp), 4.06 – 4.26 (m, 2H, O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-K-Stp5-K-MyrA2 #: 26 
Molecular formula: C100H203N29O15 Mw 2051.87 
MALDI: Not determined    
NMR: 1H-NMR (400 MHz, D2O, 17.1 °C): δ = 0.72 – 0.83 (m, 6H, -CH3, MyrA), 
1.07 – 1.25 (m, 40H, -CH2-, MyrA), 1.26 - 1.88 (m, 16H, δ-CH2/γ-CH2/β-
CH2, Lys; O=C-CH2-CH2-, MyrA), 2.10 – 2.29 (m, 4H, O=C-CH2, MyrA), 
2.40 - 2.52 (m, 18H, O=C-CH2-, Stp), 2.52 - 2.60 (m, 2H, O=C-CH2-, 
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Stp), 2.88 – 2.97 (t, J=7.8 Hz, 2H, ε−CH2, Lys), 3.04 – 3.14 (m, 2H, 
ε−CH2, Lys), 3.14 – 3.26 (m, 20H, N-CH2-, Stp), 3.27 – 3.56 (m, 60H, N-
CH2-, Stp), 4.06 – 4.26 (m, 2H, O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-K-Stp5-K-OleA2 #: 27 
Molecular formula: C108H215N29O15 Mw 2160.05 
MALDI: Not determined    
NMR: 1H-NMR (400 MHz, D2O, 16.9 °C): δ = 0.65 – 0.83 (m, 6H, -CH3, OleA), 
1.02 – 1.30 (m, 40H, -CH2-, OleA), 1.31 – 1.87 (m, 24H, β-CH2,/δ-CH2/γ-
CH2, Lys; -CH2-CH=CH-CH2, O=C-CH2-CH2-; OleA), 1.92 – 1.99 (m, 
4H, O=C-CH2, OleA), 2.40 - 2.52 (m, 18H, O=C-CH2-, Stp), 2.52 - 2.64 
(m, 2H, O=C-CH2-, Stp), 2.86 – 2.97 (m, 2H, ε−CH2, Lys), 3.04 – 3.12 
(m, 2H, ε−CH2, Lys), 3.13 – 3.27 (m, 20H, N-CH2-, Stp), 3.30 – 3.54 (m, 
60H, N-CH2-, Stp), 4.04 – 4.25 (m, 2H, O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-C-Stp1-K-CapA2 #: 30 
Molecular formula: C37H72N8O7S Mw 773.08 
FAB: 773.4 773.5 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 22.8 °C): δ = 0.78 – 0.92 (m, 6H, -CH3, CapA), 
1.20 – 1.32 (m, 16H, -CH2-, CapA), 1.32 - 1.96 (m, 16H, δ-CH2/γ-CH2/β-
CH2, Lys; O=C-CH2-CH2-, CapA), 2.18 – 2.25 (m, 2H, O=C-CH2, CapA), 
2.25 – 2.40 (m, 2H, O=C-CH2, CapA), 2.51 - 2.59 (m, 2H, O=C-CH2-, 
Stp), 2.60 - 2.73 (m, 2H, O=C-CH2-, Stp), 2.89 - 3.01 (m, 2H, β-CH2-, 
Cys), 3.12 – 3.20 (t, J=5.4 2H, ε−CH2, Lys), 3.24 – 3.34 (m, 4H, N-CH2-, 
Stp), 3.43 – 3.65 (m, 12H, N-CH2-, Stp), 4.14 – 4.25 (m, 1H, O=C-
C(R)H-NH-, Lys), 4.40 – 4.52 (m, 1H, O=C-C(R)H-NH-, Cys) ppm. 
 
Sequence: HO-C-Stp1-K-SteA2 #: 31 
Molecular formula: C57H112N8O7S Mw 1053.61 
MALDI: 1054.0 1053.8 [M+H] calc.   
NMR: 1H-NMR (400 MHz, MeOD, 23.4 °C): δ = 0.85 – 0.94 (m, 6H, -CH3, 
SteA), 1.20 – 1.32 (m, 56H, -CH2-, SteA), 1.39 - 1.85 (m, 10H, δ-CH2/γ-
CH2/β-CH2, Lys; O=C-CH2-CH2-, SteA), 2.11 – 2.20 (m, 2H, O=C-CH2, 
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SteA), 2.21 – 2.32 (m, 2H, O=C-CH2, SteA), 2.45 - 2.55 (m, 2H, O=C-
CH2-, Stp), 2.56 - 2.73 (m, 2H, O=C-CH2-, Stp), 2.84 - 2.93 (m, 2H, β-
CH2-, Cys), 3.05 – 3.34 (m, 18H, ε−CH2, Lys; N-CH2-, Stp ), 4.06 – 4.15 
(m, 1H, O=C-C(R)H-NH-, Lys), 4.42 – 4.55 (m, 1H, O=C-C(R)H-NH-, 
Cys) ppm. 
 
Sequence: HO-K-Stp2-ButA1 #: 34 
Molecular formula: C34H70N12O7 Mw 759.00 
FAB: 759.8 759.6 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 17.3 °C): δ = 0.79 – 0.86 (t, J=7.4 Hz, 3H, -
CH3, ButA), 1.34 - 1.45 (m, 2H, γ-CH2, Lys), 1.46 - 1.56 (m, 2H,-CH2-, 
ButA), 1.56 - 1.87 (m, 4H, δ-CH2/β-CH2, Lys), 2.14 – 2.23 (t, J=7.4 Hz, 
2H, O=C-CH2, ButA), 2.44 - 2.51 (m, 6H, O=C-CH2-, Stp), 2.51 - 2.60 
(m, 2H, O=C-CH2-, Stp), 2.87 – 2.96 (t, J=7.8 Hz, 2H, ε−CH2, Lys), 3.15 
– 3.26 (m, 8H, N-CH2-, Stp), 3.37 – 3.54 (m, 12H, N-CH2-, Stp), 4.18 – 
4.27 (m, 1H, O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-K-Stp2-CapA1 #: 35 
Molecular formula: C38H78N12O7 Mw 815.10 
FAB: 815.6 815.6 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 16.7 °C): δ = 0.73 – 0.82 (m, 3H, -CH3, CapA), 
1.15 – 1.26 (m, 8H, -CH2-, CapA), 1.34 - 1.44 (m, 2H, γ-CH2, Lys), 1.45 - 
1.56 (m, 2H, δ-CH2, Lys) 1.57 - 1.66 (m, 2H,O=C-CH2-CH2-, CapA), 
1.67 - 1.82 (m, 2H, β-CH2, Lys), 2.15 – 2.24 (t, J=7.4 Hz, 2H, O=C-CH2, 
CapA), 2.44 - 2.52 (m, 6H, O=C-CH2-, Stp), 2.52 - 2.60 (m, 2H, O=C-
CH2-, Stp), 2.88 – 2.96 (t, J=7.8 Hz 2H, ε−CH2, Lys), 3.16 – 3.25 (m, 8H, 
N-CH2-, Stp), 3.37 – 3.51 (m, 24H, N-CH2-, Stp), 4.16 – 4.25 (m, 1H, 
O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-K-Stp2-MyrA1 #: 36 
Molecular formula: C44H90N12O7 Mw 899.26 
ESI: 899.7128 899.7128 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 17.6 °C): δ = 0.74 – 0.81 (m, 3H, -CH3, MyrA), 
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1.17 – 1.24 (m, 20H, -CH2-, MyrA), 1.34 - 1.57 (m, 4H, δ-CH2/γ-CH2, 
Lys), 1.56 - 1.66 (m, 2H,O=C-CH2-CH2-, MyrA), 1.67 - 1.83 (m, 2H, β-
CH2, Lys), 2.16 – 2.24 (t, J=7.4 Hz, 2H, O=C-CH2-, MyrA), 2.44 - 2.52 
(m, 6H, O=C-CH2-, Stp), 2.52 - 2.58 (m, 2H, O=C-CH2-, Stp), 2.88 – 
2.96 (t, J=7.8 Hz, 2H, ε−CH2, Lys), 3.15 – 3.25 (m, 8H, N-CH2-, Stp), 
3.37 – 3.52 (m, 24H, N-CH2-, Stp), 4.18 – 4.26 (m, 1H, O=C-C(R)H-NH-, 
Lys) ppm. 
 
Sequence: HO-K-Stp2-OleA1 #: 37 
Molecular formula: C48H96N12O7 Mw 953.35 
ESI: 953.7721 953.7596 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 16.1 °C): δ = 0.71 – 0.83 (m, 3H, -CH3, OleA), 
1.16 – 1.29 (m, 18H, -CH2-, OleA), 1.31 - 1.82 (m, 12H, β-CH2,/δ-CH2/γ-
CH2, Lys; -CH2-CH=CH-CH2-, O=C-CH2-CH2-, OleA), 2.13 – 2.25 (m,  
2H, O=C-CH2-, OleA), 2.41 - 2.52 (m, 6H, O=C-CH2-, Stp), 2.52 - 2.61 
(m, 2H, O=C-CH2-, Stp), 2.86 – 2.97 (m, 2H, ε−CH2-, Lys), 3.12 – 3.25 
(m, 8H, N-CH2-, Stp), 3.36 – 3.53 (m, 24H, N-CH2-, Stp), 4.16 – 4.24 (m, 
1H, O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-K-Stp1-ButA1 #: 38 
Molecular formula: C22H45N7O5 Mw 487.64 
MALDI: 488.5 488.4 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 17.3 °C): δ = 0.79 – 0.86 (t, J=7.4 Hz, 3H, -
CH3, ButA), 1.30 - 1.46 (m, 2H, γ-CH2-, Lys), 1.46 - 1.57 (m, 2H,-CH2-, 
ButA), 1.58 - 1.85 (m, 4H, δ-CH2-/β-CH2-, Lys), 2.14 – 2.21 (t, J=7.4 Hz, 
2H, O=C-CH2-, ButA), 2.42 - 2.51 (m, 2H, O=C-CH2-, Stp), 2.51 - 2.62 
(m, 2H, O=C-CH2-, Stp), 2.88 – 2.97 (t, J=7.8 Hz, 2H, ε−CH2-, Lys), 3.15 
– 3.26 (m, 4H, N-CH2-, Stp), 3.35 – 3.58 (m, 12H, N-CH2-, Stp), 4.10 – 
4.18 (dd, J=5.3, 8.8, 1H, O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-K-Stp1-CapA1 #: 39 
Molecular formula: C26H53N7O5 Mw 543.74 
FAB/ESI: 544.5/544.4174 544.5/544.4172 [M+H] calc.   
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NMR: 1H-NMR (400 MHz, D2O, 16.5 °C): δ = 0.73 – 0.82 (m, 3H, -CH3, CapA), 
1.15 – 1.25 (m, 8H, -CH2-, CapA), 1.32 - 1.56 (m, 4H, δ-CH2/γ-CH2, 
Lys), 1.57 - 1.66 (m, 2H,O=C-CH2-CH2-, CapA), 1.68 - 1.85 (m, 2H, β-
CH2, Lys), 2.15 – 2.25 (t, J=7.4 Hz, 2H, O=C-CH2, CapA), 2.44 - 2.52 
(m, 2H, O=C-CH2-, Stp), 2.52 - 2.62 (m, 2H, O=C-CH2-, Stp), 2.87 – 
2.96 (t, J=7.8 Hz, 2H, ε−CH2, Lys), 3.15 – 3.26 (m, 4H, N-CH2-, Stp), 
3.36 – 3.55 (m, 12H, N-CH2-, Stp), 4.13 – 4.21 (dd, J=5.4, 8.8, 1H, 
O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-K-Stp1-MyrA1 #: 40 
Molecular formula: C32H65N7O5 Mw 627.90 
MALDI: 628.6 628.5 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 17.6 °C): δ = 0.76 – 0.84 (m, 3H, -CH3, MyrA), 
1.15 – 1.28 (m, 20H, -CH2-, MyrA), 1.35 - 1.57 (m, 4H, δ-CH2/γ-CH2, 
Lys), 1.58 - 1.67 (m, 2H,O=C-CH2-CH2-, MyrA), 1.68 - 1.85 (m, 2H, β-
CH2, Lys), 2.18 – 2.25 (t, J=7.4 Hz, 2H, O=C-CH2, MyrA), 2.45 - 2.53 
(m, 2H, O=C-CH2-, Stp), 2.54 - 2.64 (m, 2H, O=C-CH2-, Stp), 2.89 – 
2.99 (t, J=7.8 Hz, 2H, ε−CH2, Lys), 3.18 – 3.27 (m, 4H, N-CH2-, Stp), 
3.39 – 3.59 (m, 12H, N-CH2-, Stp), 4.12 – 4.19 (dd, J=5.4, 8.8, 1H, 
O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-K-Stp1-OleA1 #: 41 
Molecular formula: C36H71N7O5 Mw 681.99 
FAB: 682.5 682.5 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 17.1 °C): δ = 0.9 – 0.85 (m, 3H, -CH3, OleA), 
0.99 – 1.3 (m, 18H, -CH2-, OleA), 1.31 - 1.82 (m, 12H, β-CH2,/δ-CH2/γ-
CH2, Lys; -CH2-CH=CH-CH2, O=C-CH2-CH2-, OleA), 2.04 – 2.25 (m,  
2H, O=C-CH2, OleA), 2.39 - 2.64 (m, 4H, O=C-CH2-, Stp), 2.86 – 2.97 
(m, 2H, ε−CH2, Lys), 3.10 – 3.28 (m, 4H, N-CH2-, Stp), 3.32 – 3.58 (m, 
12H, N-CH2-, Stp), 4.12 – 4.19 (m, 1H, O=C-C(R)H-NH-, Lys), 6.63 – 
6.94 (m, 2H, -CH=CH-) ppm. 
 
Sequence: HO-C-Stp3-C-K-MyrA2 #: 45 
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Molecular formula: C76H151N19O12S2 Mw 1587.26 
FAB: 1587.6 1587.1 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 17.2 °C): δ = 0.71 – 0.85 (m, 6H, -CH3, MyrA), 
1.05 – 1.31 (m, 40H, -CH2-, MyrA), 1.26 - 1.90 (m, 16H, δ-CH2/γ-CH2/β-
CH2, Lys; O=C-CH2-CH2-, MyrA), 2.08 – 2.33 (m, 4H, O=C-CH2, MyrA), 
2.40 - 2.55 (m, 10H, O=C-CH2-, Stp), 2.54 - 2.67 (m, 2H, O=C-CH2-, 
Stp), 2.80 – 3.10 (m, 6H, ε−CH2, Lys + Cys), 3.12 – 3.28 (m, 12H, N-
CH2-, Stp), 3.29 – 3.58 (m, 36H, N-CH2-, Stp), 4.16 – 4.44 (m, 3H, O=C-
C(R)H-NH-, Lys + Cys) ppm. 
 
Sequence: HO-C-Stp3-C-K-OleA2 #: 46 
Molecular formula: C84H163N19O12S2 Mw 1695.44 
FAB: 1809.6 1808.2 [M+TFA] calc.   
NMR: 1H-NMR (400 MHz, D2O, 17.3 °C): δ = 0.63 – 0.82 (m, 6H, -CH3, OleA), 
1.01 – 1.33 (m, 40H, -CH2-, OleA), 1.34 - 1.89 (m, 18H, δ-CH2/γ-CH2/β-
CH2, Lys; -CH2-CH=CH-CH2, O=C-CH2-CH2-; OleA), 1.90 – 1.97 (m, 
4H, O=C-CH2, OleA), 2.40 - 2.55 (m, 10H, O=C-CH2-, Stp), 2.54 - 2.65 
(m, 2H, O=C-CH2-, Stp), 2.80 – 3.10 (m, 6H, ε−CH2, Lys + Cys), 3.12 – 
3.28 (m, 12H, N-CH2-, Stp), 3.29 – 3.61 (m, 36H, N-CH2-, Stp), 4.16 – 
4.45 (m, 3H, O=C-C(R)H-NH-, Lys + Cys) ppm. 
 
Sequence: HO-C-Stp2-K(K-MyrA2)Stp2-C-H #: 48 
Molecular formula: C94H188N26O15S2 Mw 1986.4 
MALDI: 1986.4 1986.4 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 16.7 °C): δ = 0.72 – 0.86 (m, 6H, -CH3, MyrA), 
1.07 – 1.29 (m, 40H, -CH2-, MyrA), 1.29 - 1.95 (m, 16H, δ-CH2/γ-CH2/β-
CH2, Lys; O=C-CH2-CH2-, MyrA), 2.08 – 2.28 (m, 4H, O=C-CH2-, MyrA),  
2.39 - 2.67 (m, 16H, O=C-CH2-, Stp), 2.83 – 3.15 (m, 8H, ε−CH2-, Lys + 
Cys), 3.15 – 3.30 (m, 16H, N-CH2- , Stp), 3.30 – 3.68 (m, 48H, Stp) 4.03 
– 4.19 (m, 2H, O=C-C(R)H-NH-, Cys), 4.28 – 4.40 (m, 2H, O=C-C(R)H-
NH-, Lys) ppm. 
 
Sequence: HO-C-Stp2-K(K-OleA2)-Stp2-C-H #: 49 
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Molecular formula: C102H200N26O15S2 Mw 2094.98 
MALDI: 2094.9 2094.5 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 16.7 °C): δ = 0.71 – 0.88 (m, 6H, -CH3, OleA), 
1.06 – 1.31 (m, 40H, -CH2-, OleA), 1.31 - 1.92 (m, 10H, δ-CH2/γ-CH2/β-
CH2, Lys; -CH2-CH=CH-CH2, O=C-CH2-CH2-; OleA), 2.05 – 2.27 (m, 
2H, O=C-CH2-, OleA),  2.40 - 2.69 (m, 16H, O=C-CH2-, Stp), 2.81 – 
3.14 (m, 8H, ε−CH2, Lys + Cys), 3.14 – 3.30 (m, 16H, N-CH2- , Stp), 
3.30 – 3.68 (m, 48H, N-CH2-Stp), 4.04 – 4.21 (m, 2H, O=C-C(R)H-NH-, 
Cys), 4.25 – 4.38 (m, 2H, O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-K-Stp4-K-AraA2 #: 50 
Molecular formula: C100H202N24O13 Mw 1948.83 
MALDI: Not determined    
NMR: 1H-NMR (400 MHz, D2O, 17.0 °C): δ = 0.73 – 0.86 (m, 6H, -CH3, AraA), 
1.04 – 1.30 (m, 72H, -CH2-, AraA), 1.31 - 1.98 (m, 16H, δ-CH2/γ-CH2/β-
CH2, Lys; O=C-CH2-CH2-, AraA), 2.10 – 2.29 (m, 4H, O=C-CH2, AraA), 
2.38 - 2.52 (m, 14H, O=C-CH2-, Stp), 2.52 - 2.62 (m, 2H, O=C-CH2-, 
Stp), 2.87 – 2.98 (m, 2H, ε−CH2, Lys), 3.03 – 3.14 (m, 2H, ε−CH2, Lys), 
3.09 – 3.30 (m, 16H, N-CH2-, Stp), 3.31 – 3.57 (m, 48H, N-CH2-, Stp), 
4.04 – 4.24 (m, 2H, O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-C-Stp3-C-K-H #: 51 
Molecular formula: C48H99N19O10S2 Mw 1166.55 
MALDI: 1167.3 1167.5 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 17.3 °C): δ = 1.37 - 1.49 (m, 2H, δ-CH2, Lys), 
1.59 - 1.71 (m, 2H, δ-CH2, Lys),1.80 - 1.97 (m, 2H, β-CH2, Lys), 2.44 - 
2.55 (m, 10H, O=C-CH2-, Stp), 2.55 - 2.66 (m, 2H, O=C-CH2-, Stp), 
2.81 – 2.99 (m, 4H, ε−CH2, Lys + Cys), 3.13 – 3.29 (m, 12H, N-CH2- , 
Stp), 3.33 – 3.58 (m, 36H, Stp) 3.96 – 4.05 (m, 1H, O=C-C(R)H-NH-, 
Lys), 4.33 – 4.46 (m, 2H, O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-C-Stp2-K(CapA)-Stp2-C-H #: 56 
Molecular formula: C68H138N24O13S2 Mw 1564.11 
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MALDI: 1564.4 1564.1 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 16.6 °C): δ = 0.73 – 0.83 (m, 3H, -CH3, CapA), 
1.13 – 1.28 (m, 8H, -CH2-, CapA), 1.29 - 1.92 (m, 8H, δ-CH2/γ-CH2/β-
CH2, Lys; O=C-CH2-CH2-, CapA), 2.11 – 2.20 (t, J=7.3 Hz, 2H, O=C-
CH2-, CapA),  2.42 - 2.68 (m, 16H, O=C-CH2-, Stp), 2.84 – 3.14 (m, 6H, 
ε−CH2, Lys + Cys), 3.14 – 3.29 (m, 16H, N-CH2- , Stp), 3.30 – 3.59 (m, 
48H, Stp) 4.09 – 4.18 (m, 2H, O=C-C(R)H-NH-, Cys), 4.28 – 4.39 (m, 
1H, O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-C-Stp2-K(MyrA)-Stp2-C-H #: 57 
Molecular formula: C74H150N24O13S2 Mw 1648.26 
MALDI: 1648.4 1648.1 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 16.6 °C): δ = 0.73 – 0.83 (m, 3H, -CH3, MyrA), 
1.11 – 1.22 (m, 20H, -CH2-, MyrA), 1.23 - 1.92 (m, 8H, δ-CH2/γ-CH2/β-
CH2, Lys; O=C-CH2-CH2-, MyrA), 2.11 – 2.20 (t, J=7.3 Hz, 2H, O=C-
CH2-, MyrA),  2.41 - 2.70 (m, 16H, O=C-CH2-, Stp), 2.84 – 3.13 (m, 6H, 
ε−CH2, Lys + Cys), 3.15 – 3.29 (m, 16H, N-CH2- , Stp), 3.29 – 3.68 (m, 
48H, Stp), 4.09 – 4.20 (m, 2H, O=C-C(R)H-NH-, Cys), 4.26 – 4.39 (m, 
1H, O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-C-Stp2-K(OleA)-Stp2-C-H #: 58 
Molecular formula: C78H156N24O13S2 Mw 1702.35 
MALDI: 1702.6 1702.4 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 16.7 °C): δ = 0.73 – 0.83 (m, 3H, -CH3, OleA), 
1.10 – 1.31 (m, 20H, -CH2-, OleA), 1.32 - 1.99 (m, 10H, δ-CH2/γ-CH2/β-
CH2, Lys; -CH2-CH=CH-CH2, O=C-CH2-CH2-; OleA), 2.10 – 2.20 (t, 
J=7.3 Hz, 2H, O=C-CH2-, OleA),  2.40 - 2.66 (m, 16H, O=C-CH2-, Stp), 
2.84 – 3.13 (m, 6H, ε−CH2, Lys + Cys), 3.14 – 3.30 (m, 16H, N-CH2-, 
Stp), 3.31 – 3.61 (m, 48H, Stp), 4.10 – 4.18 (m, 2H, O=C-C(R)H-NH-, 
Cys), 4.32 – 4.45 (m, 1H, O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-C-Stp2-K(AraA)-Stp2-C-H #: 59 
Molecular formula: C80H162N24O13S2 Mw 1732.43 
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MALDI: 1732.4 1732.2 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 16.6 °C): δ = 0.73 – 0.83 (m, 3H, -CH3, AraA), 
1.12 – 1.31 (m, 36H, -CH2-, AraA), 1.32 - 1.99 (m, 8H, δ-CH2/γ-CH2/β-
CH2, Lys; O=C-CH2-CH2-, AraA), 2.11 – 2.20 (t, J=7.4 Hz, 2H, O=C-
CH2-, AraA),  2.42 - 2.68 (m, 16H, O=C-CH2-, Stp), 2.83 – 3.13 (m, 6H, 
ε−CH2, Lys + Cys), 3.14 – 3.30 (m, 16H, N-CH2-, Stp), 3.31 – 3.64 (m, 
48H, Stp), 4.10 – 4.18 (m, 2H, O=C-C(R)H-NH-, Cys), 4.32 – 4.45 (m, 
1H, O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-C-Stp2-K(K-AraA2)-Stp2-C-H #: 62 
Molecular formula: C106H212N26O15S2 Mw 2155.11 
MALDI: 2152.2 2156.1[M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 16.6 °C): δ = 0.73 – 0.83 (m, 6H, -CH3, AraA), 
1.12 – 1.31 (m, 72H, -CH2-, AraA), 1.32 - 1.99 (m, 16H, δ-CH2/γ-CH2/β-
CH2, Lys; O=C-CH2-CH2-, AraA), 2.11 – 2.20 (m, 4H, O=C-CH2-, AraA),  
2.42 - 2.68 (m, 16H, O=C-CH2-, Stp), 2.83 – 3.13 (m, 6H, ε−CH2, Lys + 
Cys), 3.14 – 3.30 (m, 16H, N-CH2-, Stp), 3.31 – 3.64 (m, 48H, Stp), 4.10 
– 4.18 (m, 2H, O=C-C(R)H-NH-, Cys), 4.32 – 4.45 (m, 1H, O=C-C(R)H-
NH-, Lys) ppm. 
 
Sequence: HO-C-Stp2-K(K-CapA2)Stp2-C-H #: 66 
Molecular formula: C82H164N26O15S2 Mw 1818.48 
MALDI: 1816.6 1818.2 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 16.7 °C): δ = 0.73 – 0.83 (m, 6H, -CH3, CapA), 
1.13 – 1.28 (m, 16H, -CH2-, CapA), 1.29 - 1.92 (m, 16H, δ-CH2/γ-CH2/β-
CH2, Lys; O=C-CH2-CH2-, CapA), 2.11 – 2.20 (t, J=7.4 Hz, 2H, O=C-
CH2-CH2-, CapA), 2.11 – 2.20 (m, 2H, O=C-CH2-CH2-, CapA), 2.42 - 
2.68 (m, 16H, O=C-CH2-, Stp), 2.84 – 3.14 (m, 8H, ε−CH2, Lys + Cys), 
3.14 – 3.29 (m, 16H, N-CH2- , Stp), 3.30 – 3.59 (m, 48H, Stp) 4.09 – 
4.18 (m, 2H, O=C-C(R)H-NH-, Cys), 4.28 – 4.39 (m, 1H, O=C-C(R)H-
NH-, Lys) ppm. 
 
Sequence: HO-C-Stp2-K-MyrA2 #: 67 
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Molecular formula: C61H121N13O9S Mw 1212.76 
MALDI: 1213.4 1213.7 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 16.7 °C): δ = 0.70 – 0.84 (m, 6H, -CH3, MyrA), 
1.08 – 1.32 (m, 40H, -CH2-, MyrA), 1.32 - 1.97 (m, 10H, δ-CH2/γ-CH2/β-
CH2, Lys; O=C-CH2-CH2-, MyrA), 2.11 – 2.32 (m, 4H, O=C-CH2, MyrA), 
2.41 - 2.55 (m, 6H, O=C-CH2-, Stp), 2.55 - 2.67 (m, 2H, O=C-CH2-, Stp), 
2.83 - 2.97 (m, 2H, β-CH2-, Cys), 3.04 – 3.17 (m, 2H, ε−CH2, Lys), 3.14 
– 3.29 (m, 8H, N-CH2-, Stp), 3.29 – 3.60 (m, 24H, N-CH2-, Stp), 4.07 – 
4.24 (m, 1H, O=C-C(R)H-NH-, Lys), 4.24 – 4.40 (m, 1H, O=C-C(R)H-
NH-, Cys) ppm. 
 
Sequence: HO-C-K-Stp2-K-MyrA2 #: 68 
Molecular formula: C67H133N15O10S Mw 1340.93 
MALDI: 1341.3 1341.0 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 16.7 °C): δ = 0.70 – 0.84 (m, 6H, -CH3, MyrA), 
1.08 – 1.32 (m, 40H, -CH2-, MyrA), 1.32 - 1.97 (m, 10H, δ-CH2/γ-CH2/β-
CH2, Lys; O=C-CH2-CH2-, MyrA), 2.11 – 2.32 (m, 4H, O=C-CH2, MyrA), 
2.41 - 2.55 (m, 6H, O=C-CH2-, Stp), 2.55 - 2.67 (m, 2H, O=C-CH2-, Stp), 
2.83 - 2.97 (m, 2H, β-CH2-, Cys), 3.04 – 3.17 (m, 2H, ε−CH2, Lys), 3.14 
– 3.29 (m, 8H, N-CH2-, Stp), 3.29 – 3.60 (m, 24H, N-CH2-, Stp), 4.07 – 
4.24 (m, 1H, O=C-C(R)H-NH-, Lys), 4.24 – 4.40 (m, 1H, O=C-C(R)H-
NH-, Cys) ppm. 
 
Sequence: HO-C-K-Stp2-K-OleA2 #: 69 
Molecular formula: C75H145N15O10S Mw 1449.11 
MALDI: 1449.5 1449.1 [M+H] calc.   
NMR: 1H-NMR (400 MHz, MeOD, 16.8 °C): δ = 0.78 – 0.88 (m, 6H, -CH3, 
OleA), 1.12 – 1.35 (m, 40H, -CH2-, OleA), 1.34 - 1.89 (m, 18H, δ-CH2/γ-
CH2/β-CH2, Lys; -CH2-CH=CH-CH2, O=C-CH2-CH2-; OleA), 1.90 – 1.97 
(m, 4H, O=C-CH2, OleA), 2.40 - 2.55 (m, 10H, O=C-CH2-, Stp), 2.54 - 
2.65 (m, 2H, O=C-CH2-, Stp), 2.80 – 3.10 (m, 6H, ε−CH2, Lys + Cys), 
3.12 – 3.28 (m, 12H, N-CH2-, Stp), 3.29 – 3.61 (m, 36H, N-CH2-, Stp), 
4.16 – 4.45 (m,3H, O=C-C(R)H-NH-, Lys + Cys) ppm. 
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Sequence: HO-C-Stp2-K-OleA2 #: 70 
Molecular formula: C69H133N13O9S Mw 1320.94 
MALDI: 1321.3 1321.0 [M+H] calc.   
NMR: 1H-NMR (400 MHz, MeOD, 16.8 °C): δ = 0.85 – 0.96 (m, 6H, -CH3, 
OleA), 1.21 – 1.40 (m, 40H, -CH2-, OleA), 1.41 - 1.92 (m, 10H, δ-CH2/γ-
CH2/β-CH2, Lys; -CH2-CH=CH-CH2, O=C-CH2-CH2-; OleA), 1.93 – 2.07 
(m, 4H, O=C-CH2, OleA), 2.41 - 2.57 (m, 6H, O=C-CH2-, Stp), 2.57 - 
2.74 (m, 2H, O=C-CH2-, Stp), 2.85 - 3.08 (m, 2H, β-CH2-, Cys), 3.08 – 
3.19 (m, 2H, ε−CH2, Lys), 3.19 – 3.72 (m, 32H, N-CH2-, Stp), 4.04 – 
4.17 (m, 1H, O=C-C(R)H-NH-, Lys), 4.14 – 4.57 (m, 1H, O=C-C(R)H-
NH-, Cys) ppm. 
 
Sequence: C-Stp1-K(K-MyrA2)-Stp1-C-H #: 71 
Molecular formula: C70H138N16O11S2 Mw 1444.07 
MALDI: Not determined    
NMR: 1H-NMR (400 MHz, MeOD, 17.0 °C): δ = 0.86 – 0.95 (m, 6H, -CH3, 
MyrA), 1.22 – 1.38 (m, 40H, -CH2-, MyrA), 1.29 - 1.95 (m, 16H, δ-CH2/γ-
CH2/β-CH2, Lys; O=C-CH2-CH2-, MyrA), 2.13 – 2.20 (m, 2H, O=C-CH2-, 
MyrA), 2.20 – 2.30 (m, 2H, O=C-CH2-, MyrA),  2.43 - 2.71 (m, 8H, O=C-
CH2-, Stp), 2.84 – 3.10 (m, 8H, ε−CH2-, Lys + Cys), 3.11 – 3.64 (m, 
32H, N-CH2- , Stp), 3.94 – 4.25 (m, 2H, O=C-C(R)H-NH-, Cys), 4.44 – 
4.56 (m, 2H, O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-C-Stp1-K(K)-Stp1-C-H #: 72 
Molecular formula: C42H86N16O9S2 Mw 1023.36 
MALDI: 1024.5 1024.4 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 17.0 °C): δ = 1.37 - 1.97 (m, 12H, δ-CH2/γ-
CH2/β-CH2, Lys), 2.41 - 2.64 (m, 8H, O=C-CH2-, Stp), 2.84 – 3.11 (m, 
8H, ε−CH2, Lys + Cys), 3.17 – 3.29 (m, 8H, N-CH2-, Stp), 3.35 – 3.70 
(m, 24H, Stp) 4.10 – 4.17 (m, 2H, O=C-C(R)H-NH-, Cys), 4.38 – 4.48 
(m, 2H, O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-C-Stp1-K(K-SteA2)-Stp1-C-H #: 73 
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Molecular formula: C78H154N16O11S2 Mw 1556.28 
MALDI: 1554.4 1556.1 [M+H] calc.   
NMR: 1H-NMR (400 MHz, MeOD, 17.0 °C): δ = 0.86 – 0.97 (m, 6H, -CH3, 
SteA), 1.20 – 1.43 (m, 56H, -CH2-, SteA), 1.43 - 1.97 (m, 20H, δ-CH2/γ-
CH2/β-CH2, Lys; O=C-CH2-CH2-, SteA), 2.11 – 2.36 (m, 4H, O=C-CH2-, 
SteA),  2.42 - 2.74 (m, 8H, O=C-CH2-, Stp), 2.83 – 3.11 (m, 8H, ε−CH2-, 
Lys + Cys), 3.11 – 3.64 (m, 32H, N-CH2- , Stp), 3.94 – 4.06 (m, 1H, 
O=C-C(R)H-NH-, Cys), 4.08 – 4.25 (m, 1H, O=C-C(R)H-NH-, Cys) 4.42 
– 4.57 (m, 2H, O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-C-Stp1-K(K-OleA2)-Stp1-C-H #: 74 
Molecular formula: C78H150N16O11S2 Mw 1552.25 
MALDI: 1552.5 1552.1 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 16.7 °C): δ = 0.86 – 0.95 (m, 6H, -CH3, OleA), 
1.01 – 1.40 (m, 40H, -CH2-, OleA), 1.41 - 1.92 (m, 24H, δ-CH2/γ-CH2/β-
CH2, Lys; -CH2-CH=CH-CH2, O=C-CH2-CH2-; OleA), 2.12 – 2.32 (m, 
4H, O=C-CH2-, OleA),  2.44 - 2.73 (m, 16H, O=C-CH2-, Stp), 2.81 – 
3.22 (m, 8H, ε−CH2, Lys + Cys), 3.22 – 3.63 (m, 32H, N-CH2- , Stp), 
3.99 – 4.25 (m, 2H, O=C-C(R)H-NH-, Cys), 4.45 – 4.60 (m, 2H, O=C-
C(R)H-NH-, Lys), 7.05 – 7.33 (m, 4H, -CH=CH-, OleA) ppm. 
 
Sequence: HO-C-Stp3-K(K-MyrA2)-Stp3-C-H #: 75 
Molecular formula: C118H238N36O19S2 Mw 2529.51 
MALDI: 2529.3 2528.8 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 17.3 °C): δ = 0.72 – 0.84 (m, 6H, -CH3, MyrA), 
1.10 – 1.30 (m, 40H, -CH2-, MyrA), 1.31 - 1.96 (m, 16H, δ-CH2/γ-CH2/β-
CH2, Lys; O=C-CH2-CH2-, MyrA), 2.12 – 2.27 (m, 4H, O=C-CH2-, MyrA),  
2.41 - 2.66 (m, 24H, O=C-CH2-, Stp), 2.85 – 3.15 (m, 8H, ε−CH2-, Lys + 
Cys), 3.15 – 3.30 (m, 24H, N-CH2-, Stp), 3.30 – 3.63 (m, 72H, N-CH2-, 
Stp) 4.03 – 4.20 (m, 2H, O=C-C(R)H-NH-, Cys), 4.28 – 4.39 (m, 2H, 
O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-C-Stp3-K(K)-Stp3-C-H #: 76 
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Molecular formula: C90H186N36O17S2 Mw 2108.80 
MALDI: 2108.8 2109.8 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 17.0 °C): δ = 1.28 - 1.92 (m, 12H, δ-CH2/γ-
CH2/β-CH2, Lys), 2.41 - 2.66 (m, 24H, O=C-CH2-, Stp), 2.84 – 3.11 (m, 
8H, ε−CH2, Lys + Cys), 3.17 – 3.29 (m, 24H, N-CH2-, Stp), 3.35 – 3.70 
(m, 72H, Stp) 4.10 – 4.20 (m, 2H, O=C-C(R)H-NH-, Cys), 4.38 – 4.48 
(m, 2H, O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-C-Stp3-K(K-SteA2)-Stp3-C-H #: 77 
Molecular formula: C126H254N36O19S2 Mw 2641.72 
MALDI: 2641.4 2640.9 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 17.1 °C): δ = 0.72 – 0.86 (m, 6H, -CH3, SteA), 
1.06 – 1.31 (m, 56H, -CH2-, SteA), 1.31 - 1.94 (m, 16H, δ-CH2/γ-CH2/β-
CH2, Lys; O=C-CH2-CH2-, SteA), 2.09 – 2.27 (m, 4H, O=C-CH2-, SteA),  
2.40 - 2.68 (m, 24H, O=C-CH2-, Stp), 2.80 – 3.13 (m, 8H, ε−CH2-, Lys + 
Cys), 3.31 – 3.29 (m, 24H, N-CH2-, Stp), 3.31 – 3.68 (m, 72H, N-CH2-, 
Stp), 4.06 – 4.20 (m, 2H, O=C-C(R)H-NH-, Cys), 4.30 – 4.44 (m, 2H, 
O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-C-Stp3-K(K-OleA2)-Stp3-C-H #: 78 
Molecular formula: C126H250N36O19S2 Mw 2637.69 
MALDI: 2635.8 2638.7 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 17.3 °C): δ = 0.74 – 0.86 (m, 6H, -CH3, OleA), 
1.06 – 1.33 (m, 40H, -CH2-, OleA), 1.33 - 1.99 (m, 24H, δ-CH2/γ-CH2/β-
CH2, Lys; -CH2-CH=CH-CH2, O=C-CH2-CH2-; OleA), 2.07 – 2.30 (m, 
4H, O=C-CH2-, OleA),  2.40 - 2.66 (m, 24H, O=C-CH2-, Stp), 2.83 – 
3.14 (m, 8H, ε−CH2, Lys + Cys), 3.14 – 3.30 (m, 24H, N-CH2- , Stp), 
3.30 – 3.65 (m, 72H, N-CH2-, Stp) 4.04 – 4.14 (m, 2H, O=C-C(R)H-NH-, 
Cys), 4.29 – 4.41 (m, 2H, O=C-C(R)H-NH-, Lys)  
 
 
Sequence: HO-C-Stp4-K(K-MyrA2)-Stp4-C-H #: 79 
Molecular formula: C142H288N46O23S2 Mw 3072.23 
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MALDI: 3069.9 3071.2 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 17.1 °C): δ = 0.72 – 0.83 (m, 6H, -CH3, MyrA), 
1.11 – 1.29 (m, 40H, -CH2-, MyrA), 1.29 - 1.95 (m, 16H, δ-CH2/γ-CH2/β-
CH2, Lys; O=C-CH2-CH2-, MyrA), 2.10 – 2.28 (m, 4H, O=C-CH2-, MyrA),  
2.42 - 2.65 (m, 32H, O=C-CH2-, Stp), 2.85 – 3.15 (m, 8H, ε−CH2-, Lys + 
Cys), 3.15 – 3.30 (m, 32H, N-CH2-, Stp), 3.30 – 3.60 (m, 96H, N-CH2-, 
Stp) 4.03 – 4.20 (m, 2H, O=C-C(R)H-NH-, Cys), 4.26 – 4.38 (m, 2H, 
O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-C-Stp4-K(K)-Stp4-C-H #: 80 
Molecular formula: C112H234N48O21S2 Mw 2653.50 
MALDI: Not determined    
NMR: 1H-NMR (400 MHz, D2O, 17.0 °C): δ = 1.27 - 1.90 (m, 12H, δ-CH2/γ-
CH2/β-CH2, Lys), 2.40 - 2.67 (m, 24H, O=C-CH2-, Stp), 2.84 – 3.04 (m, 
8H, ε−CH2, Lys + Cys), 3.10 – 3.27 (m, 32H, N-CH2-, Stp), 3.35 – 3.70 
(m, 96H, Stp) 4.07 – 4.19 (m, 2H, O=C-C(R)H-NH-, Cys), 4.28 – 4.38 
(m, 2H, O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-C-Stp4-K(K-SteA2)-Stp4-C-H #: 81 
Molecular formula: C150H304N46O23S2 Mw 3184.44 
MALDI: 3188.5 3185.4 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 17.1 °C): δ = 0.74 – 0.85 (m, 6H, -CH3, SteA), 
1.08 – 1.30 (m, 56H, -CH2-, SteA), 1.29 - 1.95 (m, 16H, δ-CH2/γ-CH2/β-
CH2, Lys; O=C-CH2-CH2-, SteA), 2.09 – 2.27 (m, 4H, O=C-CH2-, SteA),  
2.39 - 2.66 (m, 32H, O=C-CH2-, Stp), 2.80 – 3.12 (m, 8H, ε−CH2-, Lys + 
Cys), 3.12 – 3.29 (m, 32H, N-CH2-, Stp), 3.29 – 3.62 (m, 96H, Stp) 4.01 
– 4.19 (m, 2H, O=C-C(R)H-NH-, Cys), 4.20 – 4.38 (m, 2H, O=C-C(R)H-
NH-, Lys) ppm. 
 
Sequence: HO-C-Stp4-K(K-OleA2)-Stp4-C-H #: 82 
Molecular formula: C148H298N48O23S2 Mw 3182.39 
MALDI: 3182.4 3182.5 [M+H] calc.   
NMR: 1H-NMR (400 MHz, D2O, 17.3 °C): δ = 0.73 – 0.87 (m, 6H, -CH3, OleA), 
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1.10 – 1.36 (m, 40H, -CH2-, OleA), 1.36 - 1.99 (m, 24H, δ-CH2/γ-CH2/β-
CH2, Lys; -CH2-CH=CH-CH2, O=C-CH2-CH2-; OleA), 2.07 – 2.29 (m, 
4H, O=C-CH2-, OleA),  2.40 - 2.70 (m, 32H, O=C-CH2-, Stp), 2.72 – 
3.13 (m, 8H, ε−CH2, Lys + Cys), 3.14 – 3.30 (m, 32H, N-CH2- , Stp), 
3.30 – 3.65 (m, 96H, N-CH2-, Stp) 4.01 – 4.21 (m, 2H, O=C-C(R)H-NH-, 
Cys), 4.21 – 4.40 (m, 2H, O=C-C(R)H-NH-, Lys) ppm. 
 
Sequence: HO-IVNQPTYGYWHY-Stp2-H #: GE11-Stp2 
Molecular formula: C99H147N27O23 Mw 2083.4 
MALDI: 2084.9  2084.4 [M+H] calc.  tr=24.34 min 
 
Sequence: HO-IVNQPTYGYWHY-H #: GE11 
Molecular formula: C75H97N17O19 Mw 1540.7 
MALDI: 1541.6  1541.6 [M+H] calc.   tr=16.39 min 
 
  
Appendix   
 
156 
 
8.8 Publications  
Original Papers 
Schaffert D, Dohmen C, Wagner E, Polymers for Nucleic Acid Delivery, European Patent Application 
(EP10165502.5) in cooperation with Roche Kulmbach 
Schaffert D, Kiss M, Roedl W, Shir A, Levitzki A, Ogris M, Wagner E, Poly(I:C) mediated tumor growth 
suppression in EGF-receptor overexpressing tumors using EGF-polyethylene glycol-linear 
polyethyleneimine as carrier, Pharm. Res., in press 
Schloßbauer A, Schaffert D, Knecht J, Wagner E, Bein T; Click Chemistry for High-Density 
Biofunctionalization of Mesoporous Silica,  J. Am. Chem. Soc. 130, 12558,2008 
Klutz K, Schaffert D , Willhauck MJ, Knoop K, Grünwald GK, Rödl W, Wunderlich N,  Zach C, 
Gildehaus FJ, Senekowitsch-Schmidtke R, Göke B, Wagner E, Ogris M, Spitzweg C, Radioiodine 
Therapy following Systemic Sodium Iodide Symporter Gene Transfer in Hepatocellular Carcinoma 
using EGF Receptor-targeted Nonviral Gene Delivery, submitted 
Schlossbauer A, Dohmen C, Schaffert D, Wagner E, Bein T, pH-Responsive Release of Acetal-Linked 
Mellitin from SBA-15 Mesoporous Silica, submitted to J. Am. Chem. Soc. 
Reviews 
Schaffert D, Wagner E; Gene Therapy: progress and prospects: synthetic polymer-based systems, 
Gene Therapy 2008, 15, 1131, 2008 
Manuscripts in Preparation 
Schaffert D, Badgujar N, Wagner E; Novel, Fmoc-Polyamino Acids for Solid-Phase Synthesis of 
Defined Polyamidoamines, in preparation  
Schaffert, D, Troiber C, Wagner E; Modular constructed Polyamidoamines for Gene Delivery, in 
preparation 
Kasper JC, Schaffert D, Ogris M, Wagner E, Friess W,  Up-scaled Preparation and Development of a 
Lyophilized Formulation with Long-Term Stability for Plasmid/LPEI Polyplexes – A Step Closer from 
Promising Technology to Clinical Application, in preparation 
 
Poster Presentations 
Schaffert D, Kiss M, Roedl W, Shir A, Ogris M, Wagner E, Poly-IC mediated killing of glioblastoma 
cells with novel, EGF-receptor targeted conjugates based on polyethyleneimine, Poster Presentation 
at Cellular Delivery of Therapeutic Macromolecules 2008, Cardiff 
Appendix   
 
157 
 
Schaffert D, Kiss M, Roedl W, Shir A, Ogris M, Wagner E, Poly-IC mediated tumor growth suppression 
using novel, targeted polyethyleneimine based carriers in an EGF-receptor overexpressing therapeutic 
model, Poster Presentation at the Nanoman Summarizing Workshop 2009, Venice 
  
 
 
  
Appendix   
 
158 
 
8.9 Curriculum Vitae 
Personal Details 
Address:  David Schaffert 
Montenstr. 2 
   80639 Munich, Germany 
Date of birth:  12/04/1980 
Place of birth: Wesel 
Nationality:   German 
Marital status:  not married 
 
Professional Experience 
Ludwig-Maximilians-University, Faculty of Chemistry & Pharmacy, Munich 
Dept. Pharmaceutical Biology & Nanomedicine 
Scientific Associate/PhD student  02/07 – 08/10 
 
Pharmacy “Max-Weber-Platz-Apotheke”, Munich 04/08 – 04/10 
 Part-time pharmacist 
 
International Ludwigs-Pharmacy, Munich 05/06 – 10/06 
 Practical training as pharmacist 
 
Scil Technology, Martinsried 11/05 – 04/06 
 Practical training as pharmacist 
 
Education 
Licensure as pharmacist  12/06 
Studies of pharmacy    10/00 – 10/05 
Ludwig-Maximilians-University, Munich.  
A-levels (Abitur) 9/91 – 06/00 
“Nepomucenum”, Coesfeld 
 
  
Appendix   
 
159 
 
8.10 Acknowledgements 
Most people believe that a PhD thesis is a solitary expression of a single mind (and 
generally something only done by funny people). They are wrong. Utterly. A thesis is 
always a more or less short story of a group of people struggling for scientific truth (or 
vocational survival). I have to express my thanks to a lot of people and the following 
list is short of being complete, but I did my best. 
I have to thank my supervisor Prof. Dr. Ernst Wagner for giving me the opportunity to 
perform this work in his research group. I want to express my appreciation for the 
scientific freedom he granted me and his support for my sometimes absurd ideas. 
Many thanks for all the support and helpful discussions.  
Furthermore I have to thank the “Last Kärntener” Dr. Manfred Ogris for his big 
repertoire of tasteless jokes (even surpassing mine) and his endless patience 
whenever the chemist used the FACS machine.  
Special thanks go to the members of the IndieLab (Nicole, Markus, Gelja, Miriam) for 
providing shelter to me and their patience in listening to what they called the worst 
mixture of music ever. Additionally, I have to thank Nicole for helping me out with the 
everyday questions when I started. 
To the best technicians ever: Melinda and Wolfgang for their patience and assistance 
during our shared projects. Ursula, Anna for their constant concern regarding my 
food intake and their encouraging spirit. Marcus for being the funniest German-
Croatian mixed blood I ever met. To Olga for her help with the pleasures of university 
bureaucracy.  
Christian D. for numerous hangovers, some of the most frustrating Spicker games in 
my life and for party-crashing Venice. Christian M. for, hangovers (again), and for 
introducing me to the Frequency festival (St. Pölten, Austria) and numerous pool 
rounds in the Bavaria casino. Special thanks go to my “meatbuddy” Arzu for BBQ 
support and “funny times” and to Rebekka for being a voice of reason in an otherwise 
mad environment. Prajakta for adopting me and her freshers guide to Indian customs 
(especially food). Irene for being the best Spanish visiting scientist ever (Qué raro!) 
and her patience in teaching me the correct pronunciation of Spanish swearwords. 
Martina for never giving up on me in cultural and in opera related topics. To Naresh 
(king of the dudes) for his “laid back” attitude – science was fun with you. Thomas I 
have to thank for performing countless siRNA transfections and his enthusiasm in 
doing so. 
Appendix   
 
160 
 
To Dr. Lars Allmendinger and the members of the Analytical Department, without 
their help this thesis would never have ended.  
Thanks to the workgroup of Prof. Wanner personified by Jörg, Thomas and Lars for 
accepting me as “synthetic biologist” and their help in numerous work and non-work 
related issues. I have to express my gratitude to Roche Kulmbach for numerous 
MALDI related experiments and the opportunity to discuss nucleic acid-chemistry 
related topics with them. 
To the newbies (Alex, Claudia, Laura, Raphaela, Flo, Daniel, Uli) - may your stay in 
the lab be short and productive. To Andi for discussions and some really good 
concerts. Stefan Prill for his help with the beloved MALDI machine. My 
master/bachelor/internship students Andrea, Christina, Dana, Johanna, Miriam, 
Nidhi, Ben, Michi, Nils, Matthias, Stasi for their work, without your help (especially 
Christinas and Andreas) this thesis would not exist.  
 
Eva for being there. On every day. During every result.  
 
Special thanks go to the “Herzogliches Brauhaus Tegernsee“ for liquid support during 
my thesis and to the Zündfunk for providing the soundtrack to it. 
 
  
Appendix   
 
161 
 
 
 
 
 
 
 
 
 
 
 
 
